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ABSTRACT 
 
DAVID HARBOURT: “An Investigation into the Role of Glucuronidation on the 
Disposition and Toxicity of Mycophenolic Acid using Targeted Quantitative 
Proteomics” 
(Under the direction of Dr. Philip C. Smith) 
 
The prodrug mycophenolate mofetil (MMF) is used clinically for 
prophylaxis of organ rejection in transplant patients.  MMF is metabolized to the 
active metabolite mycophenolic acid (MPA).  While proven useful in this setting, a 
significant fraction of patients receiving MMF chronically experience delayed-
onset diarrhea, which limits the long term effectiveness of their treatment.  MPA 
is eliminated primarily through glucuronidation by the action of UDP-
glucuronosyltransferase (UGT) 1A enzymes within the liver and intestine.  
Glucuronides in the liver are excreted into the bile by the canalicular transporter 
multidrug resistance-associated protein 2 (MRP2) where they are subject to 
enterohepatic cycling and excretion through the urine as glucuronides.   
Glucuronidation results in the formation of the inactive phenolic glucuronide 
(MPAG) and the labile acyl glucuronide (acMPAG).  While the formation of 
MPAG is the primary method of detoxification of MPA in vivo, studies have 
attempted to link formation of acyl glucuronides with adverse drug reactions 
(ADRs).  While evidence has been inconclusive in directly linking acyl 
glucuronides with toxicity, some drugs forming acyl glucuronides have been 
removed from the marketplace due to ADRs.  The overall hypothesis of this 
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dissertation project is that variable glucuronidation formation and efflux within the 
liver and gastrointestinal tract results in differential MPAG formation rates and 
thus modulates MPA toxicity. 
The study of the relationships between metabolism and transport was 
aided by quantitative measurement of relevant enzymes in humans and animals.   
This methodology was used to establish assays to quantify precise differences in 
UGT1A enzymes between the tissues in rats and humans to understand the 
differences in metabolism and toxicity of MPA between species.  This 
dissertation research examined the disposition of acMPAG and MPAG in relation 
to expression levels of Ugt1a enzymes and efflux transporters using targeted 
quantitative proteomics.  By correlating glucuronide catalysis and efflux with 
absolute quantification of Ugts and transporters, we increased our understanding 
of relationships between glucuronide formation and disposition and UGT 
enzymes.  This research helps explain some differences in metabolism and 
elimination observed between rats and humans administered MPA and these 
relationships may be applied to other xenobiotics with Phase II substrates. 
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CHAPTER 1 
 
INTRODUCTION
 
2 
A.    INTRODUCTION 
  
 Drug metabolizing enzymes affect the disposition and toxicity of many 
endogenous and exogenous chemicals.  These enzymes can alter compounds in 
a number of ways, either through the addition or subtraction of functional groups 
or by the alteration of oxidation state or arrangement of the molecule (Bock and 
Lilienblum, 1994; Ionescu C and Caira MR, 2005).  Through the actions of drug 
metabolizing enzymes, the body is able to eliminate many potential harmful 
compounds, primarily as inactive biproducts, by the usual methods of excretion 
and elimination. 
 While the impact of drug metabolizing enzymes on the disposition and 
elimination of xenobiotics is well known, additional factors include protein 
binding, metabolite disposition and toxicity, and transporters (Bock and 
Lilienblum, 1994; Coleman M, 2005; Ionescu C and Caira MR, 2005).  A single 
compound may be metabolized by different enzymes, resulting in many different 
metabolites, and are subsequently excreted into either the blood or bile by 
separate transporters, further complicating absorption, disposition, metabolism 
and excretion (ADME) studies necessary for pharmaceutical compounds. 
 The rapid development of new methods and instruments designed for 
quantitative proteomics has the potential to advance our understanding of 
relationships between drug metabolizing enzymes and transporters when 
conducting ADME studies of particular compounds of interest.  The example of 
linking the expression of particular enzymes and transporters of interest with the 
metabolism and disposition of a compound can be highlighted with the 
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immunosuppressive agent mycophenolic acid (MPA; 1,3-dihydro-4-hydroxy-6-
methoxy-7-methyl-3-oxo-5-isobenzylfuranyl-4-methyl-4-hexenoate, Figure 1.1).  
MPA is a substrate for uridine diphosphate glucuronosyltransferase (UGT) 
enzymes in the liver, kidney and intestinal tract.  Following UGT conjugation, 
MPA is excreted first into either the bile or blood by canalicular or basolateral 
transporters located in hepatocytes.  Subsequent metabolism following efflux into 
the bile or blood, hydrolysis by β-glucuronidase enzymes found in the gut flora of 
the intestinal lumen by enterocytes of the intestine, or the tubules of the kidney 
leads to elimination of glucuronide conjugates in the urine or feces (Bullingham et 
al., 1996; Bullingham et al., 1998).  While MPA is generally well tolerated, a large 
fraction of patients experience delayed-onset diarrhea, impacting lifestyle and 
potentially resulting in allograft rejection and life threatening complications 
(Davies et al., 2007).  It is possible that variability in UGT enzymes and 
transporters within the gastrointestinal tract affect MPA exposure levels, leading 
to gastrointestinal toxicity (Stern et al., 2007; Tallman et al., 2007; Tukey and 
Strassburg, 2000).   
 The structure and function of UGT enzymes within the body, along with 
differences between metabolism and expression levels between rats and 
humans are examined.  Furthermore, a background on the clinical uses of MPA 
is given, along with its fate within the body following administration.  The potential 
impact of labile acyl glucuronides are examined along with a short background 
on the recent developments within the field of quantitative proteomics.  This 
introduction should provide the reader with an understanding of the benefits that 
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quantitative proteomics can provide biological scientists, illustrated by the effect 
of altered UGT enzyme and transporter levels have on MPA disposition and 
toxicity. 
 
 
B. UDP-Glucuronosyltransferases  
B.1. Background and Function 
UDP-glucuronosyltransferases (UGTs) are a family of phase II metabolism 
enzymes that primarily convert lipophilic exogenous and endogenous 
compounds to conjugated products through the nucleophilic addition of 
glucuronic acid onto the compound.  The glucuronic acid side chain addition is 
accomplished through a nucleophilic attack onto the C1 pryanose acid side chain 
in a SN2 reaction mediated by the cofactor UDPGA and UGT enzymes (Clarke 
and Burchell, 1994; Ionescu C and Caira MR, 2005).  The UGT family of 
enzymes consists of four gene families, UGT1, UGT2, UGT3 and UGT8, with 52 
UGT enzymes described between vertebrate and invertebrate species (Tukey 
and Strassburg, 2000; Tukey and Strassburg, 2001).  In humans, 19 UGT 
enzymes have been described and separated into two gene families, UGT1 and 
UGT2, with two subfamilies each.  The UGT1A locus is found within 
chromosome 2q37 encoding nine separate functional isoforms and the inactive 
pseudogenes UGT1A2, UGT1A11, UGT1A12 and UGT1A13 (Tukey and 
Strassburg, 2001).  The UGT locus consists of a 528-534 amino acid sequence 
divided between a conserved domain toward the carboxyl tail, spanning 250 
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amino acids and a divergent domain unique to each isoform spanning 
approximately 280 amino acids starting at the amino terminus.   
 The primary function of UGT enzymes within the body is the detoxification 
of endogenous and exogenous lipophilic compounds.  Conjugation results in the 
formation of a product that is more hydrophilic and excreted into the blood or into 
the bile after a change in charge state and molecular weight addition.   In 
addition, conjugation results in the loss of pharmacological activity, with the some 
exceptions including morphine 6-glucuronide (Bailey and Dickinson, 2003; Ritter 
2000; Ionescu C and Caira MR, 2005).  Compounds that undergo conjugation 
are also less likely to form electrophilic adducts with proteins or other 
macromolecules including DNA (Bock and Lilienbaum, 1994).   A source of 
bioactivation involves the formation of electrophilic N-O-glucuronides of 
hydroxamic acids potentially resulting in hypersensitivity or chemical 
carcinogenesis (Ritter, 2000).  While electrophilic adducts of DNA have been 
linked to carcinogenesis, there is inconsistent evidence linking drug protein 
adduct formation via acyl glucuronides with toxicological outcomes (Bailey and 
Dickinson, 2003).    
 Following conjugation within the liver, it is common for glucuronide 
conjugates to be excreted into the biliary tract by the ATP-binding cassette (ABC) 
family of canalicular membrane transporters, including the multidrug resistance-
associated protein 2 (MRP2) (ABCC2/Abcc2) and the breast cancer resistance 
protein (BCRP) (ABCG2/Abcg2).  Conjugated metabolites may be cleaved back 
to the parent aglycone molecule by β-glucuronidase enzymes within the gut flora 
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of the intestinal lumen.  The parent aglycone that is liberated within the intestinal 
lumen may then be taken back up into the liver through the portal vein in a 
process known as enterohepatic cycling (EHC).  Generally, glucuronides are not 
passively absorbed due to their polarity and charge.   EHC can be manifested in 
plasma concentration versus time curves as secondary peaks after initial dose 
administration.  EHC values vary between compounds but may be responsible 
for as much as 60% of MPA systemic exposure in humans and can serve to both 
increase efficacy of the parent compound along with potential side effects 
(Bullingham et al., 1998; Naderer et al., 2005).   
 
B.2. Human UGTs 
UGTs are expressed widely in humans and have been found in some 
capacity in virtually every major organ within the body.  In humans, genes are 
expressed within two separate families and four subfamilies.  Nomenclature for 
the UGT gene family is denoted with an Arabic numeral, the gene subfamily with 
a letter and specific gene with an Arabic numeral (Mackenzie et al., 1997).  In 
humans, UGT genes are transcribed from chromosomes 2q37 (1A) and 4q2 
(2B).  The UGT1A enzymes are transcribed from 12 unique promoter sequences 
with the four common 3’ exons and one unique 5’ exon to form nine functional 
enzymes and four pseudogenes (Ritter et al., 1992; Owens and Ritter, 1995; 
Tukey and Strassburg, 2000; Tukey and Strassburg, 2001; 
<http://som.flinders.edu.au/FUSA/ClinPharm/UGT/>).   
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UGT1A1 is the most widely expressed of the human UGT enzymes 
(hUGTs) and is known to conjugate numerous endogenous steroid and thyroid 
hormones, in addition to many exogenous compounds, but is best known for 
bilirubin detoxification (Ritter et al., 1991; Tukey and Strassburg, 2000).  Its role 
in bilirubin conjugation is responsible for this being the most intensly studied UGT 
isoform.  Expression of UGT1A1 has been detected primarily in the liver and 
throughout the gastrointestinal tract.  Unlike other drug metabolizing enzymes, 
UGTs undergo oligermerization, either within or between isoforms, drastically 
impacting activity levels (Bock and Kohle, 2009; Meech and Mackenzie, 1997; 
Levesque et al., 2007).  UGT1A6 has a similar distribution of tissue expression 
compared to 1A1 but has been found to catalyze and detoxify primarily 
exogenous compounds.  The advent of RT-PCR technology allowed for tissue 
expression studies of individual UGT isoforms but quantification has still proven 
difficult.  Because human UGT1A3, UGT1A4, UGT1A5 and UGT1A7, UGT1A8, 
UGT1A9 and UGT1A10 display up to 93% sequence homology, antibody 
generation for Western blotting has proven to be an arduous task and perhaps 
unresolvable.  Of the 17 active human UGT isoforms identified, only UGT1A1, 
UGT1A6 and UGT2B7 display proper structural diversity to allow for specific or 
selective antibody generation (Tukey and Strassburg, 2001).    A fourth antibody 
for quantification of UGT1A9 has been generated from the laboratory of J. Ritter 
at Virginia Commenwealth University (VCU), but cross-reactivity with UGT1A7-10 
due to structural homology has hindered reliability of quantification.  A similar 
attempt has been made with UGT1A4 and UGT1A8, but again, cross-reactivity 
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with analogous isoforms has deterred development.  Because of their high 
genome sequence homology, coupled with extensive tissue expression and 
diverse substrate conjugation, a need exists for an accurate, reproducible 
method for UGT quantification.    
 
B.3. Rat Ugts 
In rats, the UGT gene family is separated between two families and four 
subfamilies but displays a different set of conjugating isoforms.  Unlike humans, 
rat Ugt1a enzymes are encoded from the gene locus of chromosome 9q35, with 
the gene subfamilies denoted with lower case letters (Nagai et al., 1995).  Within 
the rat Ugt1a locus, Ugt1a1 is seen as a functional homolog to the human 
counterpart, but the additional Ugt1a isoforms diverge from their human 
counterparts with respect to location, sequence and substrate specificity.  In 
conjunction with the active isoforms within the rat UGT1A locus, two 
pseudogenes encoding Ugt1a4 and Ugt1a9 have been discovered within the 
genome (Shelby et al., 2003).  Despite these differences, rat models have long 
since been used for glucuronidation studies due to comparable metabolite 
generation capabilities compared to humans and the ability to perform 
cannulation studies for pharmacokinetic analyses.  Furthermore, the rat also 
serves as a powerful tool for mimicking the human hyperbilirubinemic disease 
state through the Gunn rat model.  The Gunn rat is devoid of functional Ugt1a 
enzymes due to a frameshift mutation on exon 2 and subsequently develops 
hyperbilirubinemia in addition to an increased sensitivity to xenobiotics 
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undergoing detoxification through glucuronidation (Chowdury et al., 1993).  
Unlike humans with Criglar-Najjar Syndrome, however, the rat has some bilirubin 
conjugation ability, making the Gunn rat mutation nonlethal.  Recent work 
involving Gunn rats revolves around adenovirus mediated gene therapy to 
restore expression of UGT1A isoforms within the liver and gastrointestinal tract.  
Specifically, adenovirus gene therapy Gunn rat models have been more sensitive 
to gastrointestinal toxicity of irinotecan and mycophenolic acid due to increased 
biliary efflux and subsequent hydrolysis of glucuronide conjugates resulting in 
elevated exposure of of the GI tract to toxic aglycones (Miles et al., 2006; 
Tallman et al., 2007). 
 
B.4. Detoxification and Toxicity associated with glucuronidation 
Despite the role of UGTs in the detoxification and excretion of numerous 
endogenous and exogenous compounds, there has been evidence indicating 
glucuronide conjugates have toxicological implications.  The link between UGTs 
and cancer has not yet been directly made, but mutations in UGT genomes have 
been observed in colorectal carcinoma (Guillemette, 2003; Tukey and 
Strassburg, 2000; Tukey and Strassburg, 2001).  In addition, UGT activity has 
been shown to be highly polymorphic within the gastrointestinal tract, yet 
interindividual differences are small within the liver (Strassburg et al., 1999).  One 
of the most prominent detoxification mechanisms prevalent in the UGT genome 
is the formation of bilirubin diacylglucuronide through UGT1A1 catalysis.  In 
Gunn rats and humans stricken with Crigler-Najjar or Gilbert’s Syndrome, 
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hyperbilirubinemia results from the buildup of lipophilic bilirubin that then can 
penetrate the blood brain barrier to result in encephalopathy, neural necrosis and 
death if untreated (Tukey and Strassburg, 2000).  Though a vast majority 
glucuronide conjugates are pharmacologically inactive, certain compounds such 
as morphine-6-glucuronide display increased pharmacological activity (Bailey 
and Dickinson, 2003; Ritter, 2000).  In addition to active glucuronides, an area of 
active research and continued debate revolves around acyl glucuronide catalysis 
and toxicity (Shipkova et al., 2003).  Acyl glucuronide conjugates occur through 
conjugation of carboxylic acid moiety within the affected compound, resulting in a 
product whose link to adverse drug reactions and adduct formation has been 
implicated but yet to be established (Bailey and Dickinson, 2003; Faed, 1984; 
Shipkova et al., 2003). 
C. Acyl Glucuronides 
C.1. Background 
Acyl glucuronides are controversial in drug toxicology due to their ability to 
form protein adducts with liver and plasma proteins and may have a role in 
adverse drug reactions (ADRs) (Bailey and Dickinson, 2003).  After arising from 
a carboxylate moiety within a substrate, acyl glucuronides have a series of 
potential fates within the body that may either predispose the affected organism 
to toxicity or result in harmless excretion outside the body.  One of these fates 
includes the acyl glucuronide being produced through a UGT catalyzed reaction 
followed by excretion from the liver into the bloodstream or via biliary tract into 
the intestine.  Acyl glucuronides make excellent substrates for transporters within 
11 
the hepatocyte, with the most active transporters in acyl glucuronide excretion 
including the basolateral organic anion transporters (OAT) transporters or the 
canalicular MRP2 transporter (Bailey and Dickinson, 2003).   
Besides excretion, acyl glucuronides can be subject to hydrolysis through 
the actions of esterases within the liver, blood or gastrointestinal tract.  This 
aspect is unique to acyl glucuronides compared other glucuronide conjugates 
because of the carboxylate moiety binding to the glucuronide conjugate resulting 
in ester linkage (Faed, 1984).  Unlike other glucuronides which are resistant to 
hydrolysis by esterase enzymes, acyl glucuronides may be cleaved back to the 
parent compound through the actions of esterases which are found throughout 
the body.  The cleavage of acyl glucuronides can increase a patient’s exposure 
to the parent drug, and subsequently its efficacy, through enterohepatic cycling 
or even engage the compound in systemic “futile cycling” through continuous 
cleavage and conjugation within the body (Bailey and Dickinson, 2003).  This is 
important for toxicological consequences if glucuronidation of a carboxylate 
moiety is the primary means of elimination and detoxification for a compound. 
The parent compound may exhibit cellular toxicity due to increased exposure 
throughout the body because of esterase cleavage of the acyl glucuronide.   
C.2. Acyl Migration of Ester Glucuronides  
Another possible fate of acyl glucuronide metabolites in vivo concerns acyl 
migration.  Acyl migration of glucuronide conjugates involves the initial 
conversion of O-β-1 acyl glucuronide into either an O-β-2 or an O-α-2 isomeric 
conjugate via intramolecular trans-esterification (Faed, 1984).  This reaction is 
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the result of a nucleophilic attack on an adjacent carbon by the hydroxyl group of 
the glucuronide conjugate.  Additional isomeric conjugates O-β-3, O-β-4, O-α-3, 
O-α-4 can be created during this process and each reaction beyond the initial O-
β-1 conjugate is reversible (Bailey and Dickinson, 2003; Faed, 1984).  Some 
studies have shown that back conversion into the initial biologically synthesized 
β-1 acyl glucuronide metabolite is possible at low levels within in vitro systems 
but this reaction is rare and not significant in in vivo biological systems (Bailey 
and Dickinson, 2003).  While the isomeric conjugates are similar to the O-β-1 
acyl glucuronide, they are unique because biological systems are unable to 
create them as primary products and they are resistant to β-glucuronidase 
enzymes present within the gastrointestinal tract and liver.  Even though many 
isomeric conjugates exhibit no apparent biological consequences, the ability of 
these isomers to form covalent bonds with cellular proteins and macromolecules 
may have toxicological implications resulting in ADRs seen in some compounds 
containing carboxylate moeities. 
C.3. Potential Toxicity 
Once the parent acyl glucuronide conjugate or any of its isomeric 
conjugates form protein adducts in vivo, a number of consequences are possible.   
One of the most contentious debates is the fate of the acyl glucuronide-protein 
adducts within the biological system (Bailey and Dickinson, 2003; Shipkova et al., 
2003).  Protein adducts have been demonstrated frequently with albumin, plasma 
and liver in vitro systems, yet within each system, few direct links to toxicity have 
been made (Bailey and Dickinson, 2003; Shipkova et al., 2003).  Many 
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compounds including NSAIDS rapidly form acyl glucuronides and subsequent 
protein adducts with plasma proteins and albumin, yet these drugs are generally 
regarded as safe and some such as ibuprofen are available without a 
prescription (Bailey and Dickinson, 2003).   
Drug-protein adducts formed from acyl glucuronides have been shown to 
affect cellular function of certain proteins within rats, including disruption of 
tubulin and dipeptidyl-peptidase IV function by diclofenac and zomepirac acyl 
glucuronides (Bailey et al., 1998; Bailey and Dickinson, 2003).   In addition to 
drug-protein adducts, acyl glucuronides have also been implicated in 
hypersensitivity and idiosyncratic adverse drug reactions with mixed results 
(Shipkova et al., 2003).  Numerous acyl glucuronide forming compounds 
including suprofen, zomepirac and ibufenac have been withdrawn from the 
market because of hepatoxicity, yet compared to the large number of patients 
administered these compounds, the number of adverse reactions remains small 
and unpredictable.  Moreover, no direct link between toxicity and acyl 
glucuronide exposure has been reported in animals and humans (Bailey and 
Dickinson, 2003). 
Mycophenolic acid is an immunosuppressant for prophylaxis in organ and 
solid graft transplant patients that forms both a phenolic and acyl glucuronide in 
humans (Young and Sollinger, 1994).  While the phenolic glucuronide is inactive, 
in vitro testing of the acyl glucuronide conjugate exhibited a greater efficacy for 
inhibition of leukocyte proliferation than the unconjugated parent drug (Shipkova 
et al., 2001).  Along with this evidence, cellular protein adducts have been found 
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to form as a result of the acyl glucuronide, which has led some scientists to 
believe that this metabolite is the source of delayed-onset diarrhea observed 
within patients on extended therapy along with additional side effects including 
leucopenia (Shipkova et al., 2004).  However, the evidence basing MPA toxicity 
on acyl glucuronide formation (acMPAG) remains inconsistent, not only due to 
the lack of conclusive data from in vitro testing, but also due to the fact that 
negative clinical outcomes of MPA have not been directly linked to exposure of 
acMPAG (Kypers et al., 2003).   
D. Quantitative Proteomics 
D.1. Background 
While traditional methods of quantitative proteomics involved 2D-gel 
electrophoresis or immunoassays for relative quantification, the field began to 
take off with the advent of refined electrospray ionization (ESI) and tandem mass 
spectrometry (MS/MS) techniques in the late 1980s (Whitehouse et al., 1985; 
Cañas et al., 2006).  Even though immunoassays including ELISA and Western 
Blots have been used for clinical biomarker detection for years, they have a 
number of shortcomings.  Many antibody-based assays can vary significantly 
between laboratories and are subject to cross-reactivity along with the hook 
effect (antibody saturation resulting in declining signal) that compromises the 
linear range of the assays (Hoofnagle and Wener, 2009). The refinements in both 
ionization and mass spectrometry have enabled the development of methods 
involving isotope dilution mass spectrometry applied for the quantification of 
intact proteins and peptides.  Coupled with the newer stable isotope internal 
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standards available today with an increasing assortment of mass spectrometer 
platforms and LC configurations, the field of quantitative proteomics through 
tandem mass spectrometry continues its evolvement as a primary research 
initiative for investigators interested in biomarker discovery, enzyme 
quantification, cancer research and global proteomics (Gstaiger and Aebersold, 
2009). 
While numerous methods of stable isotope labeling are offered today, one 
of the more reliable and cost effective methods involves N15 and C13 isotopes of 
peptide side chains such as the AQUA™ method (Gerber et al., 2003).  In 
addition to the AQUA™ method, other methods that have been developed within 
this decade include stable isotope labeling with amino acids in cell culture 
(SILAC), isotope coated affinity tags (ICAT), isobaric tagging for relative and 
absolute quantification (iTRAQ) reagents.  The most recent development by SJ 
Gaskell’s lab involves stable isotopes expressed and grown in E. Coli cell culture 
to form quality concatamer internal standards (QConCAT) (Beynon et al., 2005).  
As opposed to the SILAC and QConCAT methodology involving stable isotopes 
grown in cell culture, the ICAT and iTRAQ methods involve targeting the entire 
protein through either cysteine labeling (ICAT) or N-terminal labeling (iTRAQ) 
(Cañas B 2006).  One problem with the ICAT and SILAC strategy is that each of 
these methods are not suitable for wide-scale quantification due to the limited 
number of peptides containing cysteine residues and the difficulty in purifying 
proteins of interest from SILAC cultures, respectively.  While iTRAQ and 
QConCAT have been applied in absolute quantification, iTRAQ peptides have 
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been beset by problems due to lack of specificity compared to true MS/MS and 
QConCAT peptides are no longer commercially produced for proteomic 
applications (Wu et al., 2006). 
D.2. Biological Applications  
Recently, a number of new methodologies have been used for quantifying 
biological enzymes in complex matrices.  Biological enzymes such as the 
cytochrome P450 family (CYP450s), hUGTs, cancer biomarkers and membrane 
transporters have been quantified across a number of different matrices 
(Barnidge et al., 2004; Jenkins et al., 2006; Kamiie et al., 2008; Li et al., 2008; 
Wang et al., 2008).  The AQUA™ method was selected for this research project 
because the synthetic peptides are readily available for purchase through 
numerous vendors and their accuracy in quantification of specific enzymes and 
proteins has been demonstrated through previous experiments (Fallon et al, 
2008; Gerber et al., 2003).  Two AQUA™ peptides are usually selected per 
protein through a specific series of selection criteria, including the elimination of 
cysteine, methionine and tryptophan due to ionization difficulties, size limited to 
8-15 residues and no aspartic acid/glycine N-terminus to prevent cyclization.  
These selection rules, coupled with the understanding that each peptide must be 
unique to the targeted protein, two AQUA™ peptides are chosen for 
quantification of both human and rat UGT enzymes, whereas three peptides are 
used for each rat membrane transporter.  
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E. Mycophenolic Acid 
E.1. Clinical Uses 
Mycophenolic acid (MPA) is an immunosuppressant designed for 
prophylaxis in renal and hepatic transplant patients or as treatment for 
autoimmune disorders such as systemic lupus erythmatosus (Bullingham et al., 
1996; Young and Sollinger, 1994; Stern et al., 2007).  Currently MPA is available 
in either the prodrug form mycophenolate mofetil (CellCept©, Novartis) or as an 
enteric coated sodium salt (Myfortic©, Roche).   The immunosuppressive action 
of MPA is obtained through the inhibition of the ionsine monophosphate 
dehydrogenase type II (IMPDH) enzyme which converts xanthine 
monophosphate (XMP) into guanine monophosphate (GMP) in the de novo 
purine biosynthesis pathway (Young and Sollinger, 1994).  This particular 
pathway is important for lymphocyte proliferation because lymphocytes are 
unable to undergo the secondary salvage pathway for purine biosynthesis and 
IMPDH type II is unique to both B and T lymphocytes (Carr et al., 1993; Young 
and Sollinger, 1994).  MPA is coadministered as part of immunosuppressive 
therapy for transplant patients with cyclosporin A, tacrolimus or sirolimus 
combined with corticosteroids for maximum efficacy.  MPA is extensively protein 
bound (97%) and metabolized almost exclusively by UGTs into either MPA-7-O-
glucuronide (MPAG) or MPA-acyl-glucuronide (acMPAG) and eliminated through 
biliary or urinary excretion (Table 1.2, Bullinghman et al., 1996; Bullingham et al., 
1998; Hofmann La Roche; Parker et al., 1996).  While it is generally regarded as 
a safe drug and is well tolerated by patients, side effects of MPA include 
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leucopenia and an elevated infection rate.  The most severe effect exhibited in 
patients is delayed-onset diarrhea seen in 20-30% of patients (Davies et al., 
2007; Hebert et al., 1999; McDiarmid, 1996; Wang et al., 2004). 
 
E.2. Toxicity 
In humans, the toxicological source of MPA is a conflicted argument 
revolving around the fate of the acyl glucuronide within the bloodstream and 
intestinal tract.  MPA metabolized to its phenolic glucuronide by UGT1A1, 
UGT1A8 and UGT1A9 within the liver followed by excretion into the bloodstream 
or into the biliary tract by MRP2 and BCRP (Mackenzie, 2000; Miura et al., 
2008).  Peak plasma concentrations of MPA, MPAG and acMPAG are observed 
within forty five to ninety minutes of oral dosing of MMF (Bullingham et al., 1996; 
Bullingham et al., 1998; Hofmann La Roche).  While UGT1A1, UGT1A8, 
UGT1A9 and UGT1A10 are the source of the phenolic glucuronide in humans, 
acyl glucuronidation of MPA exclusively involves UGT2B7 (Mackenzie, 2000; 
Saitoh et al., 2006).  After excretion into the biliary tract or bloodstream, acMPAG 
has the ability to form covalent bonds with plasma proteins and cellular 
macromolecules, creating protein adducts (Shipkova et al., 2003).  More 
troubling is that in vitro cell systems have shown that acMPAG incubation results 
in significantly elevated cytokine levels, possibly resulting in immunogenic 
reactions (Wieland et al., 2000).  However, this evidence has yet to be shown in 
in vivo experiments which may indicate that acMPAG is excreted out of the 
system before cytokine elevation occurs.   
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A further complication of MPA metabolism and excretion involves 
polymorphisms in UGT enzymes, MRP2 and BCRP transcripts that result in 
decreased MPA clearance that is possibly be associated with intestinal toxicity in 
transplant patients (Djedi et al., 2007; Miura et al., 2008; Shipkova et al., 2005).  
Unlike its glucuronide metabolites, MPA has also shown the ability to penetrate 
the enterocyte membranes within the intestinal tract and be a source of direct 
cellular toxicity (Shipkova et al., 2005).  While attempts have been made to link 
acMPAG exposure levels with toxicity, recent studies have not been able to 
correlate elevated acMPAG exposure with GI toxicity (Kuypers et al., 2003; Shaw 
et al., 1996; Staatz et al., 2007).  This indicates that within humans, 
glucuronidation serves as a protective mechanism although the potential 
immunogenic properties of acMPAG should be monitored.   
 
E.3. Rat and Human MPA Metabolism 
The fate of MPA is similar between rats and humans despite the different 
UGT isoforms involved between the two species.  In rats, MPA is glucuronidated 
at the phenol ring by Ugt1a1, Ugt1a6 and Ugt1a7 and at the carboxylate 
functional group by rUgt2b7 to form acMPAG followed by excretion into the 
biliary tract by Mrp2 (Koboyashi et al., 2004; Miles et al., 2006; Takekuma et al., 
2007).  Compared to humans, a significantly elevated amount or fraction of the 
dose of MPAG is excreted into the biliary tract as opposed to the bloodstream 
(Takekuma et al., 2007).  Thus, the ratio between MPAG and MPA exposure 
levels is different between species.   
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Glucuronidation rates of MPA in in vitro systems have been shown to vary 
up to ten fold between species, and also genders of rats but differences in 
toxicity have not been observed across rat strains (Miles et al., 2005; Miles et al., 
2006; Stern et al., 2007).   MPAG formation rates have been shown to be higher 
in male Sprague Dawley rats and male rats have also been more resistant to 
MPA induced GI toxicity than females (Stern et al., 2007).  Ugt1a deficient Gunn 
rats and AVUgt treated Gunn rats whose rUgt expression is restored within the 
liver, exhibit lacrimation, malaise and diarrhea after MPA administration (Miles et 
al., 2006).  While Gunn rats and AVUgt treated Gunn rats exhibit no intestinal 
Ugt1a activity, Wistar and male Sprague Dawley rats expressing high levels of 
rUgt1a activity are resistant to MPA induced GI toxicity (Miles et al., 2006; Stern 
et al., 2007).  Furthermore, MPA administration to AVUgt treated Gunn rats that 
lacked intestinal Ugt activity resulted in an elevated level of intestinal toxicity 
when compared to control Wistar rats which were resistant to MPA induced GI 
toxicity (Miles et al., 2006).  This indicates that intestinal glucuronidation activity 
may help prevent GI toxicity due to decreased enterocyte MPA exposure which 
could be due to either increased metabolism or enhanced efflux.   As in humans, 
glucuronidation activity in rats is likely to be the primary source of detoxification 
of MPA and a key factor in the prevention of MPA related toxicological effects.   
 
F.  Rationale for the Proposed Project 
Glucuronidation has repeatedly been demonstrated as a determining 
factor of toxicity and disposition of numerous endogenous and exogenous 
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compounds (Bock and Lilebaum, 1994; Tukey and Strassburg, 2000).  However, 
the fate of some acyl glucuronide metabolites within body systems remains a 
contested debate.  MPA represents an excellent model compound for study due 
to its ability to form the nontoxic and inactive MPAG, in addition to the labile and 
potentially reactive acMPAG metabolite, while remaining a well-tolerated 
treatment for transplant patients.  While many papers have been published 
establishing assays to quantify proteins of interest within in vivo systems there 
have been no attempts to link enzyme expression levels assayed using 
quantitative proteomics via LC-MS/MS with their biological significance.  The 
methods developed through this proposed project, coupled with pharmacokinetic 
and acMPAG stability studies examine the relationship between MPA disposition 
and altered Ugt and transporter levels within the rat.  The overall hypothesis of 
this dissertation project is that variable glucuronidation formation and efflux within 
the liver and gastrointestinal tract results in differential MPAG formation rates and 
thus modulates MPA toxicity.  To evaluate the potential effect of glucuronidation 
on MPA toxicity, the stability, reactivity and disposition of the MPA glucuronide 
metabolites will be examined in the following aims:  
 
AIM 1:  Differences in toxicity of mycophenolic acid will be examined 
through evaluation of glucuronide disposition.  There are conflicting reports 
on acMPAG stability and reactivity.  These experiments on acMPAG stability and 
reactivity will help determine if acMPAG is a reactive metabolite that could be a 
factor in MPA GI toxicity.  In addition, a series of pharmacokinetic studies 
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evaluating MPA, acMPAG and MPAG disposition will be conducted for future 
studies comparing enzyme expression with metabolite disposition: 
a. A method to assay the acyl glucuronide metabolite of mycophenolic acid 
will be established and used to evaluate the stability of acMPAG in vitro 
and measure it within biological matrices. 
b. Acyl glucuronide reactivity will be examined through covalent binding 
studies 
c. MPAG and acMPAG will be administered intravenously to rats to examine 
the fate of the glucuronides and to determine hepatic uptake from the 
systemic circulation. 
AIM 2:  The differences in UGT enzyme expression levels will be quantified 
in vivo across human tissues involved with drug disposition.  To properly 
evaluate metabolite disposition with enzyme and transporter expression, 
methods to quantify UGT enzymes will be established.  It is important to first 
evaluate and validate our quantitative proteomic methods against established 
assays for hUGT quantification in the following experiments:  
a. A quantitative proteomic LC-MS/MS method to measure hUGT1A1 and 
hUGT1A6 levels within human liver and intestine will be established to 
validate the proposed methodology. 
b. The quantitative proteomic method will then be optimized to quantify 
enzyme levels of the hUGT1A gene family using nano-LC MS/MS 
instrumentation.   
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c. The expanded and optimized hUGT1A assay will be used to compare 
UGT enzyme expression levels in human liver, kidney and intestinal 
microsomes. 
AIM 3:  The association between varying rUGT and transporter expression 
levels and the disposition of MPA will be determined.  Once the utility and 
accuracy of hUGT quantitative assays have been evaluated, the effect of altered 
enzyme and transporter expression on MPA metabolism and disposition will be 
examined.  Experiments examining the relationship between rUgt and membrane 
transporter expression with the metabolism, disposition and toxicity of MPA are 
outlined below: 
a. An LC-MS/MS quantitative proteomic method for quantifying rUGT1A1, 
rUGT1A6 and rUGT1A7 within the liver and gastrointestinal tract will be 
established. 
b. Biliary excretion of MPA and its glucuronides administered to bile 
cannulated Wistar rats will be examined with respect to rUGT expression 
levels and in vitro glucuronidation rates. 
c. Ugt 1a1, 1a6, 1a7, Mrp2, Mrp3 and Bcrp expression levels will be 
compared between Wistar, AVUgt and TR- rats to examine the effect of the 
altered Ugt or Mrp2 protein on Bcrp, Mrp3 and UGT enzyme levels and 
MPA disposition. 
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Figure 1.1 Structure of Mycophenolic Acid and its two primary glucuronide 
metabolites formed through the action of rUgts (Miles et al., 2005; Picard et al., 
2005; Young and Sollinger, 1994) 
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Table 1.1 Localization of UGT1A mRNA in human and rat tissues with isoforms 
in bold responsible for MPA glucuronidation  
 
Enzyme Species Localization 
Ugt1a1 Rat Liver, kidney, intestinal tract, brain, lung, 
testis 
Ugt1a2 Rat Small intestine, large intestine, colon, 
stomach 
Ugt1a3 Rat Small intestine, large intestine 
Ugt1a5 Rat Liver 
Ugt1a6 Rat Large and small intestine, kidney, 
stomach, liver, lung, brain, esophagus 
Ugt1a7 Rat Small and large intestine, kidney, lung, 
ovary, spleen, stomach 
Ugt1a8 Rat Liver and kidney 
UGT1A1 Human Liver, biliary tract, colon, duodenum, 
jejunum, ileum 
UGT1A3 Human Liver, biliary tract, colon, gastric lining, 
small intestine 
UGT1A4 Human Liver, biliary tract, colon and small 
intestine 
UGT1A6 Human Liver, biliary tract, stomach, colon, small 
intestine 
UGT1A7 Human Stomach, esophagus 
UGT1A8 Human Colon, esophagus 
UGT1A9 Human Liver, colon, esophagus 
UGT1A10 Human Biliary, gastric lining, colon, esophagus, 
small intestine 
 
*Isoforms in bold indicate capability for MPA glucuronidation, table above 
includes only functional encoded proteins within UGT1A locus.  List does not 
include the isoforms rUgt1a4, rUgt1a9, UGT1A2, UGT1A11, UGT1A12 and 
UGT1A13 which encode nonfunctional pseudogenes (Mackenzie, 2000; Miles et 
al., 2006; Miles et al., 2006; Shelby et al., 2003; Strassburg et al., 1997; 
Strassburg et al., 1998; Strassburg et al., 1999; Strassburg et al., 2000).   
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Table 1.2 Estimates of MPA and MPAG pharmacokinetic parameters following a 
single oral dose of 1.5 g of MMF in healthy human volunteers (n=6) (Bullingham 
et al., 1996; Bullingham et al., 1998; Hofmann-La Roche; Parker et al., 1996).  
Data are presented as mean values +/- SD. 
 
Pharmacokinetic Parameter MPA MPAG 
Cmax (mg/L) 34.0±7.1 43.1±6.8 
Tmax (h) 1.0±0.1 1.8±0.5 
Terminal t1/2 17.9±6.5 16.1±5.2 
AUC0-∞ (mg/L*h) 101.1±23.4 480.1±105.2
CLRenal (mL/min) 1.2 (0-4.6) 33.7 (7.4) 
Exposure due to EHC 40% N/A 
Therapeutic Range 1-60 mg/L N/A 
%Dose recovered in urine 0.6% 96.3% 
%Dose recovered in feces 0.5% 5.5% 
%Dose excreted into bile 0.1% 18.0% 
* Cmax (Maxicum concentration), Tmax (Time to reach maximum concentration), 
AUC (Area under the curve) 
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A. INTRODUCTION
Mycophenolic acid (MPA) is used as an adjuvant immunosuppressive 
agent for prevention of renal and liver allograft rejection.  It is also used to treat 
several autoimmune disorders.  MPA is a selective and reversible inhibitor of the 
inosine monophosphate dehydrogenase type II enzyme, which is primarily 
responsible for the conversion of xanthine monophosphate to guanine 
monophosphate in the de novo purine biosynthesis pathway (Young and 
Sollinger, 1994).  This enzyme is particularly important for B and T lymphocytes 
that are unable to undergo the salvage pathway for purine biosynthesis and 
proliferation (Young and Sollinger, 1994).  Because the type II enzyme is found 
primarily in lymphocytes, MPA makes an ideal agent for immunosuppressive 
therapy. 
 MPA is administered as either an ester prodrug, mycofenolate mofetil, 
(MMF) or an enteric coated sodium salt (MPA-Na+) in IV or oral formulations.  
Following administration, MMF is rapidly converted to MPA and subsequently 
conjugated to form the inactive phenolic glucuronide (MPAG) or the putative 
reactive acyl glucuronide (acMPAG).  These glucuronide metabolites can then be 
excreted into the biliary tract by the canalicular multidrug resistance-associated 
protein 2 (MRP2) transporter (Kobayashi et al., 2004).  Enterohepatic cycling is 
responsible for approximately forty percent of MPA exposure in humans, which is 
visible through the presence of a secondary peak of MPA between 8-12 hours 
following dosing (Bullingham et al., 1996; Staatz et al., 2007).   
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While MMF and MPA-Na+ are generally well tolerated, side effects such 
as leucopenia, increased infection rate and diarrhea are observed in 20-30% of 
patients (Davies et al., 2007).  Diarrhea usually develops between one and three 
months into MPA therapy and in severe cases can require dosage reduction or 
cessation of therapy, increasing the chance of allograft rejection (Davies et al., 
2007).  Numerous potential causes of delayed onset diarrhea due to MMF 
therapy have been examined and investigated, but the precise origin remains 
unknown.  Due to the reactivity of acyl glucuronides, attempts have been made 
to link the acMPAG metabolite to the gastrointestinal side effects of MPA in 
humans. (Oellerich et al., 2000; Bailey and Dickinson, 2003; Heller et al., 2007).  
Indeed, in vitro studies conducted with acMPAG indicate that it has the potential 
to elevate cytokine levels, inhibit lymphocyte proliferation and form drug-protein 
adducts with plasma and liver proteins (Wieland et al., 2000; Shipkova et al., 
2001; Shipkova et al., 2002).  All of these findings could conceivably contribute to 
toxicities or affect efficacy.  
 The purpose of this investigation was to evaluate acMPAG stability under 
various conditions and to assess its covalent binding potential.  The in vitro t1/2 of 
the acMPAG metabolite and its relative stability as compared to other common 
acyl glucuronide metabolites was investigated.  Furthermore, the effects of 
plasma proteins and liver microsomes on acMPAG stability were evaluated. 
Using in vivo studies in male rats, we estimated the systemic clearance and the 
fraction of acMPAG metabolite that is converted to MPA following direct acMPAG 
administration.  The ability of acMPAG to covalently bind with albumin in vitro 
42 
was examined to evaluate its stability and reactivity.  This investigation of 
acMPAG stability coupled with in vivo and covalent binding studies, provides 
insight into whether the presence of drug-protein adducts could be a factor in 
adverse reactions to MPA. 
B.  METHODS 
Materials 
AcMPAG (reported >95% pure) was generously donated in separate 
batches by Roche Pharmaceuticals (Metby, NJ) and Novartis Pharmaceuticals.  
MMF (CellCept©) was purchased from Roche Pharmaceuticals (Nutley, NJ).  
Analytical grade acetonitrile (ACN), methyl alcohol (anhydrous) and glacial acetic 
acid (HOAc) were purchased from Fisher Scientific Co. (Pittsburgh, PA).  β-
Glucuronidase (Type β-1 from Bovine Liver), formic acid (FA), suprofen, diethyl 
ether, human serum albumin fraction V (HSA), alamethicin, magnesium chloride 
(MgCl2), phenylmethylsulfonyl fluoride (PMSF), D-saccharic acid 1, 4-lactone (D-
SL), dextrose, carboxyl methyl cellulose (CM-cellulose) and TRIZMA® 
hydrochloride were purchased from Sigma-Aldrich Co. (St. Louis, MO).  
Potassium phosphate monobasic, dibasic and sodium acetate (anhydrous) were 
obtained from Mallinckrodt Baker, Inc. (Paris, Kentucky).  Tris base was 
purchased from Bio-Rad Laboratories (Hercules, CA).  Protein concentrations 
were determined using the Pierce BCA Protein Assay Kit with bovine serum 
albumin (BSA) as the reference standard. Bond Elut solid phase extraction 
cartridges (SPE, RP-C18) were obtained from Varian Inc (Palo Alto, CA).  
Human liver microsomes (HLMs) (20 mg/mL) were purchased from BD 
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Biosciences (Franklin Lakes, NJ) (pools of 33), and human plasma (K2-EDTA 
treated) was obtained from Valley Biomedical, Inc (Winchester, Virginia).   
 
HPLC-UV Analysis 
Analysis by reversed phase HPLC utilized a HP 1050 LC equipped with a 
autosampler and an Axxiom (Moorpark, CA) C18 (15cm length, 4.6 mm 
diameter, 5 μ particle size, 100 Ǻ pore size) column, with an HP 1100 series UV 
detector set at 250 nm.  Data analysis was performed with a Chemstation 
(A.05.01, Agilent Technologies, Santa Clara, CA).  The HPLC method was 
adopted from an earlier protocol with some modifications (Wiwattanawongsa et 
al., 2001).  The mobile phase was 52% methanol/48% (0.1% formic acid (FA)) 
under isocratic conditions at a 1.0 mL/min flow rate over 24 minutes.  Stability 
experiments and pharmacokinetic analyses were conducted several different 
times over a period of weeks with small variations (<20%) in both standard error 
and stability calculations. 
 
LC-MS Conditions 
 Analysis by reversed phase LC-MS was adopted from a previous method 
using an HP 1100 series LC system and autosampler coupled to a single 
quadrapole mass spectrometer (Sciex API 100, MDS Sciex, Concord, CA)  
(Stern et al., 2007).  A Zorbax RX-C8 column (Agilent Technologies, Palo Alto, 
CA) (15 cm, 2.1 mm, 5 μ particle size) was run under gradient conditions utilizing 
acetonitrile (sovent B) and 0.1% HOAc (solvent A) mobile phase.  Linear gradient 
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conditions used were, 0 minutes, 20%B; 7 minutes, 90% B; 10 minutes, 90% B; 
11 minutes, 20% B; 15 minutes, 20% B.  Data analysis was performed by Analyst 
1.4.2 (build 1236) (Applied Biosystems, Foster City, CA).   
 
Stability Experiments in Phosphate Buffer 
Concentrations of sodium phosphate monobasic and dibasic solutions (0.1 
M) were used for pH 4, pH 7.4 and pH 9 buffers.  AcMPAG (Roche) was added 
to 50:50 ACN/0.1% HOAc (pH 3) to provide a 1 mg/mL stock and stored at -20ºC 
prior to analysis.  AcMPAG solution (75 μL, 0.1 mg/mL) was first diluted from the 
1 mg/mL stock using HPLC water then added to microcentrifuge tubes and 
brought to 0.2 mL with 150 mM phosphate buffer and incubated at 37ºC in 
duplicate.  At 0, 30, 60, 120, 240, 480, 720 and 1440 minutes, a 10μL aliquot was 
extracted and, either quenched with 800 μL of acidified acetonitrile (0.5% FA, pH 
3.2), or hydrolyzed with 10 μL of β-glucuronidase solution (final dilution of 100 
U/μL in pH 5 acetate buffer) for four hours.  Following quenching of either the 
incubated or hydrolyzed acMPAG, samples were centrifuged at 15,000g for 10 
minutes at 4ºC and dried under nitrogen.  Samples were then reconstituted with 
0.15mL of MeOH/0.1% FA (25:75) and suprofen internal standard (2 μg/mL final 
concentration) and injected for HPLC analysis.    
 
AcMPAG Stability in Plasma 
 Stability studies in plasma were processed using the same sample 
preparation protocol described in the previous section.  AcMPAG diluted stock 
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(0.1 mg/mL) was added to either human plasma (K2-EDTA treated) at 
physiological pH or plasma acidified with HOAc (pH 4), providing a final 
concentration of 40 μg/mL.  During incubation, samples (in duplicate) were 
obtained and prepared as indicated in the buffer experiments.  Samples were 
centrifuged again at 15,000g for 15 minutes at 4ºC, and the supernatant was 
extracted and dried under nitrogen gas.  After evaporation to dryness, samples 
were reconstituted with MeOH/0.1% FA (25:75) and injected onto the HPLC-UV.   
 
Stability in Human Liver Microsomes 
 HLMs (1 mg/mL) were prepared in 100 mM Tris buffer (pH 7.7) and 
incubated on ice for 10 minutes with 100 mM MgCl2 and alamethicin (20 μg/mL) 
and either tris buffer (control), PMSF (2 μM), D-SL (0.8 mM) or both PMSF and 
DS-L in duplicate in buffer.  The reaction was initiated with an aliquot of acMPAG 
(40 μg/mL final concentration, Roche) and incubated at 37°C in duplicate.  At 0, 
15, 30, 60 and 120 minutes, a 10µL aliquot was extracted and either hydrolyzed 
with β-glucuronidase (100 U/μL) or quenched with acidified ACN.  Following 
quenching, samples were then centrifuged, dried and reconstituted prior to 
HPLC-UV analysis.   
 
Covalent Binding of acMPAG in HSA 
 Covalent binding experiments were carried out under protocols that have 
been previously reported (Smith et al., 1993; Liu et al., 1996).  HSA fraction V 
was dissolved in phosphate buffer (pH 7.4, 150 mM) to 30 mg/mL and then 
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combined with acMPAG to obtain 50 μg/mL for incubation.  The mixture was 
incubated at 37ºC for 24 hours, and 0.1 mL aliquots were obtained in triplicate at 
0, 30, 60, 120, 240, 480, 720 and 1440 minutes and immediately quenched with 
1 mL isopropanol/43% phosphoric acid (50:1).  MPA was similarly incubated in 
duplicate in HSA fraction V to serve as a control.  Samples were centrifuged and 
the precipitated protein pellet was washed 10X with methanol/diethyl ether (3:1).  
After washing, the pellets were spiked with suprofen internal standard (0.4 
mg/mL in solution) and dissolved in 1 mL 0.2 M NaOH, followed by three hour 
incubation at 37ºC to hydrolyze and release covalently-bound acMPAG to form 
MPA.  To confirm MPA stability against extreme acidic or basic treatment, MPA 
was incubated with aqueous 0.1 M NaOH or 0.1 M HCl over 8 hours and its 
content monitored by HPLC.  Following hydrolysis, concentrated phosphoric acid 
was added to adjust the pH to approximately 2.  Samples were then purified by 
SPE.  Following conditioning, samples were added to SPE tubes, followed by a 
wash with MeOH/0.1% FA (20:80), and then eluted with of ACN/0.1% FA (80:20).  
The eluents were dried under nitrogen, reconstituted in MeOH/0.1% FA (25:75), 
and injected for HPLC analysis.  Chromatographic conditions were the same as 
previously described with the exception of the mobile phase (60% MeOH/40% 
0.1% FA).  Run time was ten minutes with retention times of 5.5 and 7.5 minutes 
for suprofen and MPA, respectively. 
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Animals 
Male Wistar rats (250-300 g) were purchased from Charles River 
laboratories (Wilmington, MA) and housed under a 12 hour-light dark cycle. 
Experimental methods were approved by the Institutional Animal Care and Use 
Committee (IACUC) and the Division of Lab Animal Medicine (UNC-Chapel Hill).  
Animals were acclimated for one week prior to experimentation.  Male rats (n=3) 
were administered a single bolus 2.5 mg/kg AcMPAG (in MPA equivalents) dose 
intravenously in 5% isotonic dextrose solution or IV with 50 mg/kg MMF in a 5% 
isotonic dextrose solution (6 mg/mL).  Blood was collected from the tail vein in 
0.1-0.2 mL aliquots into microcentrifuge tubes at 2, 5, 10, 15, 20, 30, 60, 120, 
180, 240, 360 and 480 minutes post IV dosing and 0, 15, 30, 60, 120, 180, 240, 
360 and 480 minutes post MMF dosing, placed on ice, and centrifuged at 
15,000g for 10 minutes.  Following centrifugation, plasma was transferred into 
microcentrifuge tubes containing acetic acid (HOAc) (pH 3, 5μL/mL) to stabilize 
acMPAG at pH~4 and stored at -20ºC until analysis.  For quantitative analysis, 
50 μL of plasma was precipitated with 300 μL of acetonitrile containing 5 μL of 
0.1mg/mL suprofen internal standard and centrifuged, dried under nitrogen and 
reconstituted in methanol/0.1% formic acid (25:75) for HPLC injection.  
Noncompartmental pharmacokinetic estimates were obtained using WinNonlin 
5.0.1 (Pharsight, Cary, NC).  Individual pharmacokinetic estimates for each rat 
were calculated based on plasma concentration data using noncompartmental 
pharmacokinetics on WinNonline and averaged (n=3) to generate parameter 
estimates. 
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C. RESULTS 
 
AcMPAG Purity 
 Initial HPLC analysis of both the Novartis and Roche acMPAG products 
revealed an additional peak eluting as a shoulder just prior to the acMPAG peak 
(Figure 2.1).  After β-glucuronidase treatment, the first peak remained and was 
later confirmed through mass spectrometry (Figure 2.2) to be a putative isomeric 
conjugate impurity of the initial acMPAG sample.  This peak was consistently 
seen throughout all stability testing and indicated that the initial samples provided 
by both the Roche and Novartis pharmaceutical companies consisted of 82% β-1 
acMPAG and 18% isomeric conjugates that are resistant to β-glucuronidase. 
 
Isomeric Conjugate Content 
 Prior to stability testing, the time dependant β-glucuronidase (1000 U/mL) 
treatment was evaluated at 2, 4 and 6 hours to determine the optimal duration of 
hydrolysis.    At two hours, there was still a significant fraction of β-1 conjugate 
that was not cleaved by β-glucuronidase, but at four and six hours, there was no 
detectable β-1 conjugate present at Rt=10.2 minutes.  Furthermore, there was no 
difference in isomeric conjugate impurity seen at Rt=9.4 minutes between the 
four and six hour treatments (18.2% at four hours, 18.5% at six hours, p=0.88, 
data not shown).  Based on these results, four hours of β-glucuronidase 
treatment was used for the subsequent stability testing in phosphate buffer and 
biological matrices. 
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Stability Experiments 
 The buffer stability experiments with acMPAG consistently showed a pH 
dependant acyl migration and hydrolysis.  While acMPAG was very stable 
through 24 hours at pH 4, all three pH conditions demonstrated a noticeable 
product loss following the first hour of incubation (Figure 2.3).  This pattern was 
seen most dramatically at pH 7.4 which demonstrated a much steeper rate of 
decline in the first 120 minutes of incubation compared to the remaining 
incubation time period up to 24 hours.  The t1/2 of 18.1 hours (Table 2.1) indicates 
that acMPAG is a moderately stable acyl glucuronide in protein free buffer under 
physiological conditions.  Comparatively, acyl glucuronides from drugs removed 
from the market such as zomepirac (t1/2 0.5 hours) and benoxaprofen acyl 
glucuronide (t1/2 1.4 hours) are much less stable under similar conditions 
(Hasegawa et al., 1982; Dong et al., 2005). 
 Relative to buffer, acMPAG demonstrated a similar yet more rapid pattern 
of decline in human plasma under both physiological (pH 7.4) and acidic (pH 4) 
conditions (Figure 2.4).  The mildly acidic condition stabilized acMPAG compared 
to physiological pH through 24 hours, but continued to display the biphasic 
decline seen in the phosphate buffer experiments (Figure 2.3).  In human 
plasma, the t1/2 was 6.7 hours, but there were no significant differences in 
isomeric rearrangement.  It is likely that the presence of esterases within the 
human plasma caused acMPAG hydrolysis to increase dramatically as compared 
with protein free phosphate buffer. 
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 Within HLMs, the initial β-1 acyl glucuronide of acMPAG maintained a 
similar pattern of degradation as seen in both the buffer and plasma experiments 
(Figure 2.5).  After an initial period of rearrangement and hydrolysis, acMPAG 
was somewhat stabilized with the inhibitors PMSF and D-SL but continued its 
decline more rapidly compared to both the buffer and plasma experiments.  
Interestingly, while the decline of the β-1 conjugate was more rapid in HLM than 
occurs with the addition of one or two protease inhibitors, the relative 
concentration of isomeric conjugates remained steady throughout the incubation 
period in all four conditions employed with HLM (Figure 2.5).  Since HLMs have 
high concentrations of esterases, cleavage back to the parent aglycone was 
more extensive in the control HLM samples compared to HLM samples with a 
thirty minute pre-incubation period with inhibitors.  As expected, the t1/2 
associated with the HLM incubation (2.6 h) was the shortest of the three 
physiological in vitro conditions tested (Table 2.1). 
 
Covalent Binding of acMPAG to HSA 
 Covalent binding in HSA in vitro was examined to evaluate the reactivity of 
acMPAG and its potential to form drug-protein adducts in vivo.  Hydrolysis of 
MPA bound (either as MPA or via isomeric acMPAG) was performed with 0.2 M 
NaOH at 37ºC.  Preliminary experiments indicated <4% loss of MPA over an 8 
hour incubation in 0.2 M NaOH (data not shown).  Covalent binding to HSA 
levels was below detection limits (<0.35 ng/mg HSA) through the first hour of 
incubation.  During the incubation period, the formation of acMPAG dependent 
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HSA adducts was minimal and lower than that reported for ibuprofen acyl 
glucuronide and almost ten fold lower than that reported for reactive ibufenac 
acyl glucuronide under the same experimental conditions (Figure 2.6, Castillo et 
al. 1995).  These data indicates that acMPAG is a fairly nonreactive acyl 
glucuronide with a low propensity for rapid accumulation of drug-protein adducts 
within the systemic circulation and tissues in vivo.   
 
AcMPAG Disposition in a Rat 
 Three male Wistar rats were dosed intravenously with 2.5 mg/kg acMPAG 
to obtain AUC and Cl estimates.  The plasma concentration profile demonstrated 
that the metabolite is rapidly cleared after IV administration, with hydrolysis being 
the primary route of loss for acMPAG.  After a 2.5 mg/kg dose (based on MPA 
equivalents), the average AUC(acMPAG)0-∞ was 1.4 mg*min/mL with the average 
parent aglycone AUC (MPA)0-∞ is 0.2 mg*min/mL (Table 2.2).  IV dosing of MMF 50 
mg/kg (based on MPA equivalents) resulted in an AUC (MPA)0-∞ of 2.9 mg/mL*min.  
Data from the IV MMF and IV acMPAG dosing to rats were used to estimate the 
MPA fraction converted from acMPAG (FacMPAG        MPA) as 0.88.  This extent of 
hydrolytic conversion indicates extensive cleavage of acMPAG back to the MPA 
aglycone, with the remaining metabolite excreted likely through the urine or bile.  
None of the rats administered a single dose of acMPAG demonstrated any signs 
of overt toxicity during the course of the experiments. 
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D.  DISCUSSION 
A few attempts have been made previously to study the stability of the 
acMPAG metabolite of MPA.  The results of these reports were ambiguous 
(Wieland et al., 2000; Shipkova et al., 1999; Shipkova et al., 2000; de Loor et al., 
2008).  We therefore sought to provide a comprehensive investigation into 
acMPAG stability using various physiological conditions that may be responsible 
for the previously reported results that were inconsistent.  Our first observation 
was that the chromatographs from both the HPLC-UV and LC-MS experiments 
indicate a significant amount of impurity is present within the samples of 
acMPAG obtained from both pharmaceutical companies prior to stability testing, 
indicating the presence of the isomeric conjugates.  It is likely that, during the 
overnight incubation process of liver microsomes with MPA used to generate the 
acMPAG metabolites, the samples underwent significant acyl migration 
(Kittelmann et al., 2003). In each of our stability experiments, there was an 
immediate loss of initial β-1 acyl glucuronide (prior to the terminal phase 
degradation period) that existed under all conditions tested.  It has been 
previously reported that while acMPAG metabolites are stable when stored in 
acidic conditions at -20ºC, this metabolite undergoes hydrolysis and 
rearrangement under some experimental settings (Shipkova et al., 1999; 
Shipkova et al., 2000, de Loor et al., 2008).  These setting include incubations in 
both plasma and phosphate buffer at both room temperature and under 
refridgeration (Shipkova et al., 2000, de Loor et al., 2008).  Our studies here 
confirm these findings and show that the primary differences in acMPAG stability 
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is that it decreases when progressing from protein-free conditions to an intact in 
vivo system. 
 The decreases in stability of acMPAG demonstrated from the 
physiological phosphate buffer incubations compared to human plasma indicate 
that the plasma protein matrix itself destabilizes the acyl glucuronide.  While the 
rates of isomeric rearrangement remain consistent between the two matrices, the 
rate of hydrolysis increases dramatically in human plasma and is responsible for 
the reduced t1/2s calculated using the concentration time plots (Figures 2.3 and 
2.4).  Esterase cleavage of acMPAG responsible for increased MPA 
concentration could also be a source for the efficacy of the acMPAG metabolite 
reported by Shipkova et al. for an in vitro assay (Shipkova et al., 2001).  
Esterases are readily present within mononuclear leukocytes and an incubation 
period of 96 hours at 37ºC could cause a significant contamination of the parent 
MPA aglycone, resulting in inhibited leukocyte proliferation (Shipkova et al., 
2001).   
 Of the three in vitro matrices chosen for this study (buffer, plasma, HLM), 
the acMPAG metabolite was found to be the least stable within the HLM matrix.  
This is likely due to not only the presence of a significant amount of esterase 
activity within the HLM but also because of β-glucuronidase enzymes within the 
liver microsomes.  The actions of these enzymes was confirmed following the 
addition of the two different inhibitors to the HLM cocktail, which decreased the 
degradation rate with the HLMs individually, but were most effective when 
combined.  PMSF is a nonspecific protease inhibitor that can be used for liver or 
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intestinal microsome preparations to prevent loss of enzyme activity (Dutton, 
1980).   
 The putative toxicity of acyl glucuronides has continued to be a source of 
investigation primarily due to the large number of nonsteroidal anti-inflammatory 
drugs (NSAIDs) forming acyl glucuronide metabolites that have been removed 
from the market because of adverse drug reactions (ADRs) (Dickinson, 1993; 
Bailey and Dickinson, 2003).  Acyl glucuronide metabolites are unique when 
compared to other glucuronides because they undergo esterase cleavage back 
to the parent aglycone and they also form isomeric conjugates through acyl 
migration (Faed, 1984).  Acyl migration results from the intraconversion of the 1-
O-β acyl glucuronide into 2-O-β, 3-O-β, 4-O-β or α isomeric conjugates and 
unlike the parent 1-O-β conjugate, they are resistant to β-glucuronidase 
hydrolysis (Sinclair, 1982; Faed, 1984).  Isomeric conjugates observed for 
numerous NSAIDs have shown the ability to bind to both plasma and liver 
proteins such as tubulin and albumin; primarily through the nucleophilic 
displacement or Schiff base mechanisms, leading to the formation of drug-protein 
adducts (Smith et al., 1990; Smith et al., 1992).  It has been hypothesized that 
these drug-protein adducts could disrupt cellular function such as seen in 
dipeptidyl peptidase IV (DPP-IV) adducts with diflunisal (King and Dickinson, 
1993; Bailey and Dickinson, 2003).  In addition, the binding of tubulin with the 
acyl glucuronides of zomepirac, tolmetin and valproic acid (VPA) may lead to the 
inhibition of hepatocyte function and subsequent liver toxicity (Bailey et al., 1998; 
Bailey and Dickinson, 2003; Cannell et al., 2003).  Many NSAIDs that form 
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unstable acyl glucuronides undergoing rapid acyl migration in phosphate buffer 
under physiological conditions have been removed from the market primarily 
because of extensive hypersensitivity reactions or hepatotoxicity (Bailey and 
Dickinson, 2003).  However, other drugs such as VPA form very stable 
glucuronide metabolites and continue to enjoy a steady market share despite 
being blamed for over 100 deaths from adverse drug reactions. 
 A common comparison of acyl glucuronide stability is the half life of the 
glucuronide in pH 7.4 phosphate buffer (100 or 150 mM) at 37°C.  Drugs forming 
unstable glucuronides including zomepirac (t1/2 0.5 hours) and suprofen (t1/2 0.7 
hours) not only have been removed from the market due to not only 
hepatotoxicity but also have shown the ability to form drug-protein adducts with 
both liver and plasma proteins (Spahn-Langguth et al., 1992; Smith et al., 1993; 
Bailey et al., 1998).  Even for these compounds, it has become difficult to directly 
link the formation of these adducts with either hypersensitivity reactions or as 
sources of drug toxicity, but it is possible that a rapid buildup in drug-protein 
adducts in vivo could disrupt cellular function in either the liver or result in 
lymphocyte sensitization as seen with diflunisal-albumin adducts in rats (King 
and Dickinson, 1993; Worrall and Dickinson, 1995).  
 While stability in phosphate buffer is seen as the standard means of 
comparison for acyl glucuronide reactivity, the ability to bind and form covalent 
drug-protein adducts is more physiologically relevant.  One consistent pattern 
seen with acyl glucuronides is the inverse relationship between acyl glucuronide 
t1/2 in phosphate buffer and the number of covalent adducts (mol carboxylate/mol 
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protein) formed by these same conjugates (Spahn-Langguth et al., 1992).  This 
pattern is seen with reactive glucuronides (zomepirac/tolmetin), as well as stable 
acyl glucuronides (beclobric acid and VPA), for two reasons.  The first is that 
unstable acyl glucuronides are more likely to form isomeric conjugates that are 
more readily able to form drug-protein adducts through both the imine 
mechanism and the transacylation mechanism (Smith et al., 1990, Spahn-
Langguth et al., 1992).  However, the parent O-β-1 acyl glucuronide can only 
form these same adducts through the transacylation mechanism (Spahn-
Langguth et al., 1992).  Furthermore, isomeric conjugates are resistant to 
cleavage by β-glucuronidase enzymes, which can lengthen their in vivo 
residence time, along with their exposure to liver and plasma proteins (Faed, 
1984; Spahn-Langguth et al., 1992).  The t1/2 of acMPAG of 18.1 hours within 
phosphate buffer indicates that it is a fairly stable acyl glucuronide, which would 
be unlikely to rapidly form isomeric conjugates and drug-protein adducts in vivo.  
This was supported by the covalent binding studies where the highest level of 
drug-protein adduct formation (1.2 mmol MPA/mol protein, Figure 2.6) was a 
fraction of that seen in a similar incubations of ibuprofen (IBP) (6 mmol IBP/mol 
HSA), which is considered a stable and less reactive acyl glucuronide (Castillo et 
al., 1995).  However, even though beclobric acid is moderately stable in 
phosphate buffer and may be classified as a fairly unreactive acyl glucuronide, it 
was still removed from the market in 1992 due to extensive hepatotoxicity 
(Spahn-Langguth et al., 1992; Mayer et al., 1993).  
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 While it has been shown that plasma protein adducts formed by diflusinal 
are readily immunogenic when administered to rats, this same reaction was not 
seen with naproxen, an NSAID that is still available as an over-the-counter 
medication (King and Dickinson, 1993; Worrall and Dickinson, 1995).  This 
variety of potential immunogenic and hepatotoxic reactions to these drug protein 
adducts remains a contentious debate today because it encompasses not only 
reactive acyl glucuronides but also reactive acyl-CoA metabolites among other 
reactive intermediates that could lead to drug toxicity of carboxylic acids 
(Boelsterli, 2002).  Because of this, it is difficult to classify whether the drug-
protein adducts formed by acMPAG that have been found in both the liver and 
colonic tissue could be a pattern of toxicity or a harmless secondary effect also 
seen with aspirin and ibuprofen (Dickinson, 1993; Dickinson et al., 1994; Castillo 
et al., 1995). However, due to the stability of acMPAG under standard in vitro 
conditions, coupled with its low levels of covalent binding in vitro, indicate that the 
reactivity of acMPAG is probably an insignificant factor in MPA side effects.   
  One potential effect of these adducts and of unstable acyl glucuronides is 
the presence of either immunogenic reactions or hepatoxicity.  Outside of a small 
amount of isolated cases where a brief elevation of serum transaminases were 
seen in the reported clinical chemistry of two tested patients administered MMF 
for treatment of atopic dermatitis, there have been no literature reports of 
significant MMF related hepatotoxicity (Hantash and Fiorentino, 2006; Morath et 
al., 2006; Zwerner and Fiorentino, 2007).  In addition, while elevated cytokines 
have been seen with in vitro incubations of acMPAG, MPA continues to be a 
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primary standard used for preventing immunogenic reactions along with 
prevention of renal allograft and hepatic allograft rejection (Davies et al., 2007; 
Heller et al., 2007; Staatz and Tett, 2007; Zwerner et al., 2007).  As of this report, 
no renal toxicity or autoimmune disorders have developed as a consequence to 
MPA administration, either on a short-term or long-term dosing regimen. 
 The primary side effect of MMF administration besides an increased 
infection rate, which is commonly seen in patients on any form of long-term 
immunosuppressive therapy, is the presence of delayed-onset diarrhea (Hantash 
and Fiorentino, 2006; Morath et al., 2006; Zwerner and Fiorentino, 2007).  A 
recent attempt at linking these side effects with either a direct increase or 
decrease in acMPAG blood levels was inconclusive (Heller et al., 2007).  An 
alternative theory for the mechanism of delayed onset diarrhea could be due to 
the actions of MPA itself.  MPA is designed to inhibit the IMPDH enzyme type II 
to prevent purine synthesis, leading to lymphocyte proliferation, and thus modify 
the response to either an extensive autoimmune reaction or allograft rejection 
(Young and Sollinger, 1994).  However, because lymphocytes rely on the de 
novo purine synthesis pathway utilizing the IMPDH enzyme to synthesize purine 
nucleotides as opposed to the salvage pathway, lymphocyte proliferation is 
inhibited in patients on MPA therapy.  Lymphocyte cytotoxicity is also seen in in 
vitro cultures of lymphocytes treated with MPA because of this same mechanism 
(Allison and Eugui, 1994).  Numerous other cell types, including enterocytes, rely 
on this pathway for proliferation through the IMPDH type I enzyme.  Prolonged 
exposure to MPA seen in transplant patients on extended MMF/MPA therapy 
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could result in a consistent exposure to high local concentrations of MPA within 
the intestinal lumen through the actions of the gut flora producing β-
glucuronidase enzymes.  The fraction of acMPAG cleaved to MPA in the 
systemic circulation of rats, to 0.88, indicates that a large portion of acMPAG 
formed and effluxed into the blood is hydrolyzed back into the parent aglycone.  
Efficient hydrolysis in vivo is supported by the large amount of β-glucuronidase 
and esterase hydrolysis displayed in the HLM incubations along with the 
significant hydrolysis within the plasma (Figure 2.4 and 2.5).  AcMPAG could 
serve as a secondary source of MPA within the systemic circulation and intestinal 
lumen, which over time could be a factor in MPA intestinal toxicity, even if the 
metabolite itself is not proven to be the source of drug toxicity.    
 In conclusion, the data presented here indicate that acMPAG is a fairly 
stable acyl glucuronide with low relative reactivity compared to other metabolites 
of this type.  It is a labile metabolite in the systemic circulation and minor 
metabolite in plasma and bile, thus there is little evidence to support this 
metabolite as a likely reactive metabolite to be associated with the adverse drug 
reactions of MPA. 
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Figure 2.1.  HPLC-UV chromatogram of 0.1 mg/mL acMPAG solution before 
(top) and after (bottom) β-glucuronidase treatment.  Retention times as indicated 
for isomeric conjugates (9 min), AcMPAG (10 min), suprofen (14 min), and MPA 
(22.5 min). 
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Figure 2.2.  LC-MS selected ion chromatogram of AZT (266 m/z, 2.6 min), 
Isomeric Conjugates (495 m/z, 7.2 min), AcMPAG (495 m/z, 7.2 min) and MPA 
(319 m/z, 8.5 min) both before (top) and after (bottom) β-glucuronidase treatment 
for four hours. 
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Figure 2.3.  Stability of acMPAG (■) in aqueous buffer performed at pH 4 (top), 
pH 7.4 (middle) and pH 9 (bottom).  Fractions were averaged from experiments 
run in duplicate (variation between samples <25%).  Degradation to isomeric 
conjugates of acMPAG (   ) and MPA (▲) are shown. 
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Figure 2.4.  Stability and degradation of acMPAG (■) to isomeric conjugates (   ) 
and MPA (▲) is shown in human plasma at pH 4 (top) and physiological pH 
(bottom) for 0.1 mg/mL acMPAG.  Fractions were averaged from experiments 
run in duplicate (variation <25%).  
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Figure 2.5.  AcMPAG (■) stability in HLM when incubated under control 
conditions (top left), HLM with DS-L inhibitor (0.8 mM, bottom left), HLM with 
PMSF (2 mM, top right) and HLM with both inhibitors added (bottom right).  
Fractions were averaged from experiments run in duplicate (variation <30%).  
Degradation to isomeric conjugates of acMPAG (   ) and MPA (▲) are shown.   
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Figure 2.6.  Covalent binding of acMPAG to HSA over a 24 hour incubation 
period when incubated with 0.67 mM acMPAG.  Binding was measured following 
cleavage of bound acMPAG to MPA.  Data is presented as mean ± SD (n=3). 
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Figure 2.7.  Mean plasma concentrations of acMPAG (■) and MPA (▲) (in MPA 
equivalents of μg/mL) for male Wistar rats (n=3) following a 2.5 mg/kg IV dose of 
acMPAG (Roche).  Data is presented as mean ± SD. 
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Table 2.1.  Half life values of acMPAG in various matrices. 
Condition k (h -1) t1/2 (h) 
pH 4 Buffer 0.01 >100b 
pH 7.4 Buffer 0.04 18.1 
pH 9 Buffer 0.18 3.8 
Human Plasma 0.10 6.7 
Human Liver Microsomes 0.27 2.6 
In vivo IV injection c 1.37 0.5 
aFirst order half-life estimated by terminal log-linear decline (>3 data points) 
bListed as >100 hours due to insufficient terminal end phase data through 24 hours. 
cValue in male Wistar rats  
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Table 2.2   Noncompartmental pharmacokinetic estimates obtained following 2.5 
mg/kg IV injection of acMPAG (in MPA equivalents) in a 5% dextrose solution in 
male Wistar rats (n=3). 
 
AUCacMPAG0-∞ 
(mg/mL*min) 
1.3 ±0.2   
AUCMPA0-∞  
(mg/mL*min) 
0.28 ± 0.03  
FacMPAG         MPA 0.88 
CLacMPAG (ml/min) 2.0 ± 0.3  
Terminal t1/2 (min) 26.1  
Vss-acMPAG (mL) 19.6 ± 2.5  
*VMPA (mL) 254.3 ± 31.3  
*VMPA was obtained following administration of 50 mg/kg MMF IV to male Wistar 
rats (n=3) (See Chapter 4) 
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CHAPTER 3 
 
QUANTIFICATION OF UDP-GLUCURONOSYLTRANSFERASE ENZYME 
EXPRESSION LEVELS WITHIN HUMAN LIVER, INTESTINAL AND KIDNEY 
MICROSOMES USING nanoLC TANDEM MASS SPECTROMETRY 
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A. INTRODUCTION 
 
 UGT enzymes catalyze the formation of glucuronide conjugates of Phase 
II metabolism.  Through the actions of the cofactor uridine disphosphate 
glucuronide acid (UDPGa) and UGT enzymes, glucuronidation encompasses the 
most common and clinically important of the Phase II metabolic pathways.  In 
humans, the UGT genome consists of two families and three subfamilies.  The 
UGT1A locus found on chromosome 2q37 encodes for nine functional enzymes 
located throughout the body and is responsible for converting a large number of 
endogenous and exogenous compounds to more hydrophilic conjugates, 
ultimately for excretion outside the body (Owens and Ritter, 1995).  Traditional 
quantification methods have been used to evaluate relative hUGT levels 
including Western blots, ELISA and RT-PCR studies, but these methods lack the 
sensitivity, reproducibility and dynamic range to properly examine expression.  
Furthermore, the correlation between mRNA levels measured using RT-PCR and 
protein expression is often poor, making these methods unreliable for evaluation 
of protein expression in biological systems (Izukawa et al., 2009).  In addition, the 
high degree of sequence homology between hUGT enzymes (as high as 94% in 
some isoforms) prevents the raising of antibodies against specific UGT isoforms, 
with few exceptions (Tukey et al., 2000).   
 Traditional approaches to protein quantification include differential gel 
electrophoresis (DIGE) which involves separation through 2D-gel electrophoresis 
followed by fluorescent tagging of lysine side chains (Bantscheff et al., 2007).  
While multiple proteins may be monitored through the DIGE technique through 
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the use of alternate fluorescent tags, it is often difficult to distinguish high and low 
molecular weight proteins, and DIGE often lacks the sensitivity to detect low 
abundant proteins (Wu et al., 2006).  In recent years, advances in electrospray 
ionization (ESI), coupled with sensitive tandem mass spectrometry (MS/MS), has 
allowed for the development of several different approaches at relative 
quantification of proteins.   Methods for relative protein quantification within cells 
include in vivo metabolic labeling within enriched media (C13, N15, O18), followed 
by digestion and quantification of labeled peptides to evaluate changing 
expression of proteins of interest (Beynon et al., 2005; Gu et al., 2004; Hsu et al.,  
2005; Huttlin et al., 2009).  These methods have been used to determine 
expression changes in myoglobins, immune response, HIV levels, glycoproteins 
and mitochondrial proteins.  Recently, label-free techniques have also been used 
that can evaluate global expression changes, but these methods are not 
commonly employed due to variability across instrumentation platforms and ion 
suppression from complex matrices (Bantscheff et al., 2007).   
 Along with the use of capillary LC-MS/MS for relative quantification for 
global proteomics, stable isotope internal standards also have been developed 
for targeted absolute quantitative proteomics.  Labeling techniques such as ICAT 
and iTRAQ can be utilized for relative quantification or for absolute quantification 
if a known amount of targeted peptide is added during sample preparation (Gygi 
et al., 1999; Hardt et al., 2005; Jenkins et al., 2006; Zieske et al., 2006).  
However, because ICAT reagents only target peptide with cysteine groups, the 
number of potential targeted peptides is limited (Wu et al., 2006).  Furthermore, 
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iTRAQ methods can encounter difficulties in precursor ion selection in complex 
matrices (Wu et al., 2006).   Although both ICAT and iTRAQ methods have 
greatly increased sensitivity and selectivity of peptide/protein analysis when 
compared with gel based methods further improvement and more general 
approaches are being developed (Wu et al., 2006). 
 Other approaches using stable isotope labels have had more recent 
success with quantifying proteins and peptides.  Barr et al. were able to 
accurately quantify apolipoprotein A-1 using unique heavy-labeled peptides (Barr 
et al., 1996).  Following these initial experiments, both C-reactive protein (CRP) 
and PSA were quantified within human plasma by preselecting heavy        
isotope-labeled internal standards added prior to a tryptic protein digestion 
(Barnidge et al., 2004; Kuhn et al., 2004).  Using sensitive capillary LC coupled 
with MS/MS, it was found that using isotope dilution mass spectrometry, the 
concentration levels of PSA and CRP were comparable to immunoassay with 
lower detection limits (Barnidge et al., 2004; Kuhn et al., 2004).  These methods 
fostered the development of stable isotope labeling with amino acids in cell 
culture (SILAC), absolute quantification (AQUA) and Quantitative Concatamer 
(QCAT) stable isotope standards and have been applied more recently for 
determining gonadotropin releasing hormone (GnRH) across different MS 
platforms (Thomas et al., 2008).  While QCAT standards require development of 
recombinant protein expression in cell lines to produce heavy labeled internal 
standard proteins for quantification, heavy isotope-labeled peptides can be 
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readily prepared following preselection using standard peptide synthesis 
methods.   
 The continued development of quantitative proteomics is significant for 
biological scientists interested in understanding precise levels of protein 
expression.  By being able to precisely quantify enzymes involved in drug 
metabolism, scientists will be better able to describe differences between species 
to evaluate the effects of induction and inhibition, and to provide more accurate in 
vitro and in vivo predictions of drug elimination.  Furthermore, the use of targeted 
absolute quantitative proteomics also may be used for quantification of enzymes 
for which specific antibodies are unavailable and for proteins yet to be 
discovered.  These techniques will continue to open new avenues for drug 
metabolism studies that will now be able to directly establish relationships 
between enzymes and metabolite levels. 
 While capillary LC connected to triple quadrupole tandem MS is common 
instrumentation for MRM quantification, other platforms have been successfully 
implemented for these purposes.  LC-MS/MS has been applied using quadrupole 
time of flight mass spectrometry (Q-TOF) for both metabolite detection and 
peptide quantification (Jeanville et al., 2000; Spaulding et al., 2006).  In addition, 
a new MS platform that couples capillary LC to a linear ion trap time of flight 
mass spectrometer (LIT-TOF) from Hitachi Hi-Technologies has been utilized for 
both qualitative and quantitative mass spectrometry (Deguchi et al., 2007; Ito H 
et al., 2006; Ito S et al., 2008).   Most recently, Ito et al. were able to successfully 
quantify a novel glycosylated phospholipid and demonstrate that the LIT-TOF 
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platform was not only very sensitive, but also has a dynamic range approaching 
three orders of magnitude (Ito S et al., 2008).   
 We have previously demonstrated the utility of quantifying hUGTs using 
stable isotope standards and tandem MS (Fallon et al., 2008).  While this method 
was successfully applied for quantification of two of the nine active human UGT 
isoforms, it is necessary to extend this method for the remaining hUGT1A 
isoforms to not only better examine the relationship within and across species, 
but to also be able to quantify other UGT1A isoforms that lack a specific 
antibodies.  By taking advantage of the increased sensitivity offered by capillary 
LC compared to standard bore HPLC and extending the LC gradient for better 
separation of labeled and unlabeled peptides, we will be able to selectively 
quantify all hUGT1As in a single chromatographic run.  Here we present a 
method to quantify the entire hUGT1A proteome of nine active UGTs using 
capillary LC coupled to a LIT-TOF mass spectrometer using the extracted MRM 
mode. 
B.  METHODS 
Materials 
 Analytical grade acetonitrile and methyl alcohol (anhydrous) were 
purchased from Fisher Scientific Co. (Pittsburg, PA). Ammonium bicarbonate, 
dithiothreitol, iodoacetamide, ammonium hydroxide, formic acid, 2,2,2-
trifluoroethanol (TFE) and TPCK (L-1-tosylamido-2-phenylethyl chloromethyl 
ketone) treated trypsin from bovine pancreas (≥ 10,000 BAEE units/mg protein) 
were purchased from Sigma-Aldrich Co. (St. Louis, MO). Bond Elut solid phase 
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extraction cartridges (C18 100mg, 1mL) were purchased from Varian, 
Inc. Recombinant UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10 and control 
supersomes were purchased from BD Biosciences (San Jose, CA). Human liver 
microsomes (HLMs) (20 mg/mL) were purchased from BD Biosciences (pool of 
33) and Xenotech LLC (Lenexa, KA) (pool of 50). A human liver microsome 
library of individual donors (n=10, 20 mg/mL) was purchased from Human 
Biologics International (Scottsdale, AZ). Human kidney microsomes were 
purchased from BD Biosciences (pool of 33, 20 mg/mL) and a human intestinal 
microsome library of individual donors (n=3, mixed gender) were graciously 
donated by Dr. Mary Paine (UNC-Chapel Hill, Chapel Hill, NC) (Paine et al., 
2006).  Pooled human intestinal microsomes (HIMs) were obtained from 
Xenotech LLC (Lenexa, KA) (8 donors, mixed gender).  Protein concentrations 
were determined using the Pierce BCA Protein assay Kit, in which bovine serum 
albumin is used as the standard.  
 
Instrumentation 
 Samples were analyzed using capillary LC attached to a linear ion trap 
time of flight (LIT-TOF) mass spectrometer (Hitachi High-Technologies, Tokyo, 
Japan).  The LC column was a monolithic C-18 column (GL Sciences, Tokyo, 
Japan, 150 mm, 0.075 mm ID).  The instrument was operated in positive ion 
mode for multiple reaction monitoring (MRM) analysis.  Data analysis was 
performed using NanoFrontier LD-ECD Data Processing software (Hitachi High 
Technologies, Tokyo, Japan) 
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Stable Isotope Labeled Internal Standards 
Synthetic peptide standards (8-15 mer), each containing one amino acid 
heavy labeled with 13C [98%] and 15N [95%], were purchased from Thermo 
Electron (Thermo Scientific, Waltham, MA) using methods and selection criteria 
as previously reported (Fallon et al., 2008). For each UGT isoform, two unique 
peptides were purchased for analysis and validation. The peptides were selected 
according to manufacturer recommendations and previously published guidelines 
(Beynon et al., 2005; Gerber et al., 2003).  Amino acid sequences for the nine 
UGT1A isoforms were obtained using the Universal Protein Resource Knowledge 
Base (UniProtKB).  Peptide uniqueness of tryptic fragments was verified by NCBI 
Blast (National Center for Biotechnology Information Basic Local Alignment 
Search Tool). Amino acid analysis on each peptide to determine sample purity 
which was conducted at the Center for Structural Biology, Wake Forest 
University School of Medicine, Winston-Salem, NC.  Some amino acids were 
excluded from the analysis because of known acid hydrolysis effects (e.g., bonds 
between isoleucine and valine [peptide 3] are not easily broken) and the possible 
cyclization and isomerization of aspartic acid adjacent to glycine or isoleucine 
(peptides 2 and 3). 
Known variable single nucleotide polymorphisms (SNPs) were also 
considered during peptide selection.  While at the time of purchase there were no 
known interferences with SNPs along the targeted protein sequence, reports 
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indicate that there are potential conflicts due to polymorphisms for UGT1A1 
(Peptide 2, frequency <1%), UGT1A6 (Peptide 4, frequency ~4% in Caucasians) 
and UGT1A7 (Peptide 11, frequency ~2% in African Americans) (Kadakol et al., 
2000; Krishnaswamy et al., 2006; Villeneuve et al., 2007).  Furthermore, while it 
is initially intended to obtain two unique peptides per isoform, the dearth of 
unique peptides for UGT1A8 and UGT1A9 that are amendable to the LC-MS 
approach only provided one unique peptide for these isoforms along with one 
peptide that is shared between the two enzymes.   
 
Sample Preparation 
 Aliquots of 50 µg of microsomal protein, recombinant enzyme or UGT 
control supersomes were denatured and digested as previously reported with 
some modifications (Fallon et al., 2008).  Samples of digested protein matrix with 
heavy labeled peptides added as internal standards, 10 pmol for each peptide, 
excluding peptide 16 and 17, (Table 3.1) and the residual acetonitrile was 
removed by evaporation under nitrogen for ~5 min were then denatured and 
reduced by heating at 95 ºC for 10 min in 5 mM dithiothreitol (sample volume 90 
µL; buffer 50 mM ammonium bicarbonate). This was followed by alkylation with 
100 mM iodoacetamide stock for 20 min in the dark. Samples were dissolved in 
150 µL 50 mM ammonium bicarbonate (volume brought to 150 μL with HPLC 
water); with trypsin enzyme/protein ratio = 1:50; for 4 h at 37 ºC. The reaction 
was then quenched by addition of 50 µL acetonitrile. Following centrifugation at 
1000g for 10 min, the organic content was removed by evaporation under 
nitrogen for ~10 min. An aliquot of 0.9 mL of 50 mM ammonium bicarbonate was 
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then added in preparation for solid phase extraction. SPE cartridges were 
conditioned with methanol and distilled water. Samples were then added and the 
cartridges were washed with 1 mL 10 mM ammonium acetate (pH 3) then eluted 
with acetonitrile/25 mM formic acid (40:60). The eluate was evaporated to 
dryness under nitrogen at 42ºC in a water bath, and samples were reconstituted 
with 250 μL (80:20) acetonitrile/25 mM formic acid at pH 3 (pH was adjusted to 3 
by drop wise addition of ammonium hydroxide) to minimize sample loss from 
glass tubes. Following initial reconstitution, samples were transferred and dried 
under nitrogen at 42 ºC, then reconstituted in 50 μL (15:85) acetonitrile/25 mM 
formic acid at pH 3.  Samples were stored at -20 ºC until analyzed by LC-MS/MS. 
  
MRM Selection 
 All peptide heavy labeled standards were directly infused into the LIT-TOF 
mass spectrometer at a rate of 2 μL/min for MRM and MS optimization.  Upon 
infusion, a vast majority of the peptide standards were doubly charged.  Peptide 
5, 16 and 17, were found to be triply charged or greater and were ultimately 
excluded because of inadequate MRM selection.  For each peptide, two MRMs 
above 500 m/z were selected to be used for quantification.  MRM selections were 
then confirmed following an optimized LC gradient elution of a solution of          
10 pmole aliquots of each selected peptide.  These peptides were then subject to 
MRM spectrum analysis using the LIT-TOF in scanning mode.   
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LC/MS Conditions 
 The mobile phase used for analysis consisted of 25 mM formic acid in 
water (solvent A) and acetonitrile (solvent B).  A NanoFrontier L series (Hitachi-
High Technologies, Tokyo, Japan) using a nano-flow HPLC was coupled to an 
AT10PV nano-flow gradient generator and connected to a LIT-TOF instrument 
with an electrospray ion source (Deguchi et al., 2004).  An Upchurch M-435 
microinjection valve (Upchurch Scientific, Oak Harbor, WA) was used as the 
sample injector (Ito et al. 2008).  A 1 μL injection (approximately 0.5 μg of 
digested protein) was loaded onto a 5 cm trap column (C18, 2.1 mm ID, 5 μ 
particle size) at a rate of 10 μL /min for 4 minutes.  The sample was then 
transferred onto the analytical column and analyzed under the following linear 
gradient conditions, 0 min, 5% B; 30 min, 55% B; 30.1 min, 100% B; 40 min, 
100% B; 40.1 min, 5% B and then equilibrated until 65 min.  The gradient pump 
maintained a 100 μL/min flow rate while the nanoflow pump was run at 200 
nL/min during analysis. MS conditions were similar to a previous report by Ito et 
al. (Ito et al., 2008) except the AP1 temperature was set a 120ºC, with an 
isolation time of 50 ms.   
 
Calibration Curves 
 Recombinant enzymes of all UGT1A isoforms excluding 1A5 (not 
commercially available) were used to establish recombinant enzyme calibration 
curve points representative of 0.19 μg, 0.75 μg, 1.5 μg, 3.0 μg and 6.0 μg of 
recombinant microsomal protein.  To keep volumes consistent for the tryptic 
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digests, each recombinant enzyme was taken through a series of serial dilutions 
using tris buffer, pH 7.4.  Prior to the tryptic digestion, 10 pmol of each heavy 
labeled peptide standard was added and the response ratio between the labeled 
and unlabeled peptides was used to establish a calibration curve and to verify 
linearity.  Equality of response between the labeled and unlabeled peptides along 
with complete tryptic digestion was assumed in the creation of the calibration 
curves. Calibration curves were constructed by comparing response of unlabeled 
peak area to labeled peak area for each MRM selected.  These MRMs standard 
curves were calculated in units of pmol/mg protein (microsomal protein) and used 
the response ratio between unlabeled and labeled peptides in the unknown 
microsomal protein fitted to the calibration curves to calculate enzyme 
concentrations.    
 
Ion Suppression/Matrix Effects 
 Aliquots containing 25 μg of each recombinant enzyme microsomes were 
digested as described earlier in two separate groups in triplicate.  The internal 
standard of heavy labeled peptides was added at either before the tryptic digest 
or following reconstitution.  The internal standard solution was also added to a 
0.1 mL aliquot of the reconstitution buffer, in triplicate, with peak areas of the 
heavy peptides serving as a baseline.   
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Interday and Intraday Variability 
 To examine intraday variability, five replicate calibration curves along with 
human liver, intestinal and kidney microsomes (n=5) were digested within the 
same day and analyzed on the nanoLC LIT-TOF instrumentation.  Individual 
peptide measurements for four of the UGT1A isoforms using two peptides for 
quantification were averaged to obtain final enzyme expression levels (Table 
3.5).  Interday variability experiments were carried out in a similar manner with 
five replicate standard curves along with digests of human liver microsomes 
analyzed over five separate analyses and days.   
 
Human Liver and Intestinal Microsomal Library 
 To compare the newly established method to the initial method 
established by Fallon et al., a library of ten individual liver microsomal donors 
were digested and analyzed in duplicate (Fallon et al., 2008).  Individual donors 
of intestinal microsomes (n=3) were also digested and analyzed in duplicate 
using the response ratios generated to compare against calibration curves 
analyzed in duplicate and prepared within the same day.  For the human liver 
microsomal library, the enzyme expression levels of hUGT1A1 and hUGT1A6 
were compared against those results obtained by the previous assay (Fallon et 
al., 2008). 
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C. RESULTS 
MRM Scheduling 
 Following initial scouting gradient runs and MRM optimization on the LIT-
TOF, it was found that peptides of interest eluted between 17 and 32 minutes.  
Further increases in the %B at the beginning of the LC gradient or increases in 
slope of the gradient to decrease run times resulted in band broadening or loss of 
signal.  Peptides eluted consistently with six separate time windows (T1 0-17 min, 
T2 17-19.5 min, T3 19.5-22.0 min, T4 22.1-26.4 min and T5 26.5-28 min, T6 28.1-
32 min) and were optimized using MRM scheduling with NanoFrontier LD-ECD 
software.  Extraction of selected MRMs from a single chromatographic run is 
shown in Figure 3.1. Peptide 5 and 14 were not consistently detectable using the 
LC gradient due to insufficient singly charged MRMs and were excluded from 
sample analysis.  MRM time segments assigned are listed in Table 3.2 and were 
used for the remaining analyses. 
 
Calibration Curves 
 Calibrants for each of the hUGT isoforms were quantified using 
procedures described in METHODS.  Initial curves were converted to pmol/mg 
protein units for enzyme concentration calculations.  Each peptide produced two 
MRM calibration curves resulting in as many as four curves per UGT isoform.  
For each interday enzyme measurement, curves performed in duplicate 
produced replicate expression data which was then averaged between the two 
MRMs per peptide to obtain final enzyme concentration levels.  Calibration 
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curves produced a linear range between 0.19 μg and 6.0 μg of recombinant 
microsomal matrix with a LOD approximately one third of the lowest 
concentration on the calibration curve (approximately 1 pmol enzyme/mg 
protein).  Calibration curves were generally similar between MRMs for each 
peptide, and MRM ratios between labeled standards and unlabeled peptide were 
averaged to generate expression ratios (Table 3.5).  Any peptides that did not 
generate quality product ion scans, stable and reproducible LC retention times or 
sufficient sensitivity or precise quantification (%C.V. <25% with repeat sampling) 
were excluded from all hUGT enzymatic analyses.  All R2 values for calibration 
curves were between 0.96 and 0.99 including the hUGT1A9 intraday calibration 
curve indicated in Fig (3.3). 
 
Ion Suppression 
 Ion suppression varied between time segments, but was most evident for 
segment 4 and 6.  While peptide 1 demonstrated significant ion suppression 
(92% for both MRMs), most ions eluting during segment 4 and 6 demonstrated 
>75% ion suppression and ion some cases ion suppression was >90% (Table 
3.2).   Peptides eluting early benefited from minimal ion suppression and 
recovery of these peptides was generally >75%, which is similar to our previous 
assay validation studies (Fallon et al., 2008).   While ion suppression levels were 
slightly lower in the 25 μg recombinant microsomal protein samples, compared to 
the human liver microsomal protein samples, the recombinant microsomal 
protein ion suppression studies are presented due to the limitations in linearity 
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discovered in the calibration curves.  Because the linear range of the method 
was established using the calibrations curves constructed with digests of 
recombinant microsomal protein, the recombinant microsomal protein matrix was 
used to determine loss of signal due to ion suppression. 
 
Intraday and Interday Variability 
 Intraday variability measurements (n=5) for the hUGTs provided 
reproducible results with minimal variation (<25%) between samples.  hUGT1A1 
enzyme levels were 22.7 pmol/mg protein in human liver microsomes (Table 3.3) 
which is similar to what we reported earlier (Fallon et al., 2008).  hUGT1A6 levels 
were 8.5 pmol/mg protein (Table 3.3).  However, hUGT1A6 demonstrated less 
variability (16.7% C.V. compared to 19.9% of hUGT1A1, (Table 3.3)) but was not 
as reproducible as the other isoforms found in the liver.  Peptides for isoforms 
hUGT1A7, hUGT1A8 and hUGT1A10 were below detection limits in the liver, 
which agree with previous reports of their lack of UGT liver expression based on 
mRNA (Ohno et al., 2009; Strassburg et al., 1997; Tukey et al., 2000).  In 
addition, UGT1A3, UGT1A4 and UGT1A5 were below detection limits in the 
intestine (Ohno et al., 2009; Tukey et al., 2000).  In contrast, UGT1A3 and 
UGT1A5 were the only isoforms below detection limits in the kidney.  With few 
exceptions, all C.V. values were below 20% for each of the UGT enzymes (Table 
3.4).  Intraday variability studies produced similar results both with regards to 
variability and expression (Table 3.3). 
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Human Liver, Intestine and Kidney UGT Expression 
 The data from liver microsomes indicated that hUGT1A1, hUGT1A9 and 
UGT1A5 consistently had the highest enzyme levels among the UGTs.  While 
UGT1A3, UGT1A4 and UGT1A6 were readily detectable, their expression levels 
(3.2 pmol/mg protein for 1A3 to 8.5 pmol/mg protein for 1A6, (Table 3.3) were 
generally 50-75% lower when compared to the other three enzymes.  UGT1A1 
expression was the highest within the liver along with UGT1A3, UGT1A5 and 
UGT1A6.   UGT1A8 was found at its highest levels within the intestine while 
UGT1A7, UGT1A9 and UGT1A10 were most extensively expressed in the 
kidney. 
 
Human Liver and Intestinal Libraries 
 Expression studies from the human liver and intestinal libraries are shown 
in Table (3.4).  UGT1A1 expression varied five fold (7.0 pmol/mg protein to 32.6 
pmol/mg protein) which was the general trend for liver expression of the other 
measurable isoforms.  An exception was UGT1A9, where variation was more 
than ten fold in the liver (9.0 pmol/mg protein to 96.4 pmol/mg protein in liver).  
Unlike in the liver library, the intestinal library enzyme expression data indicated 
less variability between patients.  Most isoforms demonstrated between 1.5 to 3 
fold variability between the lowest and highest concentration (Table 3.4).   One 
exception was UGT1A8 which demonstrated five fold variability (1.9 pmol/mg 
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protein to 9.4 pmol/mg protein) in the intestine.   Isoforms that were determined 
to be below detection limits within the pooled microsomal studies were also not 
detected within any of the individual library specimens.   
 To further validate the LIT-TOF based assay for UGT expression, 
UGT1A1 and UGT1A6 enzyme rank orders and enzymatic levels were compared 
between the current assay and the UGT1A1/1A6 assay previously developed on 
the ABI 3000 (Fallon et al., 2008).  Both correlation plots indicated a strong 
correlation (r=.92 for UGT1A1, r=.75 for UGT1A6, Fig. (3.4). Furthermore, the 
rank orders for each isoform within the library specimens were very similar and 
most of the enzyme levels validated in the previous method varied <20% from 
the values of the current assay (Fallon et al., 2008). 
 
Recombinant UGT Enzyme Concentrations 
 Using the calibration curves generated following digestion of recombinant 
microsomal protein, calibration curves were extrapolated to obtain UGT isoform 
expression levels in the recombinants.  Based on the calibration curves, isoform 
concentration levels ranged from 0.83 nmol/mg protein to 2.74 nmol/mg protein 
indicating that recombinant microsomal protein stocks contained approximately 
5-20% recombinant UGT protein (Table 3.7).  Generally, isoforms expressed at 
high levels within the tested microsomal samples were found in high 
concentrations in the recombinants with the exception of UGT1A4 whose 
concentration in the recombinant microsomal protein stocks (2.23 nmol/mg 
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protein) ranked third among the recombinant UGT1A isoforms despite low 
expression levels in the liver, kidney and intestine (Table 3.5).   
 
D. DISCUSSION 
 In recent years, the use of stable isotope internal standards with tandem 
MS methods to quantify biologically active proteins has become more common.  
The goal of this report was to develop a method that could successfully quantify 
all of the human UGT1A enzymes within a single chromatographic run using 
capillary LC-MS/MS, which is the preferred platform within the proteomics 
community (Bantscheff et al., 2007; Domon et al., 2006; Thomas et al., 2008).  
While triple quadrupole mass spectrometry has been applied for quantification in 
many investigations of quantitative proteomics via isotope dilution, hybrid 
instruments including the LIT-TOF used in this report have been applied for 
similar investigations and displayed the selectivity and sensitivity desired to 
quantify biological enzymes within complex matrices.  Thus a range of MS 
platforms can be successfully employed for targeted quantitative proteomics.   
 The UGT1A protein sequence is 530 amino acids in length and consists of 
five exons, of which amino acids residing in the C terminus (exons 2-5) are 
shared between each 1A isoform (Tukey et al., 2000).  The N terminal region is 
subject to individual enzyme splicing, resulting in the 9 unique active isoforms 
and 4 pseudogenes in humans (Owens and Ritter, 1995; Tukey and Strassburg, 
2000).  Because of this, amino acid sequences unique to each isoform are often 
a small list, making peptide selection limited.  It is desired in targeted quantitative 
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proteomics to select two unique peptides and at least two MRMs over 500 m/z 
for optimal sensitivity and selectivity (Anderson and Hunter, 2006).  However, the 
limited selection window for UGT1A8 and UGT1A9 resulted in the selection of 
only one unique peptide for each isoform along the peptide and the sequence 
TYSTSYTL*EDLDR, which was shared between the two isoforms.  Furthermore, 
peptides containing reactive/unstable amino acids such as methionine and 
cysteine, which are normally excluded based on selection criteria, were selected 
and employed due to a lack of unique peptides for some UGT1A isoforms.    
  Peptide 15 (FFTLTAYAV*PWTQK), an internal standard for UGT1A4 that 
contains a tryptophan residue, would normally be excluded based on selection 
criteria, yet the peptide produced consistently linear standard curves (r2>0.97, 
data not shown) and low C.V. values on interday and intraday variability testing 
(Table 3.4).  Reproducible product ions could not be obtained for peptide 16 
(VTLGYTQGF*FETEHLLK) and peptide 17 (GHQVVVL*TLEVNMYIK) because 
the parent ions from these peptides were from the +3 to +5 charge states, 
making both MRM analysis and chromatography cumbersome and often 
unresolvable.  In addition, one peptide that was not successful was peptide 5 
from UGT1A3 (HVLGHTQL*YFETEHFLK).  This peptide was also beset by a 
quadruply charged parent ion as a result of multiple histidine residues within the 
sequence.  Along with peptide 5, 16 and 17, peptide 10 (TYSTSYTL*EDLDR) 
was excluded from UGT analysis due to lack of specificity for a particular isoform 
since its peptide sequence was shared by both UGT1A8 and UGT1A9.  Often the 
best peptides of those employed for UGT analysis contained single or multiple 
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proline residues that exhibit the well documented “proline effect” that is 
responsible for favorable cleavage near proline sites under collision induced 
dissociation (CID) MS conditions (Vaisar and Urban, 1996).  Based on our 
experience, optimal peptide selection is of the utmost importance for accurate 
quantification of proteins digested to peptides. While guidelines recommend that 
peptides as large as 16mer may be selected, it is often smaller peptides between 
8-10mer in length containing proline and no reactive residues (C, M, W) that 
perform better for high sensitivity MRM based peptide quantification (Beynon et 
al., 2005; Gerber et al., 2003; Kamiie et al., 2008).  
 Initial analysis was performed with an extended gradient of 2-60% B over 
sixty minutes.  Assay length (95 minute run time) and lack of signal intensity 
resulted in several alterations, including a higher starting %B, but this was again 
inadequate due to peak splitting and band broadening with the stable isotope 
standards.  Following further modification, a 5-55% B gradient over thirty minutes 
provided both the highest signal intensity and shortest run time on the 
instrumentation.  Peptides eluted between 17 and 32 minutes over five distinct 
time segments.  To maximize MRM collections, eight to sixteen transitions were 
monitored over the five primary segments, enabling quantification of all UGT1As 
within a single chromatographic run.  While the current LIT-TOF has a limit of 
monitoring 100 MRM transitions within a single chromatographic run, it proved 
useful to monitor the 66 MRM transitions needed to measure all of the peptides 
of interest within this study and could be applied for other proteomic 
investigations. 
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 With the exception peptide 5, 16 and 18, all peptides generated calibration 
curves that were linear between 0.19 and 6.0 μg of recombinant microsomal 
protein.  When the stable isotope calibrants were incorporated, this represented 
a range of 1 pmole to 140 pmole per mg protein.  Because variability was <30% 
between the peptide MRMs monitored, MRM values for each UGT1A isoform 
were averaged to generate expression datasets.  For peptides with only one 
unique peptide, two MRM measurements were averaged from the single peptide.  
The highest detected UGT concentration was 96.4 pmol/mg protein of UGT1A9 
within the kidney; however, even this concentration was well within the linear 
range of the assay.  Wang demonstrated that some CYP isoforms are expressed 
in much higher concentration than UGT enzymes (>300 pmol/mg protein), 
indicating that the digested protein levels may need to be adjusted between 
assays to remain within the linear range of some instruments (Wang et al., 2008).  
 Enzyme expression data generated for the liver, intestine and kidney 
generally agree with previous reports for both mRNA expression and in vitro 
glucuronidation profiles (Izukawa et al., 2009; Nakamura et al., 2008; Tukey and 
Strassburg, 2000; Wen et al., 2007).  Within the liver, UGT1A1, 1A5 and 1A9 
were consistently expressed at a higher level than 1A3, 1A4 and 1A6 (Table 3.3, 
3.4 and Figure 3.5).  While there have been conflicting reports of the 
predominately extrahepatic UGTs 1A7, 1A8 and 1A10 being present in the liver, 
none of these enzymes were detected in either pooled or individual HLMs 
(Strassburg et al., 1997; Strassburg et al., 1998; Li et al., 2008).  Of particular 
note was the high level of expression for UGT1A5 (Figure 3.5), which has been 
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difficult to characterize and not successfully detected until recently (Finel et al., 
2005).  Within the liver, the highest variability in individual donor specimens was 
found with UGT1A1 and UGT1A9 isoforms, both which are polymorphic (Kadakol 
et al., 2000; Strassburg et al., 1997; Tukey et al., 2000; Villeneuve et al., 2007).   
 Within the intestinal tract, expression of UGT1A1 and 1A6 was 
approximately 35% of expression seen in livers, which concurs with our previous 
investigation into these isoforms (Fallon et al., 2008).  Furthermore, previous 
studies by Wen et al. with etoposide, a UGT1A1 and 1A8 probe substrate 
indicated that the Vmax of etoposide glucuronidation in the intestine was 
approximately 30% of liver levels (Wen et al., 2007).  However, the low levels of 
UGT1A enzymes found within the recombinant microsomal protein stocks 
coupled with the difficulties in in vitro/in vivo activity extrapolations indicate that 
protein concentration may not always correlate well with protein activity when 
using recombinant microsomal protein in probe substrate and in vitro 
glucuronidation studies (Table 3.7) (Miners et al., 2006).  While UGT1A1, 1A6, 
1A7, 1A8, 1A9 and 1A10 were all detected within the intestine, levels were 
appreciably lower than liver hepatic enzyme levels, and only UGT1A8 was 
expressed at a higher level within the intestine than the other two tissues using 
microsomes.  Individual patient levels of UGT1A8 were highly variable within the 
intestine, yet there have been few UGT1A8 polymorphisms reported with 
appreciable effects on glucuronidation (Lévesque et al., 2007).  An additional 
mechanism or unreported polymorphism could be responsible for this large 
variation.   
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 Expression levels within the kidney microsomes were much higher than 
the intestine and sometimes higher than seen in the liver.  Particularly, UGT1A9 
was expressed (81.4 pmol/mg protein, Figure 3.5) at a level nearly four fold that 
of the liver.  While mRNA and protein correlation is often poor, recent reports 
characterizing UGT mRNA expression indicated UGT1A9 was highly expressed 
within the human kidney (Nakamura et al., 2008; Ohno and Nakajin, 2009).  
However, it is important to note that when making comparisons between mRNA 
assays and with the hUGT assay, one must take into account the numerous 
polymorphisms within the hUGT gene family that result in high expression 
variability in the tissue populations.  Altered protein expression affected by SNPs 
or other polymorphisms in human tissues could account for the low level 
discrepancies in 1A3 expression within the intestine and kidney in both the UGT 
assay and mRNA values.  In addition, some isoforms including 1A1 and 1A4 
expressed at low levels within the kidney may benefit from the increased 
sensitivity using targeted proteomics (Nakamura et al., 2008; Ohno et al., 2009).  
Despite some differences in mRNA expression, UGT expression within the 
kidney coincides with MPA glucuronidation levels that are also three fold higher 
in the kidney compared to the liver and fifteen fold higher than those seen in the 
intestinal tract (Picard et al., 2005).  Not only were enzyme levels highest in the 
kidney for UGT1A4, 1A7, 1A9 and 1A10, but only UGT1A3 and UGT1A5 were 
not detected, making the kidney a potentially important organ for clearance via 
glucuronidation in the body. 
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 By combining the advantages of capillary LC coupled with the new LIT-
TOF instrumentation, we developed and applied a method to detect all of the 
active human UGT1A isoforms within a single chromatographic assay.  Our 
assay demonstrates acceptable variability (<25%) with comparable sensitivity 
relative to our earlier method performed using older triple quadrupole (ABI 3000) 
instrumentation.  The use of capillary LC allowed for a dramatic reduction of 
protein needed for the assay without a loss of sensitivity.  Furthermore, we are 
now able to compare absolute expression levels of UGTs within different tissues 
in humans that are comparable with previous reports of relative mRNA 
expression and RT-PCR studies.  The significant levels of UGT expression within 
the kidney demonstrate that this organ could have a potentially important role in 
glucuronide disposition within the body.  Liver expression was generally higher 
than levels seen within the intestine, but more UGT1A isoforms were detected in 
kidney compared with the liver.  The data obtained here confirms previous 
reports of UGT1A5 expression in the liver (Nakamura et al., 2008; Ohno et al., 
2009). 
While the liver is seen as the primary organ involved in metabolite 
disposition, the importance of other organ systems within the body should not be 
underestimated.  The emergence of novel targeted quantitative proteomic 
methods based upon LC-MS/MS will allow the explosion of protein expression 
studies, especially for the many proteins not amenable to developing specific 
antibodies.  The ability to quantify specific proteins within and between species 
without a reliance on specific antibodies not only opens many new avenues of 
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research into xenobioltic metabolism but also within the areas of protein-protein 
interactions, enzyme regulation and induction/inhibition studies with proteins that 
were not previously amenable to antibody based assays. 
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Figure 3.1.  UGT isoforms and stable isotope standards were separated using 
segmented MRMs in the base peak chromatogram of a human liver microsomal 
digest.  Five time segments (17-19.5 min, 19.6-22.5 min, 22.6-26 min, 26-28 min, 
and 28.1-32 min) were used for MRM scheduling.  First extracted ion 
chromatogram (XIC) shows peptide 1 from UGT1A1, eluting at 20.3 min in 
segment 2 representing 22.7 pmol/mg protein.  Labeled and unlabeled MRMs for 
the second XIC representing peptide 4 from UGT1A6 from segment 3 
representing 8.5 pmol/mg protein. 
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Figure 3.2.  TOF spectrum analysis of peptide 1 (Table 3.1) following injection of 
10 pmol of peptide on LC-MS/MS to confirm MRM optimization of 557.3 (y4) and 
753.4 (y6) ions used for quantification. 
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Figure 3.3.  Standard curve of MRM 2 of peptide 12 (Table 3.1) representative of 
UGT1A9 obtained from five intraday measurements of recombinant digests 
(r2=.99).  A 1 µg aliquot of 6.0 µg of digested microsomal protein was injected on 
column, with a peak area ratio (PAR) of unity equivalent to 132 pmol/mg protein 
in the prepared sample. 
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Figure 3.4.  Correlation analysis between UGT1A1 (A) and UGT1A6 (B) enzyme 
expression levels obtained by the LIT-TOF and the ABI 3000 (r=.92).  UGT1A1 
analysis was performed on ten human liver microsomal samples performed in 
duplicate using the nano LC LIT-TOF MS system.   
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Figure 3.5.  Comparison of human UGT enzyme expression from five replicate 
measurements of digests of pooled human liver, intestinal and kidney 
microsomes.  Data are presented as mean values with standard deviation error 
bars of each enzyme obtained from averages of two MRMs from one or two 
peptides as detailed in Methods.      
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Table 3.1.  Peptide standards for the UGT isoforms measured using LIT-TOF 
with their sequence and optimized MRMs used for UGT analysis. 
 
UGT Isoform Sequence IS MRMs 
(labeled) 
Unknown 
MRMs 
(Unlabeled) 
Rt (min) 
509.4/557.3 504.4/547.3 20 1A1 (peptide1) TYPVPF*QR 
509.4/753.4 504.4/743.4   
462.7/526.3 457.7/526.3 18.50 1A1 (peptide 2) DGAF*YTLK 
462.7/681.4 457.7/671.4   
526.5/724.6 523.5/718.6 21 1A1 (peptide 3) DIVEV*LSDR 
526.5/823.6 523.5/817.6   
1A3 (peptide 5) HVLGHTQL*YFETEHFLK ** ** ** 
681.3/885.5 678.3/879.5 30.1 1A3 (peptide 6) YLSIP*TVFFLR 
681.3/1085.6 678.3/1079.6   
839.9/764.4 836.9/758.4 27.5 1A4 (peptide 15) FFTLTAYAV*PWTQK 
839.6/1020.5 836.9/1014.5   
1A4 (peptide 16) VTLGYTQGF*FETEHLLK ** ** ** 
1A5 (peptide 17) GHQVVVL*TLEVNMYIK ** ** ** 
666.3/855.4 663.3/849.4 29.8 1A5 (peptide 18) YLSIPAV*FFLR 
666.3/1055.6 663.3/1049.6   
659.8/799.3 656.8/793.3 26.0 1A6 (peptide 4) SFLTAP*QTEYR 
659.8/971.4 656.8/965.4   
750.5/1027.5 747.5/1021.5 30.5 1A6 (peptide 7) IYPVP*YDQEELK 
750.5/1223.8 747.5/1217.8   
793.8/1046.4 790.3/1039.4 18.5 1A7 (peptide 8) TYSTSYTL*EDQDR 
793.8/883.4 790.3/876.4   
835.9/649.3 830.9/649.3 24.5 1A7 (peptide 9) ESCFDAVF*LDPFDR 
835.9/919.4 830.9/909.4   
786.3/518.3 786.3/518.3 18.8 1A8/1A9 (peptide 10) TYSTSYTL*EDLDR 
786.3/647.3 786.3/647.3   
699.3/990.4 694.3/980.4 24.1 1A8 (peptide 11) EFMDF*ADAQWK 
699.3/875.4 694.3/865.4   
481.7/536.2 479.7/532.2 18.1 1A9 (peptide 12) AFAHA*QWK 
481.7/744.3 479.7/740.3   
792.8/661.2 789.3/661.2 20.2 1A10 (peptide 13) TYSTSYTL*EDQNR 
792.8/882.4 789.3/875.4   
702.8/740.3 699.3/740.3 24.3 1A10 (peptide 14) EFMVF*AHAQWK 
702.8/897.4 699.3/897.4   
** Indicates that MRM analysis aborted due to insufficient product ion sensitivity 
following infusion of pure peptide. 
a: MRM values were obtained following infusion and LC analysis of stable 
isotope internal standards.   
b: Bold* amino acid indicates presence of C13, N15 heavy label to generate a 
mass difference between four and ten daltons. 
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Table 3.2.  Ion suppression and matrix effect determination following tryptic digestion of recombinant 
enzyme represented with % intensity of signals from selected stable isotope internal standards. 
 
MRM Segment I II III III/IV V 
MRM 481.7/536.2 509.4/557.5 699.3/990.4 659.8/971.5 666.3/855.4 
*%Signal 64.8 7.7 90.5 91.9 6.9 
MRM 481.7/744.3 509.4/753.4 699.3/875.4 659.8/799.3 666.3/1055.6 
*%Signal 96.9 7.9 28.4 74.3 34.9 
MRM 
793.8/883.4 792.8/661.2 835.9/919.4 839.9/1020.5 681.3/855.5 
*%Signal 89.5 100.9 73.1 25.1 10 
MRM 793.8/1046.4 792.8/882.4 835.9/649.3 839.9/764.4 681.3/1085.6 
*%Signal 83.3 61.7 73.1 22 11.8 
 
*Compares % signal relative to stable isotope standard signal intensities in solution of reconstitution buffer 
(ACN/0.1% FA pH 3.0 (15:85)) relative to the addition of internal standard after reconstitution following SPE 
at the end of sample preparation.  %C.V. varied between 2.8% and 27.6% but was generally <15% for all 
standards 
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Table 3.3.  Comparison of UGT Expression through intraday variability measurements that were averaged 
following five replicate digestions of human liver, intestinal and kidney microsomes.  Data are presented as 
averages of two MRMs from one or two peptide representatives for each UGT.   
                       hUGT Isoform 
Tissue 1A1 1A3 1A4 1A5a 1A6 1A7 1A8 1A9 1A10 
HLMd (pmol/mg 
protein) 22.7 3.2 7.4 19.5 8.5 
* * 22.4 * 
% C.V. 19.9 12.6 8.4 11.8 16.7 * * 15.5 * 
HIMe (pmol/mg 
protein) 9.7 
* * * 3.5 7.3 18.2 8.8 5.5 
%C.V. 5.7 * * * 35.0 17.0 28.0 9.8 32.4 
HKM (pmol/mg 
protein) 7.0 
* 9.1 * 2.5 13.4 5.6 81.9 16.7 
%C.V. 14.4 * 32.5 * 17.3 6.9 9.1 18.1 16.0 
 
* Denotes enzyme levels were below detection limits (0.5 pmol/mg protein) 
a Denotes quantification based on one point calibration curve due to lack of recombinant enzyme 
b Experiments were run in duplicate with 100 μg liver microsomal protein, 100 μg of kidney microsomal 
protein and 50 μg intestinal microsomal protein 
c Data are average of 2 MRMs per peptide.  
d Indicates sample pooled human microsomal protein purchased from Xenotech LLC  
 
**Samples were analyzed on the Hitachi NanoFrontier L/LIT-TOF instrument with a monolithic column (75 μm 
X 150 mm) at 250 nL/min using a linear gradient conducted as follows:  0 min, 5% B; 5 min, 5% B; 30 min, 
55% B; 30.1 min, 100%B; 40 min, 100% B; 40.1 min, 5% B; reequilibration until 65 minutes. LIT-TOF was 
operated in positive mode using Scheduled MRMs optimized as indicated in Methods.   
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Table 3.4.  Comparison of UGT Expression through interday variability measurements that were averaged 
following five between day replicate digestions of human liver from two separate pools and pooled intestinal 
microsomes.  Data are presented as averages of two MRMs from one or two peptide representatives for 
each UGT.   
                    hUGT Isoform 
Tissue 1A1 1A3 1A4 1A5a 1A6 1A7 1A8 1A9 1A10 
HLMd (pmol/mg 
protein) 27.6 5.3 6.6 14.1 5.3 
* * 19.9 * 
%C.V. 13.1 23.8 16.0 9.3 15.4 * * 9.0 * 
HLMe (pmol/mg 
protein) 29.1 3.3 6.2 17.6 6.4 
* * 22.2 * 
%C.V. 16.2 27.7 14.0 7.6 8.3 * * 9.8 * 
HIMd (pmol/mg 
protein) 11.2 
* * * 2.0 6.0 10.5 5.2 4.6 
%C.V. 18.2 * * * 18.3 30.9 15.0 13.1 38.3 
 
* Denotes enzyme levels were below detection limits (0.5 pmol/mg protein) 
a Denotes quantification based on one point calibration curve due to lack of recombinant enzyme 
b Experiments were run in duplicate with 100 μg liver microsomal protein and 50 μg intestinal 
microsomal protein 
c Data are average of 2 MRMs per peptide.  
d Indicates sample pooled human microsomal protein was purchased from Xenotech LLC (X) 
e  Microsomal protein which was purchased from Becton Dickinson (B&D) 
 
**Samples were analyzed on the Hitachi NanoFrontier L/LIT-TOF instrument with a monolithic column (75 μm 
X 150 mm) at 250 nL/min using a linear gradient conducted as follows:  0 min, 5% B; 5 min, 5% B; 30 min, 
55% B; 30.1 min, 100%B; 40 min, 100% B; 40.1 min, 5% B; reequilibration until 65 minutes. LIT-TOF was 
operated in positive mode using Scheduled MRMs optimized as indicated in Methods.   
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Table 3.5.  Peptide hUGT measurements using the LIT-TOF.  Enzyme concentrations were obtained following 
calibration curve generation and all enzyme isoform concentrations calculated by combining peptides are shown.  
Enzyme concentrations from individual peptides were obtained following replicate digests of pooled human intestinal 
microsomes (n=5).  UGT isoforms not included on the table (UGT1A3, 1A4, 1A5, 1A8, 1A9) were determined by 
averaging two MRMs from one peptide due to the rejection of the secondary peptide based on selection criteria. 
                    hUGT Isoform 
 1A1 1A6 1A7 1A10 
Peptide 1 3 4 7 8 9 13 14 
UGT 
concentration 
(pmol/mg 
protein) 
13.30 9.76 4.63 3.40 8.97 8.78 5.95 6.10 
(%C.V.) (15.0) (4.9) (15.9) (22.4) (5.3) (6.7) (11.8) (19.3) 
 
*Samples were analyzed on the Hitachi NanoFrontier L/LIT-TOF instrument with a monlithic column (75 μm X 
150 mm) at 250 nL/min using a linear gradient conducted as follows:  0 min, 5% B; 5 min, 5% B; 30 min, 55% 
B; 30.1 min, 100%B; 40 min, 100% B; 40.1 min, 5% B; reequilibration until 65 minutes. LIT-TOF was operated 
in positive mode using scheduled MRMs optimized as indicated in Methods.   
**Peptide Selection Rules for Quantification:  1) If recombinant protein available, must produce a linear standard 
curve with a %C.V. <25% at the base of the calibration curve, 2) must produce a %C.V. <25% on both 
interday/intraday validation, 3) if two peptides are used for protein quantification average protein concentrations must 
be within 50% of each other.  
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Table 3.6.  UGT concentrations obtained from three individual intestinal 
microsomal donors (HIM) and ten individual donors of liver microsomal protein 
(HLM) performed on the LIT-TOF in duplicate.   
hUGT Isoform 
Specimen 1A1 1A3 1A4 1A5 1A6 1A7 1A8 1A9 1A10
HIM-1 9.9 * * * 3.2 10.8 9.4 8.2 7.8 
HIM-21 3.0 * 5.8 * 1.5 6.1 1.9 5.6 3.9 
HIM-27 8.7 * 4.8 * * 8.4 7.0 5.9 2.4 
AVG±SD 7.2±3.7 * 5.3±0.7 * 2.3±1.2 8.4±2.4 6.1±3.8 6.6±1.4 4.7±2.8
%C.V. 51.3 * 13.4 * 49.8 28.0 62.8 21.7 59.3 
HLM-216 23.8 8.9 4.7 15.6 4.7 * * 16.9 * 
HLM-218 15.3 8.1 7.7 17.7 2.1 * * 9.0 * 
HLM-219 20.6 2.9 1.8 14.2 6.8 * * 23.5 * 
HLM-222 32.6 10.5 4.4 11.6 6.8 * * 17.3 * 
HLM-224 17.5 3.4 4.9 22.4 4.5 * * 11.6 * 
HLM-225 25.3 6.1 1.5 18.0 6.7 * * 17.9 * 
HLM-228 7.0 27.5 4.4 10.9 3.6 * * 96.4 * 
HLM-230 15.9 7.4 4.7 16.2 3.9 * * 16.1 * 
HLM-233 18.4 * 7.8 12.1 9.6 * * 36.4 * 
AVG±SD 18.3±7.8 9.9±7.4 4.6±2.0 15.3±3.5 5.2±2.3 * * 26.7±25.6 * 
%C.V. 43.0 75.2 44.9 22.9 43.4 * * 95.7 * 
 
Variability between enzyme measurements was generally <25%.   
Sections marked with an * indicate enzyme concentrations that were below 
detection limits (0.5 pmol/mg protein).   
 
**Samples were analyzed on the Hitachi NanoFrontier L/LIT-TOF instrument 
with a monolithic column (75 μm X 150 mm) at 250 nL/min using a linear 
gradient conducted as follows:  0 min, 5% B; 5 min, 5% B; 30 min, 55% B; 30.1 
min, 100%B; 40 min, 100% B; 40.1 min, 5% B; reequilibration until 65 minutes. 
LIT-TOF was operated in positive mode using Scheduled MRMs optimized as 
indicated in Methods.   
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Table 3.7.  Recombinant hUGT enzyme isoform concentrations using the LIT-TOF.  Enzyme 
concentrations were obtained following calibration curve generation. 
                    hUGT Isoform 
 1A1 1A3 1A4 1A6 1A7 1A8 1A9 1A10 
Lot Numbera 73760 93819 92773 70201 30991 36867 18663 96097 
hUGT Isoform 
Concentration 
(nmol/mg 
protein) 
1.31 0.80 2.23 1.10 2.25 0.83 2.74 0.75 
 
a Gentest hUGT1A5 was not available for calibration curve generation.  UGT1A2, UGT1A11, 
UGT1A12 and UGT1A13 are pseudogenes that do not produce active proteins in humans. 
*Samples were analyzed on the Hitachi NanoFrontier L/LIT-TOF instrument with a monlithic 
column (75 μm X 150 mm) at 250 nL/min using a linear gradient conducted as follows:  0 min, 5% 
B; 5 min, 5% B; 30 min, 55% B; 30.1 min, 100%B;40 min, 100% B; 40.1 min, 5% B; reequilibration 
until 65 minutes. LIT-TOF was operated in positive mode using scheduled MRMs optimized as 
indicated in Methods.   
**Peptide Selection Rules for Quantification:  1) If recombinant protein available, must produce a 
linear standard curve with a %C.V. <25% at the base of the calibration curve, 2) must produce a 
%C.V. <25% on both interday/intraday validation, 3) if two peptides are used for protein 
quantification average protein concentrations must be within 50% of each other.  
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A. INTRODUCTION 
 
Glucuronidation is a phase II metabolism process that involves the 
conjugation of glucuronic acid by uridine disphosphate glucuronosyl transferase 
(UGT) enzymes to many exogenous and endogenous lipophilic compounds to 
yield a polar, anionic product for urinary or biliary excretion.  Glucuronidation 
enzymes in mammals are composed of two families and three subfamilies and 
are present throughout the body (Shelby et al., 2003).  One of the primary sites 
for glucuronidation activity is the liver, where compounds are subsequently 
excreted into either the bile or the sinusoid following conjugation. The process of 
biliary or sinusoidal excretion of glucuronide conjugates is aided by a number of 
transporters from the ATP binding cassette (ABC) family, including the multidrug 
resistance-associated protein 2 and 3 (Abcc2/Abcc3, Mrp2/Mrp3)  and the breast 
cancer resistance protein (Abcg2/Bcrp) (Westley et al., 2006). The actions of 
these glucuronidation enzymes and transporters facilitate the elimination of many 
compounds. 
Mycophenolic acid (MPA) is used primarily as part of first line adjuvant 
immunosuppressive therapy following renal or hepatic transplantation.  MPA 
selectively inhibits the ionosine monophosphate dehydrogenase enzyme type II 
(IMPDH II) enzyme that inhibits the de novo purine biosynthesis pathway in 
lymphocytes (Platz et al., 1991).  Following administration, MPA is conjugated by 
UGT enzymes within the liver to either the pharmacologically inactive phenolic 
glucuronide (MPAG) or its potentially labile acyl glucuronide (acMPAG).   MPAG 
and acMPAG are subsequently excreted into the bile and intestinal tract via 
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MRP2/Mrp2 or BCRP/Bcrp, either for elimination through the feces or cleavage 
by β-glucuronidase enzymes back to MPA and subsequent reuptake through the 
portal vein back into the liver (Bullingham et al., 1998; Staatz et al., 2007).  
Enterohepatic cycling is common in MPA dosing both in rats and humans, and in 
humans, it is responsible for 10-61% of MPA exposure (Bullingham et al., 1998; 
Naderer et al., 2005; Staatz et al., 2007).  While MPA is generally well tolerated, 
side effects including leucopenia, an increased infection rate and delayed onset 
diarrhea in 20-30% of patients can sometimes result in dosage reduction or 
cessation of therapy with potential life threatening complications (Davies et al., 
2007). 
The field of quantitative proteomics rapidly advanced following the 
development of electrospray ionization (ESI) in 1985 that allowed for analysis of 
intact proteins and peptides (Cañas B et al., 2006; Whitehouse et al., 1985).  In 
addition to the development of ESI, several types of stable isotope standards 
have allowed for precise quantification of several proteins, including apo A-I (Barr 
et al., 1996), thyroglobulin (Hoofnagle et al., 2006), C-reactive protein (Kuhn et 
al., 2004), prostate specific antigen (Barnidge et al., 2003), yeast regulatory 
proteins and phosphoproteins (Gerber et al., 2003) and gonadotropin releasing 
hormone (Thomas et al., 2008).  More recently, the development of absolute 
quantification strategies to evaluate expression levels of CYP enzymes, 
membrane transporters and UGT enzymes has become particularly important to 
biologists and the pharmaceutical industry due to their ability to relate expression 
levels and metabolite profiles, i.e. in vitro/in vivo predictions, or to evaluate the 
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induction/inhibition ability of particular compounds of interest (Alterman et al., 
2005; Fallon et al., 2008; Jenkins et al., 2006; Kamiie et al., 2008.; Li et al., 2009; 
Wang et al., 2008). 
Previously, our lab has explored quantification of hUGT enzymes within 
liver, kidney and intestinal segments using both standard bore LC coupled with 
triple quardrupole instrumentation and nanoLC linked to an LIT-TOF mass 
spectrometer (Fallon et al., 2008).  While these experiments were successful in 
quantifying all of the enzymes of interest, they lacked sufficient sensitivity or 
throughput capability to quantify extremely low abundant proteins on a larger 
scale.    Moreover, to apply quantitative proteomics when an experiment is 
sample limited, such as with cell culture or biopsy samples, more sensitive 
methods are needed.  Li et al. and Kamiie et al. indicated that some particular 
membrane proteins of interest are expressed at levels below the 1 pmol/mg 
protein limit of quantification of our previous assays (Li et al., 2008; Kamiie et al., 
2008).  By combining the advantages of nano-UPLC chromatography with the 
new ABI 5500 QTRAP mass spectrometer, we are now able to use the 
advantages in sensitivity and spray efficiency provided by capillary LC and 
increase throughput with UPLC particle technology. 
We present a method for quantification of rUgt 1a1, 1a6 and 1a7 and the 
membrane efflux transporters Mrp2, Mrp3 and Bcrp in rat tissues.  In addition, 
through in vitro incubations and pharmacokinetic experiments the enzyme 
expression in separate strains of male rats were related to the disposition of MPA 
and its glucuronide conjugates.  This experimental approach also allowed 
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determination if particular strains of rats may be sensitive to MPA induced 
delayed onset diarrhea due to MPA exposure within the intestinal tract. 
 
B. METHODS 
 
Materials 
Analytical grade acetonitrile, methyl alcohol (anhydrous), potassium 
hydroxide, ammonium acetate, ethyl acetate and glacial acetic acid (HOAc) were 
purchased from Fisher Scientific Co. (Pittsburgh, PA). Ammonium bicarbonate, 
dithiothreitol, iodoacetamide, ammonium hydroxide, formic acid, TPCK treated 
trypsin from bovine pancreas (= 10,000 BAEE units/mg protein) alamethicin, 
magnesium chloride (MgCl2), phenylmethylsulfonyl fluoride (PMSF), D-saccharic 
acid 1, 4-lactone (D-SL), dextrose, carboxyl methyl cellulose (CM-cellulose), 
chymostatin (catalog no. C-7268), leupeptin (L-2023), aprotinin (A-1153), antipain 
(A-6191), pepstatin A (P-5318), methyl (tri-O-acetyl-α-  -glucopyranosyl 
bromide)-uronate, β-casein and TRIZMA® hydrochloride were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). Tris base was purchased from Bio-Rad 
Laboratories (Hercules, CA).  Bond Elut solid phase extraction cartridges (C18 
100mg, 1mL) were purchased from Varian, Inc. Rat Ugt 1a1, 1a6 and 1a7 
recombinant enzyme and control supersomes were obtained from transfected 
HepG2 cells out of the lab of Joe Ritter (VCU Medical Center, Richmond, Va).  
Human liver microsomes (20 mg/mL) were purchased from Xenotech LLC 
(Lenexa, KA) (Lot 1037, pool of 50). Rat liver microsomes (RLMs) and 
membrane protein fractions from Wistar, TR- and Gunn (j+/-) rats were prepared 
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rats were prepared using standard methods (Miles et al. 2006; Stern et al. 2007). 
Protein concentrations were determined using the Pierce BCA Protein assay Kit, 
in which bovine serum albumin is used as the standard. 
 
Animals 
Male Wistar rats (250-300 g) and Mrp2 deficient TR- rats (250-300 g) were 
purchased from Charles River laboratories (Wilmington, MA) and housed under a 
12 hour-light dark cycle. Male adenovirus treated Gunn rat livers were obtained 
from the lab of J. Ritter at Virginia Commonwealth University (Richmond, VA) 
following AVUgt restoration using previously established methods (Miles et al., 
2006). Experimental methods were approved by the Institutional Animal Care 
and Use Committee (IACUC) and the Division of Lab Animal Medicine (UNC-
Chapel Hill).  Animals were acclimated for one week prior to experimentation.  
Male rats (n=5) were administered either a single oral 50 mg/kg MMF suspension 
in 1% CMC (10 mg/mL) or a 50 mg/kg MMF IV infusion dissolved in 5% dextrose 
at pH 4 over a thirty minute time period.  Following anesthesia using 
ketamine/xylezine, the bile ducts were cannulated, and blood was collected from 
the tail vein in 0.1-0.2 mL aliquots into microcentrifuge tubes. Time points for 
blood and bile collection were 15, 20, 30, 60, 120, 180, 240, 360 and 480 post 
dosing.  Blood samples were placed on ice and centrifuged at 10,000g for 12 
minutes, and plasma was transferred into vials acidified with HOAc (pH~4, 
5μL/mL) and kept at -20°C until analysis.  Bile samples were collected in 
microcentrifuge tubes containing acetic acid (HOAc) (final pH 4, 5μL/mL) and 
stored at -20ºC until analysis.  For quantitative analysis, 0.050 mL of plasma was 
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precipitated with 0.3 mL acetonitrile containing  suprofen internal standard and 
centrifuged, dried under nitrogen and reconstituted in methanol/0.1% formic acid 
(25:75) for HPLC injection.  Pharmacokinetic measures were obtained by 
noncompartmental methods using WinNonlin 5.0.1 (Pharsight, Cary, NC).  
Statistical analysis was performed using a one way ANOVA to separate 
parameters across different rat strains (p=0.05).  MPA exposure from 
enterohepatic cycling was determined from the equation: 
MPA Exposure=
)(inf)0(
)(inf)0()(inf)0(
)(
)()(
Cannulated
CannulatedIntact
MPAAUC
MPAAUCMPAAUC
→
→→ −  
 
HPLC-UV Analysis 
Analysis by reversed phase HPLC utilized a HP 1050 LC equipped with a 
autosampler and an Axxiom (Moorpark, CA) C18 (15cm length, 4.6 mm 
diameter, 5 μ particle size, 100 Ǻ pore size) column, with an HP 1100 series UV 
detector set at 250 nm.  Data analysis was performed with a Chemstation 
(A.09.01, Agilent Technologies, Palo Alto, CA).  The HPLC method was adopted 
from an earlier protocol with the some modifications (Wiwattanawongsa et al., 
2001).  The mobile phase was 52% methanol/48% (0.1% formic acid (FA)) under 
isocratic conditions at a 1.0 mL/min flow rate over 15 minutes. 
 
MPAG Biliary Elimination 
MPAG was synthesized as previously indicated following isolation of MMF 
from Cellcept© tablets (Roche Pharmaceuticals, Nutly, NJ) at pH 10 and 
extracted using ethyl acetate (Wiwattanawongsa et al., 2001).  After extraction, 
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the solution was evaporated and the residue was dried overnight prior to NMR 
analysis.  Once MMF purity was confirmed, one gram of purified MMF was added 
to a solution of pyridine, 0.6 g of silver carbonate and one gram of methyl (tri-O-
acetyl-α-  -glucopyranosyl bromide)-uronate under gentle stirring overnight.  
Briefly, the reaction was then diluted with toluene and filtered then washed with 
HCl, 0.3 M KOH and water, dried with MgSO4 and rotary evaporated.  The crude 
product was then subject to saponification in acetone with 0.1 M NaOH followed 
by the addition of Amberlite IR-120 (H+ form) and filtering with toluene washing.  
The product was dried and obtained through the addition of heated ethanol 
(~80ºC) in minimal amounts and petroleum ether dropwise.  The yellowish 
solution was placed in -20ºC overnight and product identity was confirmed 
through HPLC, LC-MS and NMR. 
Purified MPAG was solubilized in 5% dextrose solution (5 mg/mL) and 
administered IV to male Wistar rats following bile cannulation.  Blood (0.25 mL) 
and bile (0.5 mL) was collected at 5, 15, 30, 60, 120, 180, 240, 360 and 480 
minutes.  Blood samples were centrifuged for plasma collection and bile was 
placed in -20ºC prior to analysis. 
 
Tissue Collection and Microsome Preparation 
At the conclusion of the pharmacokinetic studies, rats were euthanized via 
thoracotomy and the livers, kidneys and the entire intestinal tract from the pylorus 
to the distal colon was removed and placed on a bed of ice.  Livers and kidneys 
were collected and snap frozen in liquid nitrogen and placed at -80ºC prior to 
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microsome and membrane protein fraction collection.  Intestine segments were 
taken in 10 cm fractions according to protocols previously indicated by Miles et. 
al (Miles et al., 2006). 
 
In vitro MPA Glucuronidation Studies 
In vitro glucuronidation rates were based upon previous studies using 1 
mM MPA and 1 mg/mL microsomal protein with minor modifications (Stern et al., 
2007).  Reactions were terminated at 15 and 30 minutes with 1 mL of acetonitrile 
with suprofen as internal standard.  Following centrifugation, drying and 
reconstitution, 50 µL was injected onto an HP1050 system with the UV detector 
set at 250nm. 
 
Stable Isotope Labeled Internal Standards 
Peptide standards (7mer-15mer), each containing one amino acid heavy 
labeled with 13C [98%] and 15N [95%], selected according to previous methods 
(Fallon et al., 2008) were purchased from Thermo Electron (Thermo Scientific, 
Waltham, MA). For each rUGT isoform, two synthetic peptide standards were 
purchased but three synthetic standards were purchased as representatives for 
each transporter of interest. The peptides were purchased for rUgt1a1, 1a6 and 
1a7, along with the canalicular transporters rMrp2 and rBcrp and the basolateral 
transporter rMrp3 due to their principle effect on MPA metabolism and 
distribution within rats.  The peptides were selected according to manufacturer 
recommendations and previously published guidelines (Beynon et al., 2005; 
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Fallon et al., 2008; Kamiie et al., 2008). The selection criteria along with previous 
guidelines established within our lab were used in all peptide selections. 
Amino acid analysis and LC-MS was conducted on each peptide to determine 
exact amount present as previously described (Fallon et al., 2008). Amino acid 
analysis was conducted at the Center for Structural Biology, Wake Forest 
University School of Medicine, Winston-Salem, NC.  While some peptides 
exhibited purity levels of 90%, many peptide purity levels were between 75-85%.  
The peptides purchased are listed in Table 4.1 together with optimal MRM 
transitions for quantitation. 
 
Sample Preparation and Tryptic Digestion 
Calibration curves were generated containing 0.075, 0.19, 0.75, 1.5, 3.0 and 
6.0 µg of microsomes for recombinant rat Ugts 1a1, 1a6 and 1a7 with protein 
normalized to 25 µg by the addition of HLMs.  A blank containing 25 µg of rUGT 
control supersomes, with protein normalized in the same way was prepared for 
each calibration curve.   Rat liver, intestinal or kidney microsomal protein or 
membrane protein fractions prepared from the same rat tissues using the 
Novagen Native Membrane Protein Extraction Kit (EMD Chemicals, Gibbstown, 
NJ) were prepared prior to digestion. Samples were denatured and digested as 
previously described with slight modifications (Fallon et al., 2008).  Samples were 
denatured by heating at 95 ºC for 11 min after the addition of 5 mM dithiothreitol 
(sample volume 90 µL), followed by alkylation by iodoacetimide (IAA, 10 µL of 
100 mM solution added) for 20 under darkness. Heavy labeled peptides were 
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then added as internal standards (1 pmol of peptides 1-15, Table 4.1) and the 
residual acetonitrile (< 5 µL) was removed by evaporation under nitrogen. 
Samples were then digested with trypsin in 50 mM ammonium bicarbonate; 
enzyme/protein ratio = 1:50; overnight at 37ºC. The reaction was then quenched 
by acetonitrile, centrifuged at 1000g for 10 min and the organic content was then 
removed by evaporation under nitrogen for ~10 min. Ammonium bicarbonate (0.9 
mL, 50 mM solution) was then added in preparation for solid phase extraction. 
SPE cartridges were conditioned with methanol and HPLC water. Samples were 
then added and the cartridges were washed with ammonium acetate (10 mM, 
pH3), then with acetonitrile/0.1% FA in water solution (10:90). Peptides were 
eluted from SPE with a 1 mL 65:35 solution of acetonitrile/0.1%FA. The eluate 
was evaporated to dryness under nitrogen at 42ºC in a water bath and samples 
were reconstituted with 200 μL of 15% acetonitrile/0.1% formic acid at pH 3 (pH 
was adjusted to 3 by drop wise addition of ammonium hydroxide). Samples were 
stored at -20 ºC until analyzed by LC-MS/MS. 
 
LC Conditions 
Following tryptic digestion and sample preparation, peptides from tissue 
samples were injected onto a Waters nanoACQUITY UPLC system (Waters 
Corporation, Milford, MA) with a Waters Symmetry® loading column (length, 
2cm; internal diameter, 180 µm; particle size, 5µ).  Samples were loaded onto 
the loading column for 3 minutes using 95% Solvent A at 5 μL/min followed by 
gradient elution through a bridged ethylene hybrid (BEH) column (length, 10cm; 
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internal diameter, 150 µm; particle size, 1.7µ; pore size, 100Å).  The mobile 
phase consisted of 98% HPLC water and 2% acetonitrile with 0.1% formic acid 
(Solvent A) coupled with 98% acetonitrile and 2% HPLC water with 0.1% formic 
acid (Solvent B). Injection volume was 2 μL and the flow rate was held constant 
at 2.0 μL/min. Gradient; 15% B from 0 to 5 min, 15% to 65% B at 25 min, to 99% 
at 25.1 min, hold at 99% until 30 min, then to 15%B at 30.1 min with equilibration 
until 40 minutes. 
 
 
MS/MS Analysis 
MS instrumentation consisted of an ABI QTRAP 5500 system with a 
Nanospray III ion source operated in positive ion mode (Applied Biosystems, 
Foster City, CA).  All data acquisition and method development was carried out 
using Analyst Software (version 1.5, build 3655, Applied Biosystems, Foster City, 
CA). A majority of the heavy labeled peptides were found to be doubly charged 
when infused into the mass spectrometer in 1 µg/mL concentrations in mobile 
phase (50:50). Two MRM transitions, with product ions that were generally 
>500amu (and precursor ion as doubly charged ion, except for peptide 9 which 
was triply charged), were chosen for each heavy labeled peptide following 
optimization as shown in Table 4.1, i.e. 30 MRMs for monitoring the heavy 
labeled standards. Two additional MRM transitions were chosen for the 
corresponding unlabeled peptides from digested recombinant enzyme and 
microsomal samples with adjustment based on the masses of the unlabeled 
peptides. Thus, there were four MRM transitions monitored per peptide, giving a 
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total of 60 MRMs, which were acquired between the rat UGT enzymes of interest 
and the three transporters potentially involved in MPA glucuronide efflux.  Due to 
the similar nature of many of the peptides, there were several distinct time 
windows of peptide elution, allowing for the development of a scheduled MRM 
method. Following optimization, total scan time per MRM was set to 100 msec 
using an 80 sec scan window for each MRM. MS ion voltage was set at 4000V, 
curtain gas 30 L/min, entrance potential 10V, source temperature set at 160ºC, 
nebulizer gas set at were maintained 14 L/min while the declustering potential 
(DP), collision energy (CE) and collision cell exit potential (CXP) were optimized 
for each MRM.  A majority of MRM product ions were y ions with some b ions 
used for quantification. The MRM transitions acquired are listed in Table 4.1. 
 
C. RESULTS 
Rat MPA Pharmacokinetics 
After administration of MMF to bile cannulated Wistar rats via either the 
oral or intravenous routes, the exposure to MPA was essentially the same (11.6 
vs 10.3 mg/ml*min, respectively) which indicates that oral bioavailability of MPA 
via the prodrug was essentially complete (Table 4.2,  Figures 4.1, A, B).  Thus, 
CL/F and CL were similar and not statistically different (Table 4.2).  The terminal 
half-lives were also not statistically different following these two routes of input 
into bile cannulated Wistar rats (Table 4.2).  The peak concentrations of both 
MPA and MPAG were within 60 min following oral dosing.  Systemic exposure to 
the primary metabolite, MPAG, was also not measurably different between the 
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oral and intravenous dose of MMF, which resulted in ratios of MPAG/MPA to be 
similar as well with values below 1.0, reflecting less relative systemic exposure in 
rats to MPAG relative to humans where the ratio is often above five in healthy 
volunteers. 
Biliary excretion in cannulated Wistar rats provided estimates of apparent 
biliary clearance.  The apparent biliary clearance is defined as “apparent” due to 
it measuring amounts of glucuronides in bile relative to parent, MPA, in plasma.  
The apparent biliary clearance thus reflects metabolism and then excretion of the 
glucuronide(s) into bile.  Mean values for apparent biliary clearance were 1.1 and 
0.8 mL/min the bile cannulated Wistar rats after the intravenous and oral doses 
of MPA, respectively.  These were not statistically different and represent biliary 
clearance following metabolism as major route of elimination with approximately 
60% of the dose excreted in bile when the rats were cannulated and 
enteroheptatic recycling was not permitted.   
MPA and MPAG disposition in Wistar rats, without bile duct cannulation, 
after an intravenous dose allowed an estimate of enterohepatic recycling.  The 
mean AUC for MPA was 14.3 mg/ml*min following IV dosing of MMF to Wistar 
rats and 12.3 mg/ml*min following oral dosing which was much higher than 
obtained with cannulation (Table 4.2, Figure 4.2B) and a secondary peak was 
noted.  From the AUC differences, an estimate for the fraction of dose that is 
subject to enterohepatic recycling in the Wistar rat is between 20-39% using both 
IV and oral formulations (Table 4.2). 
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When TR- rats were administered MMF orally with bile duct cannulation, 
the systemic exposure to MPA was reduced to a mean AUC of 6.1 mg/ml*min 
from 11.6 in Wistar rats (Table 4.2).  The TR- rats did have substantially elevated 
systemic exposure to MPAG (Figure 4.1C) relative to normal Wistar rats, 
resulting in an MPAG/MPA level of 6.7 compared with MPAG/MPA values of 0.63 
and 0.53 in the Wistar oral and IV dosing groups (Table 4.2) 
 
MPAG in Bile 
Within five minutes following a 2.5 mg/kg dose of MPAG (in MPA 
equivalents), between 40-50% of the original dose is excreted within the bile.  A 
significant secondary fraction (~30%) is present within the blood and remained 
detectable up to three hours post dosing (Figure 4.4).  While there was initially a 
large fraction of the MPAG dose excreted into the bile, MPAG elimination through 
the bile dropped off dramatically after five minutes to levels below detection limits 
for four hours, when a small fraction was detected until the end of the study.  At 
the end of the collection period (0-8 hr), 53% of the original MPAG dose was 
eliminated in bile with the remaining fraction eliminated in the urine and a small 
amount undergoing hydrolysis and subsequent hydrolysis in vivo followed by 
conjugation and elimination. 
 
In Vitro Glucuronidation Studies 
Following incubation periods of 15 and 30 minutes with 1 mM MPA, 
hepatic and intestinal microsomes obtained from TR- rats generally exhibited 
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higher glucuronidation formation rates (nmol/min/mg protein) than the Wistar rat 
tissue specimens, although the difference was not significant (ANOVA one way, 
p=0.45).  Furthermore, glucuronidation rates were generally lower in the middle 
segments of the gastrointestinal tract in both the TR- and Wistar rats (Figure 4.5) 
which is consistent with previous reports (Miles et al., 2006).   MPA conjugation 
rates were the highest within the liver microsomes of both animal strains, and our 
findings on TR- and Wistar rats generally agreed with previously reported 
glucuronidation rates (Westley et al., 2006; Miles et al., 2006). 
 
Stable Isotope Standards 
Upon infusion into the MS with electrospray ionization, all heavy labeled 
peptides produced doubly charged parent ions with the exception of Peptide 6 
and Peptide 9 (Table 4.1).  However, following inconsistent retention times and 
inadequate sensitivity of Peptide 6 during method development, it was infused 
again for optimization of the doubly charged parent ion that ultimately yielded 
better sensitivity and reproducible retention times on the LC-MS/MS.  While our 
previous experiments relied on peptides with product ions >500 m/z, inadequate 
sensitivity of the product ions of peptide 2 and peptide 13 made it necessary to 
expand product ion selections beyond this window (Fallon et al., 2008).   Due to 
the increased size of the protein sequences for the transporters of interest 
relative to the rUgts, coupled with the need for accurate quantification at the base 
of the calibration curves, three stable isotope standards were utilized for MRM 
quantification.    However, due to %C.V. values >25% for peptide 12 (Mrp3) at 
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levels below 1 pmol/mg protein, this peptide was not used for quantification 
(Table 4.3). 
Calibration Curves 
Recombinant microsomal protein was serially diluted to generate a six 
point calibration curve for each rUgt enzyme and to establish lower limit of 
detection (LLOD) values of the LC-MS/MS instrument.  Calibration curves were 
constructed following five replicate digests and averaged for each calibrant to 
obtain %C.V. values used to evaluate accuracy and precision.  All peptide MRMs 
generated calibration curves with R2 values >0.98; however, both MRMs of 
peptide 1, peptide 3 and peptide 4 also demonstrated %C.V. values of <10% at 
the base of their respective calibration curves (Figure 8).  While peptides 2, 5 and 
6 had slightly higher %C.V. values for rUgt quantification, all %C.V. were <20% 
for the analytical procedures. 
 
Validation 
Efficiency of tryptic digestion was evaluated by monitoring the ratios of 
missed cleavages following a timed digest of 50 µg of β-casein.  Missed 
cleavages were monitored through two MRMs from the peptides DERFFSDK 
(522.4/496.2, 522.4/481.1) and FFSDK (643.4/625.2, 643.4/349.2) along with 
IAKYIPIQYVLSR (782.3/764.3, 782.3/782.4) and YIPIQYVLSR (626.4/975.6, 
626.4/488.2) representing incomplete and complete digestion.  Complete 
digestion efficiency was observed when only MRMs from FFSDK and 
YIPIQYVLSR were observed following overnight digestion (Figure 4.9).  Interday 
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and intraday precision was obtained following five replicate digestions of pooled 
RLMs or membrane fractions prepared from frozen Wistar rat livers.  All %C.V. 
values for each of the casein digests were <20% while the difference in enzyme 
expression between the tissue and casein sample sets was minimal (Table 4.3). 
Calibration curves were generated for each of the peptide MRMs 
representative of the three rUgts (peptides 1-6).  All calibration curves were linear 
between 0.075-6.0 µg of microsomal protein (R2>0.98) (Figure 4.8).  The lower 
limit of detection (LLOD) was established at 15 fmol/mg protein by monitoring the 
signal: noise ratio at the lowest end of the calibration curves.  Enzyme 
expression measured in microsomes were obtained by averaging converted peak 
area ratios (unlabeled/labeled) of each peptide MRM with %C.V. <20% at the 
lowest end of the calibration curves.  The low end of the calibration curve was 
used to indicate optimal linear range for the tested peptides.  Values for %C.V. 
for transporters were determined through interday and intraday testing of Wistar 
liver membrane fractions.  Peptide 12 was eliminated for quantitative purposes 
because %C.V. values were >25% in both interday and intraday samples (Table 
4.3). 
 
Rat Microsomes 
Microsomal digests of Wistar, TR- and adenovirus treated (AVUgt) rat 
tissues (Miles et al. 2006) were examined for rUgt expression following validation 
of the quantitative proteomic method.  It has been previously reported that TR- 
rUgt levels are upregulated using a general rUgt1a antibody in a Western Blot 
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when compared with Wistar rat expression levels; however, this was not seen 
across all tissues (Johnson et al., 2006).  Using our specific quantitative 
proteomic method, while rUgt 1a1 was significantly upregulated in the TR- rat 
livers no other significant differences according to one way ANOVA analysis in 
rUgt expression of rUgt 1a1, 1a6 and 1a7 for any of the other tested tissues 
(Figure 4.10).  There was a general increase in rUgt1a1 and rUgt1a7 expression 
both between the Wistar and TR- rat tissues and proceeding down the segments 
of the GI tract within both sets of rat intestines (Figure 4.10).  Of the three 
isoforms, rUgt1a7 expression was often lower than rUgt1a1 and rUgt1a6 across 
all tissues with the exception of the S3 and S4 segments within the TR- rat GI 
tract.  Often expression levels of this isoform were below 1 pmol/mg protein, 
which would have been <LOD in our previous hUGT targeted proteomic assays 
established (Fallon et al., 2008). 
 
Rat Membrane Fractions 
Rat membrane fractions were isolated using the Novagen Membrane 
Extraction Kit from tissues following pharmacokinetic analysis and euthanasia.  In 
the Wistar rat tissue samples, rBcrp was the most abundant of the three 
transporters expressed, between 0.9 and 2.0 pmol/mg protein.  In the liver and 
kidney, there were no significant differences in transporter expression, and rBcrp 
expression was relatively unchanged between intestinal segments.  Expression 
of rMrp3 was generally higher in the liver and kidney as opposed to the GI tract 
and also was present in higher levels descending into the colonic segment (S4).  
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Expression levels of rMrp3 and rMrp2 were highest within the colonic segments 
of the intestine while rBcrp expression was minimal (Figure 4.11). 
In the TR- rats, as expected, rMrp2 was below detection limits in all 
samples, while both rMrp3 and rBcrp were dramatically upregulated in the liver 
and kidney.  In the liver, rMrp3 was the most abundant of the two transporters, 
which has been previously reported; however, rBcrp was expressed in a higher 
amount than rMrp3 in the kidney (Johnson et al., 2006).  In the intestine, there 
was a reversal of transporter expression, where rMrp3 was highest in S1 and S4 
of the GI tract while rBcrp expression was more abundant in segments S3 and 
S4 (Figure 4.11).  AVUgt rat liver expression of rMrp2 was not statiscally different 
compared with Wistar rat livers but both rMrp3 and rBcrp expression was 
significantly lower compared to Wistar rats (Figure 4.11). 
 
Correlation Analysis 
Correlation results were obtained following evaluation of both in vitro 
glucuronidation levels and enzyme and transporter expression across liver, 
kidney and intestinal segments from Wistar, TR- and AVUgt treated Gunn rats.  A 
strong correlation was seen between rUgt1a1 and rMrp2 (R2=0.75, Figure 4.14) 
but no correlations were observed between any other rUgt enzymes or 
transporters (R2<0.20, data not shown).  However, in vitro glucuronidation rates 
were found to correlate strongly with rMrp2 expression values across all species 
and tissues (Figure 4.12, 4.13).  In addition, a strong correlation (R2=0.76) was 
found between in vitro glucuronidation rates and rUgt1a1 across all tissue types; 
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however, there was no correlation between rUgt1a6 and glucuronidation rates 
(R2=0.18, Figure 4.12).  While it has been previously reported that in vitro MPA 
metabolism correlates with rUgt1a7 expression, initially correlation tests between 
the two conditions did not correlate across all tested liver, kidney and intestinal 
samples (Miles et al. 2006) (R2=0.21, data not shown).  When liver and kidney 
samples were removed from the dataset, the correlation improved (Figure 4.12) 
and supports previous reports that indicate in vitro glucuronidation rates depend 
on rUgt1a7 expression within the gastrointestinal tract (Miles et al., 2006). 
 
D. DISCUSSION 
 
The field of targeted quantitative proteomics has rapidly advanced over 
the last decade; however, many studies have not been able to link protein 
quantification with physiological effects.  In particular, drug metabolizing enzymes 
and protein biomarkers are of interest to many scientists due to the need to 
understand metabolism endpoints in preclinical testing and to increase to the 
likelihood of early detection of disease biomarkers for patients in the clinic.  Here 
we have attempted to examine the differential expression levels of both rUgt 
enzymes and transporters using in vitro and in vivo glucuronidation of MPA as a 
probe substrate. 
While MPA total clearance values varied slightly between Wistar and TR- 
rats (1.7 mL/min vs. 2.5 mL/min, Table 4.2), there was great variability in biliary 
clearances (1.1 mL/min vs. 0.09 mL/min, Table 4.2).  Initial pharmacokinetic 
 142 
studies centered on determining any differences in AUC or clearance levels 
between oral and IV dosing in Wistar rats.  Even though initial plasma 
MPA/MPAG plasma concentrations differed slightly due to first pass metabolism 
observed upon oral dosing of MMF compared with IV dosing, none of the 
pharmacokinetic parameters were significantly different between the Wistar rats 
(Table 4.2).  Furthermore, MPA/MPAG plasma concentration time curves were 
virtually identical after sixty minutes in both cannulated and Wistar rats after oral 
and IV dosing with intact bile ducts.  Both the oral and IV dosed Wistar rats 
demonstrated an increase in MPA plasma concentration between four and six 
hours post dosing, an indicator of enterohepatic cycling, which is typically seen 
between six and eight hours post dosing in humans and responsible for a 
significant fraction of overall MPA exposure in humans.  Using the IV and oral 
dose studies both the bile cannulated rats and control animals with intact bile 
flow, it was found that approximately between 20-39% of overall MPA exposure 
results from enterohepatic cycling.  Enterohepatic cycling is important for both 
rats and humans because it represents not only an increase in mean residence 
time and overall exposure to the parent compound, but can also increase efficacy 
and potential side effects, especially if intestinal metabolism or exposure to the 
parent drug is associated with toxicity. 
Previous experiments (Chapter 2) demonstrated that rats rapidly excrete 
acMPAG that is not cleaved by esterases within the body following IV 
administration of the pre-formed acyl glucuronide metabolite.  While previous 
experiments have indicated that acyl glucuronides can be taken back into the 
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liver following IV administration, it is also important to consider the possibility of 
rapid cleavage of the acyl glucuronide back to the parent aglycone, which may 
then be available for hepatic uptake and metabolism within the liver.  MPAG, 
which is resistant to esterase cleavage, was also administered intravenously to 
Wistar rats to evaluate the potential for reuptake and excretion of the intact 
glucuronide.  Following IV administration, MPAG is excreted rapidly into the bile 
within five minutes, but plasma levels of MPAG decrease rapidly to below 
detection limits within three hours.  Of the original IV dose of MPAG, 53% is 
ultimately excreted within the bile, indicating that glucuronide metabolites may be 
taken back up into the liver intact (Figure 4.4).  This could possibly serve as a 
tertiary source of parent aglycone exposure following potential β-glucuronidase 
cleavage within the liver, in addition to the initial dose and parent aglycone that is 
reabsorbed during enterohepatic cycling. 
The side effects of MPA are well documented, but of particular concern is 
the 20-30% fraction of the patient population that suffers from debilitating delayed 
onset diarrhea (Davies et al., 2007).  This particular side effect is troubling not 
only because of lifestyle factors, but also because many patients that exhibit this 
symptom must either alter MPA dosing levels or resort to second line therapy.  
Second line therapy can result in allograft rejection, leading to not only life 
threatening complications for the patients but also substantial increases in patient 
care costs for the individuals.  Within the body, MPA is detoxified through the 
actions of UGT enzymes in the liver and gastrointestinal tract, leading to the 
formation of two glucuronides, MPAG and acMPAG, which are then excreted in 
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bile and urine.  Even though many attempts have been made to link acMPAG 
exposure levels with the GI toxicity of MPA, no distinct correlations have been 
found and in vitro studies of the acMPAG metabolite indicate that compared with 
many acyl glucuronide metabolites, it is a fairly stable and unreactive metabolite 
(Chapter 2; Shipkova et al., 2003).  Therefore, our lab in collaboration with Miles 
and Ritter (VCU Medical Center, Richmond, VA) investigated different rat strains 
that exhibit variable rUgt and transporter expression, then modulated rUgt 
expression through the use of AVUgt Gunn rats (Miles et. al 2006).  MPA 
exposure in plasma varied, thus MPA toxicity also varied. 
While TR- rats demonstrated much lower MPA biliary clearance values 
during the pharmacokinetic experiments, CLtotal was generally higher than Wistar 
rats tested under the same conditions with bile collection.  Biliary clearance of 0.1 
mL/min and Febile below 10% in TR- rats were consistent with what has been 
previously reported (Westley et al., 2006).  The retention of some biliary efflux of 
MPAG in TR- rats indicates that glucuronide efflux into the bile involves 
additional canicular transporters besides Mrp2.  While BCRP single nucleotide 
polymorphisms have been linked to altered MPA exposure levels in humans, 
Bcrp is likely a minor factor in rat MPAG elimination due to the low biliary 
clearance levels observed in TR- rats (Miura et al., 2008). 
Analysis of in vitro glucuronidation demonstrated no statistically significant 
differences between Wistar and TR- rat tissue samples.  Generally, there was a 
modest increase in MPA glucuronidation rates between Wistar and TR- rat liver 
and kidney samples (Figure 4.5).  Westey et al. reported a modest increase in 
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TR- rat liver glucuronidation rates and attributed this as being due to increases in 
rUgt1a enzymes (Johnson et al., 2006; Westley et al., 2008).  However, because 
a general antibody for all rUgt1a isoforms was used in determining changes in 
rUgt expression levels, it has been difficult to determine if the increase in rUgt 
expression can be related to increased MPA glucuronidation capacity.  In order 
to more precisely examine this relationship, it was beneficial to develop an assay 
to quantify rUgt1a1, 1a6 and 1a7, which are primarily responsible for MPA 
glucuronidation within rats (Miles et al., 2005). 
Targeted quantitative proteomic assays were performed on the 
nanoACQUITY UPLC system connected to the QTRAP 5500 using 15 stable 
isotope (C13, N15) internal standards.  Standards were selected and purchased 
following in silico digest of each respective protein of interest following selection 
rules (avoid extensive hydrophilicity/hydrophobicity, 8mer-16mer in length, no   
D-G N terminus, no C or W residues) that we have previously outlined  (Fallon et 
al., 2008).  In addition, peptide selections were based on previous experience 
with peptides used in hUGT quantification, where it was found that multiply 
charged peptides are much more common with multiple histidine residues and 
proline residues generate preferential MRM product ions (Fallon et al., 2008; 
Vaisar and Urban, 1996).  Only two peptides were selected for quantification of 
each of the three rUgts studied due to their shorter protein sequences, which 
resulted in a lack of ideal stable isotope peptide standards.  Upon infusion, all 
peptides were doubly charged with the exception of peptide 6 
(TVSV*SHTSQEDQEDLNR) and peptide 9 (LIHDLLVLF*LNPQLLK), which were 
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triply charged.  While peptide 9 demonstrated excellent reproducibility on the LC-
MS/MS system, peptide 6 lacked consistent reproducible LC retention times.  
Peptide 6 was then optimized again on the MS/MS system following infusion.   
Even though the triply charged state was approximately ten fold more abundant 
than the doubly charged state, peptide 6 was optimized using the doubly charged 
ion and subsequently produced consistent and reliable LC retention times and 
adequate MS/MS sensitivity.   Despite careful evaluation during the peptide 
selection process, peptide 12 (YP*GLELVLK, rMrp3) was ultimately excluded 
from the analysis due to excessive variability when applied to assays for the 
analysis of membrane fractions.  Unlike previous experiments (Chapter 3), all 
peptides produced strong MRM product ion spectra and were easily resolvable 
on the nano-UPLC MS/MS system. 
The LC properties of the stable isotope standards and their corresponding 
unlabeled peptides from the digested proteins produced several distinct windows 
of peptide retention times (Figure 4.7).  This was addressed by the development 
of a scheduled MRM method to optimize instrument dwell times and ensure that 
enough data points are collected across a peak.  While previous experiments 
with scheduled MRMs were based on peak widths between 60-90 seconds 
allowing for generous dwell times (Fallon et al., 2008), the advantages of UPLC 
often resulted in peak widths as small as 10 seconds for particular peptides 
(Figure 4.7).     Because of this, it became necessary to shorten dwell times from 
60ms employed on the API 3000 to approximately 3-5ms using scheduled MRMs 
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on the QTRAP 5500 to acquire sufficient points across a particular MRM peak for 
all 60 MRMs analyzed within a single LC run. 
Calibration curves for each peptide representing a rUgt enzyme were 
established to validate the lower limit of quantification (LLOQ) and linear range of 
the assay with injection of approximately 0.2 µg of digested protein on column.  
At the low end of the calibration curve (75 fmol/mg protein) the signal to noise 
ratio (S:N) was approximately 25:1 for each peptide, resulting in a 30 fmol/mg 
protein LLOQ value.  To validate the effectiveness of peptides used for 
quantification of membrane transporters, the %C.V. values from the interday and 
intraday analysis were evaluated since recombinant transporters were not 
available to determine linear ranges of the assays.   Any targeted peptides with 
%C.V. values >25% were excluded from the analysis.  Peptide 12 was excluded 
from all transporter analyses because %C.V. values were >25% for both MRMs 
in both the interday and intraday validations.  All other peptide %C.V. values 
were below 20% during validation and the MRM measurements for each peptide 
were averaged to generate the transporter expression data.  Transporter 
expression levels not only agreed between peptide MRMs on the QTRAP 5500 
but also between the three peptides employed for quantification of rMrp2 and 
rBcrp and the two peptides used for quantification of rMrp3 (Table 4.5; Table 
4.6). Compared to our previous targeted proteomic assays for human UGTs 
using the LIT-TOF with capillary LC (Chpater 3), the %C.V. values obtained on 
the ABI 5500 were generally lower but no significant differences in assay 
precision have been observed across any of the three instrument platforms 
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evaluated to date (Fallon et al., 2008).  However, the limit of detection of the ABI 
5500 (rUgt 1a1, 1a6, 1a7 and transporters) was fifty fold lower (0.01 pmol/mg 
protein vs. 0.5 pmol/mg protein) compared to both the ABI 3000 (for hUGT1A1 
and 1A6) and the LIT-TOF (for all active hUGT1A isoforms).  
After assay development and validation, Ugt enzymes between Wistar, 
TR- and AVUgt rats were analyzed on the LC-MS/MS system.  Previous 
experiments using Western Blots have indicated that rUgt1a enzymes increase in 
concentration from the duodenum section of the GI tract descending into the 
colon (Miles et al., 2006; Shelby et al., 2003).  In addition, mRNA analysis 
indicates that rUgt1a1 is the most prevalent isoform of the rUgt enzymes followed 
by rUgt1a6 and rUgt1a7 (Miles et al., 2006; Shelby et al., 2003).   Current RT-
PCR assays lack consistent sensitivity to detect rUgt1a7 within the liver, and 
these same studies detected this isoform within each section of the intestinal 
tract.  Using the LC-MS/MS analytical procedure, we were able to detect rUgt1a7 
in the liver, kidney and intestinal tracts in both Wistar and TR- rats.  
Consistent with previous reports, rUgt1a1 was the most prominent 
enzyme within the liver in across all rat strains (Figure 4.10).  Ugt1a7 was 
expressed at the highest levels within the colon in both Wistar and TR- rats with 
a general trend of increasing expression from the duodenum to the colon of the 
GI tract.  Despite altered expression levels of rUgt1a1 and rUgt1a7 across tissue 
segments of the GI tract, expression of rUgt1a6 remained relatively unchanged.  
MPA glucuronidation within the kidney was approximately 40% of the levels 
within the liver, which was supported by both in vitro glucuronidation studies, but 
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also by previous experiments using selective antibodies with Western Blots 
showing that rUgt1a1 and rUgt1a7 levels were approximately half of those seen 
in the liver (Stern et al., 2007).  Miles et al. reported that rUgt1a7 preferentially 
glucuronidates MPA compared to rUgt1a6 and rUgt1a1 in rats, which suggests 
that MPA glucuronidation rates should be higher within liver and colon compared 
to other tissues (Miles et al., 2005; Miles et al., 2006).  While MPA toxicity is 
minimal within the liver, MPA toxicity within the colon is one of the primary 
sources of delayed onset diarrhea.  The higher levels of rUgt1a7 and MPA 
glucuronidation capacity likely help protect Wistar rats, which are resistant to 
MPA toxicity, while Gunn rats, which lack all rUgt1a activity within all organs, are 
susceptible to MPA induced side effects (Miles et al., 2006). 
While there were no statistically significant differences in rUgt1a6 and 
rUgt1a7 expression between Wistar and TR- rats, rUgt1a1 was significantly 
upregulated in TR- rat livers (Figure 4.10).  Previous reports of glucuronidation in 
TR- rat livers indicate a slight increase in glucuronidation catalysis, but significant 
upregulation of rUgt expression when measured using Western Blots and RT-
PCR (Johnson et. al 2006; Westley et al. 2006).  The expression studies 
presented here using targeted quantitative proteomics indicate that while rUgt1a1 
expression significantly increases in TR- rats, it is likely that alterations in 
transporter expression also factor in overall differences in MPA exposure 
between TR- rats and Wistar rats.  This is because previous studies have 
indicated that rUgt1a1 is not the primary rUgt isoform involved in MPA 
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glucuronidation in the rat due to its higher Km and Vmax compared with rUgt1a7 
(Miles et al., 2006).   
Many previous experiments with membrane transporters have indicated 
that rMrp2 is highly expressed within the liver, kidney and brush border of the 
intestinal tract (Johnson et al., 2006).   In addition, rBcrp and rMrp3 are also both 
highly expressed within the liver with variable expression within the intestinal 
tract.  The experiments presented here have indicated that rMrp2 is highly 
expressed within the liver, kidney, duodenum and colon and found at lower levels 
within the jejunum and ileum.  In Wistar rats, rMrp3 is present at lower levels than 
both rMrp2 and rBcrp except within the colon, and rMrp3 lacks any discernible 
pattern of expression within the intestinal tract.  Compared to previous reports in 
the literature, levels of rMrp2 in Wistar rats found here by quantitative proteomics 
were approximately three fold lower than those reported in Sprague Dawley rats 
(Li et al., 2008).  Because of the lack of genetic homogeneity within the outbred 
Sprague Dawley rat strains, along with differences in methodology, it is difficult to 
directly compare transporter expression levels between labs and species.   Miles 
et al. noted that Sprague Dawley rats have approximately three fold higher in 
vitro MPA glucuronidation rates compared with Wistar rats (20.7 nmol/min/mg vs 
6.0 nmol/min/mg) (Miles et al., 2006).  The data presented in Figure 4.13 show 
that rMrp2 expression and in vitro glucuronidation rates correlate strongly, and 
enhanced rMrp2 expression could be a compensatory effect of increased 
glucuronidation capacity that varies with rat strain. 
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Unlike rMrp2, rBcrp was highly expressed within the liver and kidney but 
expression drops off within the intestinal tract.  rBcrp levels within the liver and 
kidney (1.8 pmol/mg protein, Figure 4.11) were slightly higher than those 
reported by Li et al. within Sprague Dawley rats (Li et al., 2009).  Using absolute 
quantitative proteomics, it is possible to compare values between labs, which 
were not feasible when using relative measurements with Western Blots to 
evaluate protein expression.  Expression of rBcrp within the intestinal tract of rats 
was largely unchanged descending from the duodenum to the colon and was the 
least prominent of the three tested transporters in the colon.  While the three 
efflux transporters within the Wistar and AVUgt strains were moderately 
expressed, tissue levels of the transporters changed substantially when 
compared with TR- rats (Figure 4.11). 
There was a significant difference in rMrp3 levels within the tissues of the 
TR- rats with rMrp3 expression increasing five fold in both the liver and kidney 
relative to Wistar rats (Figure 4.11).  Alterations in transporter expression were 
more modest between Wistar and TR- rats within the intestinal tract with minor 
decreases in rBcrp expression and increases in expression of rMrp3 primarily 
within the duodenum and colon.  Previous reports with Western Blots of Wistar 
and TR- rats indicated a 500% increase in rMrp3 expression in TR- rat livers with 
minor decreases between TR- rats and Wistar rats across the intestinal tract in 
both rMrp3 and rBcrp expression (Johnson et al., 2006).  The data presented 
here supports those earlier studies with some exceptions for rBcrp within the liver 
and rMrp3 within the intestinal tract.  While Figure 4.11 shows slight increases in 
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rMrp3 levels in both the duodenum and colon, previous studies using Western 
Blot studies reported decreases in expression of both transporters of interest in 
rats (Johnson et al., 2006).  It is likely that differences in sample preparation 
(cellular homogenate vs. membrane fractions) and tissue handling 
(homogenizing buffers, tissue extract conditions) contribute to this variability in 
discernible expression levels.  In addition, the differences in assay methodology 
and lack of linearity of relative quantification with a Western Blot compared with 
targeted quantitative proteomics also contribute to variability in membrane 
transporter expression levels seen between the quantitative proteomics and the 
Western Blot method (Hoofnagle and Werner, 2009).  The combination of 
increased levels of rMrp3 and rUgt1a1 enzymes, together with the decrease in 
efflux to bile by loss of rMrp2 contributes to the increased MPAG levels seen 
within the TR- rat plasma, while the maintenance of 10% of MPAG bilary 
excretion in TR- rats compared with Wistar rats within the bile indicate that rBcrp 
is likely a minor factor in the biliary excretion of MPAG in control Wistar rats. 
Levels of both rMrp3 and rBcrp in AVUgt rats were largely unchanged with 
slight but not statistically significant increases in rMrp2 expression (Figure 4.11).  
Liver transporter levels in AVUgt rats were lower than the control Wistar strains 
and significantly lower than TR- rat livers (p<0.05).  Gunn rats, the rUgt1a 
deficient background strain of the AVUgt rats, have been reported to possess 
upregulated rMrp3 transporter expression compared to Sprague Dawley rats 
(Higuchi et al., 2004).   Interestingly, this was not seen within our experiments, 
although it should be noted that mRNA expression of rMrp3 is actually decreased 
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in Gunn rats and it is possible that nuclear receptor cofactors could be altered by 
enhanced rUgt expression (Higuchi K et al., 2004).  In addition, compensatory 
changes in transporter expression in AVUgt rats may not be linear since it takes 
four days for the adenovirus vector to restore rUgt expression within the liver 
after IV administration to Gunn rats (Miles et al., 2006).  This delayed response in 
transporter expression following rUgt restoration in Gunn rats could explain the 
lack of changes in tranporter expression levels.    
While the experiments performed here were able to correlate rUgt1a1 
expression with rMrp2, no other relationships were established between rUgt 
isoforms and tested transporters.  Correlating expression levels of each tested 
rUgt isoform with each individual transporter generated very poor correlations 
(R2<0.20, Figure 4.12, 13, 14), indicating that large scale coordinate up or down 
regulation of rUgt enzymes and transporters is unlikely.  While many nuclear 
factors are shared between the two types of proteins (pregnane X receptor 
(PXR), constitutive androstane receptor (CAR), aryl hydrocarbon receptor (AhR)) 
there are many different regulatory sequences within the genome and protein 
sequences of each protein affecting expression at different levels (Wong et al., 
2005).  In humans, many primary transcription factors involved in UGT 
expression such as the cdx2 domain within the intestine, hepatocyte nuclear 
factor 1-alpha (HNF-1α) and the TATA box have not been linked to altered 
transporter expression (Strassburg et al., 1997; Tukey and Strassburg, 2000).  
The large differences in the type and behavior of the regulatory sequences 
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between the two types of proteins may explain their lack of coordinate and 
compensatory expression between subtypes and isoforms. 
 While there was no observed coordinate expression between the three 
efflux membrane transporters and the three rUgt enzymes of interest, there were 
strong correlations observed between MPAG formation levels with some of the 
membrane transporters and rUgts.  A very strong correlation was observed 
between rMrp2 and MPA glucuronidation activity across all tissues, potentially 
indicating that while individual compensatory regulation is unlikely between rUgts 
and transporters, overall glucuronidation capacity could factor in efflux 
transporter expression (Figure 4.12-14).  This is also seen in TR- rat livers, 
where rMrp2 expression is absent yet rUgt1a enzymes and rMrp3 are both 
upregulated, resulting in increased glucuronide conjugate concentrations within 
the blood due to increased efflux into the sinusoid of hepatocytes (Figure 4.1) 
(Johnson et al., 2006).  Miles et al. have previously established a strong 
correlation between rUgt1a7 expression and MPA glucuronidation activity levels 
in rats (Miles et al., 2006).  Initially, this relationship was not seen in our 
experiments; however, once the data from the intestinal tract was isolated from 
the liver and kidney rUgt studies, a strong correlation was observed between 
rUgt1a7 levels and MPA glucuronidation (Figure 4.12).  The higher levels of 
rUgt1a1 within the liver and kidney likely contributed to the nonlinear relationship 
between rUgt1a7 levels and MPA glucuronidation activity.   
 This research successfully developed a targeted quantitative proteomic 
method to analyze the primary rUgt1a isoforms and membrane transporters 
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involved in MPA metabolism and hepatic efflux in rats.  While coordinate 
regulation between individual rUgt isoforms and membrane transporters is 
unlikely due to the high degree of sequence homology between UGT enzymes, 
resulting in a number of similarities in substrate specificity between isoforms, 
glucuronidation activity could potentially result in higher expression levels of 
membrane transporters involved in glucuronide efflux (Meech and Mackenzie, 
1997; Tukey and Strassburg, 2000).  Previous experiments have suggested that 
acMPAG is not reactive enough to be a primary factor in MPA induced toxicity, 
so the increased expression of rUgt enzymes within the intestinal tract of both the 
Wistar and TR- rat livers could potentially limit MPA exposure to intestinal 
epithelial cells and toxicity within the gastrointestinal tract (Arns, 2007; Saitoh et 
al., 2005; Stern et al., 2007).  The likely combination of rMrp3 and rUgt1a1 
upregulation within the liver of TR- rats contributes with the loss of rMrp2 to 
elevated levels of MPAG and decreased levels of MPA within the blood while 
markedly decreased biliary clearance indicates that rBcrp is not a primary 
transporter involved in MPAG efflux in the rat.  The continued development of 
targeted quantitative proteomics will continue to advance our understanding of 
the relationship between protein expression and metabolite disposition, providing 
investigators with an improved  ability to properly evaluate the inter relationships 
of transporter protein and enzyme activity levels in tissues.    
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Figure 4.1.  The disposition of MPA (  ) and MPAG (■) in plasma of bile 
cannulated rats after administration of 50 mg/kg MMF (33 mg/kg MPA 
equivalents) to Wistar rats (oral dosing, A and IV dosing, B) and oral dosing (C) 
to TR-rats. Data are presented as Mean±SE, n=5. 
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Figure 4.2.  The disposition of MPA (  ) and MPAG (■) in plasma of Wistar rats 
without bile duct cannulation is shown after administration of 50 mg/kg MMF (33 
mg/kg in MPA equivalents).   A, oral dose; B, intravenous dose.  Data is 
presented as Mean±SE, n=5. 
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Figure 4.3.  Total biliary excretion of combined acMPAG and MPAG in Wistar 
and TR- rats after a single 50 mg/kg dose of MMF (33 mg/kg in MPA 
equivalents).  Biliary excretion values are shown for oral (■, top) and IV (   ) 
dosing to Wistar rats and oral dosing to TR- (■, bottom) rats.  Data represents 
mean ±SE of biliary excretion values (n=5).  In all cases acMPAG was a minor 
component of bile representing ~5% of MPA equivalents in bile.  MPA was not 
measureable in bile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 160 
 
 
0
50
100
150
200
0 50 100 150 200 250 300 350 400 450 500
Time (min)
M
PA
G
 (u
g/
m
L)
0
200
400
600
800
1000
To
ta
l B
ili
ar
y
Ex
cr
et
io
n 
(μ
g)
, (
--
-)
M
PA
G
 (u
g/
m
L)
To
ta
l B
ili
ar
y
Ex
cr
et
io
n 
(μ
g)
, (
--
-)
 
 
Figure 4.4.  MPAG bile and plasma levels following 2.5 mg/kg IV MPAG (in MPA 
equivalents) administration to male Wistar rats with bile cannulation.  Solid lines 
indicate plasma concentration data while total biliary excretion levels are 
demarcated by dashed lines.  Symbols indicate mean values (n=3) for MPAG in 
bile (  ), MPAG in plasma (■) and MPA in plasma (▲).  Data are presented as 
mean±SE (n=3). 
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Figure 4.5.  In vitro MPA glucuronidation rates for tissues from Wistar and TR- 
rats extracted following pharmacokinetic studies.  MPA (1mM) incubations were 
stopped at 15 and 30 minutes and the obtained MPAG concentrations were 
averaged between the separate time periods to generate glucuronidation profiles. 
Data are presented as mean+SE (n=4). 
*S1-S4 refers to intestinal segments obtained following rat euthanasia             
(S1-duodenum, S2-10cm segment of jejunum, S3-10 cm distal to caecum, S4- 
colon) 
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Figure 4.6.  Representative product ion scan of 1 μg/mL infusion of peptide 3 
heavy labeled standard (ENQF*DALFR, parent ion 575.4) on the QTRAP 5500 
system yielding product ions for MRM quantification of peptide 3 representing 
rUgt1a6.  Product ions y4 and y5 were selected for quantification based on 
signal intensities. 
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Figure 4.7.  MRM chromatogram of 1.5 µg recombinant rUgt microsomal protein 
digest (containing rUgt1a1, 1a6 and 1a7) equivalent to 1.6 pmol/mg protein 
analyzed on the nanoACQUITY UPLC/QTRAP 5500 system.  Extracted ion 
chromatograms from two MRMs of heavy labeled peptide 3 (ENQF*DALFR) and 
its corresponding unlabeled peptide representative of rUgt1a6 MRMs are 
enlarged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 164 
y2 = 0.4942x + 0.0246
R2 = 0.995
y1 = 0.5211x + 0.0293
R2 = 0.9975
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0 2 4 6
Micrograms of recombinant 1a6 microsomal protein
Pe
ak
 A
re
a 
R
at
io
 
(u
nl
ab
el
ed
/la
be
le
d)
570.4/621.4
570.4/506.4
Pe
ak
 A
re
a 
R
at
io
 
(u
nl
ab
el
ed
/la
be
le
d)
 
 
Figure 4.8.  Calibration curves constructed from 5 replicate digests for two 
MRMs (y1 570.4/621.4, y2 570.4/506.4) of peptide 3 representative of rUgt1a6.  
Data is presented as mean ± SE. 
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Figure 4.9.  Time dependant tryptic digestion of β-casein protein using specific 
MRMs from two peptides monitoring missed cleavages sites performed in 
triplicate.  Peptide MRMs representing complete (solid line) digestion obtained 
from peptides FFSDK (   ) and YIPIQYVLSR (  ) and incomplete digestion (dotted 
line) from DERFFSDK (  ) and IAKYIPIQYVLSR (  ).  Peak areas ratios were 
obtained from the peptide MRMs using peptide 4 (ENQF*DALFR) as the internal 
standard.  Measured area ratios were then compared between missed cleavage 
peptides to generate time dependant digestion curve.   
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Figure 4.10.  Graph indicates mean+SE (n=3 animals in duplicate) rUgt 
expression levels in tested rat tissues obtained following pharmacokinetic 
studies.  One way ANOVA statistical analyses were used to evaluate potential 
significant differences in expression between each enzyme isoform across all 
tested tissues along with evaluating strain differences in rUgt expression.  
*W refers to Wistar rat samples while TR- refers to TR- rats samples AV tissues indicates livers 
that were obtained from Dr. Ritter representing adenovirus (AVUgt) treatment of native Gunn rats 
to restore glucuronidation capacity  
**S1-S4 refer to different segments of the GI tract extracted following euthanasia of rats with S1 
containing the duodenum and S4 the distal colon as detailed in METHODS 
a Significantly different between other tissue samples (rUgt1a1) (p<0.05) 
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Figure 4.11.  Graph indicates mean+SE (n=3) rat transporter expression levels 
in rat tissues following pharmacokinetic studies.  Representative transporters 
evaluated were rMrp2 (Abcc2), rMrp3 (Abcc3) and rBcrp (Abcg2).  One way 
ANOVA statistical analyses were used to evaluate potential significant 
differences in expression between each transporter across all tested tissues 
along with evaluating strain differences in rat transporter expression.  
*All rMrp2 measurements were <LOD (0.01 pmol/mg protein) in TR- rat tissues 
**W refers to Wistar rat samples while TR- refers to TR- rats samples AV tissues were obtained 
from Dr. Ritter representing AVUgt treatment of native Gunn rats to restore glucuronidation 
capacity. 
***S1-S4 refer to different segments of the GI tract extracted following euthanasia of rats with S1 
containing the duodenum and S4 the distal colon 
a rMrp3 significantly different between other tissue samples across all tested rat strains (p<0.05) 
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Figure 4.12.  Correlation analysis relating glucuronidation activity (MPA 
catalysis) levels in rat liver (■), intestine (  ) and kidney (▲) (averaged, n=3 
animals) to protein expression data obtained using quantitative proteomics.  
Correlation analysis was performed for glucuronidation rate vs. rUgt1a1 (A), 
glucuronidation rate vs. rUgt1a6 (B), glucuronidation rate vs. intestinal rUgt1a7 
(C).  Data points are averaged (n=3) from tissue measurements from microsomal 
protein or membrane fractions in Wistar, TR- and AVUgt rats (liver only).  In vitro 
rates were matched with enzyme expression for each strain and tissue type to 
obtain R2 values.   
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Figure 4.13.  Correlation analysis relating glucuronidation activity (MPA 
catalysis) levels in rat liver (■), intestine (  ) and kidney (▲) (averaged, n=3 
animals) to protein expression data obtained using quantitative proteomics.  
Correlation analysis was performed for glucuronidation rate vs. rMrp2 (A), 
glucuronidation rate vs. rMrp3 (B), glucuronidation rate vs. intestinal rBcrp (C).  
Data points are averaged (n=3) from tissue measurements from microsomal 
protein or membrane fractions in Wistar, TR- and AVUgt rats (liver only).  In vitro 
rates were matched with enzyme expression for each strain and tissue type to 
obtain R2 values.   
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Figure 4.14.  Correlation analysis relating rUgt expression levels in rat liver (■), 
intestine (  ) and kidney (▲) (averaged, n=3 animals) to protein expression data 
obtained using quantitative proteomics.  Correlation analysis was performed for 
glucuronidation rate vs. rUgt1a1 (A), glucuronidation rate vs. rUgt1a6 (B), 
glucuronidation rate vs. intestinal rUgt1a7 (C).  Data points are averaged (n=3) 
from tissue measurements from microsomal protein or membrane fractions in 
Wistar, TR- and AVUgt rats (liver only).  Expression levels of rUgt enzymes were 
matched with rMrp2 levels for each strain and tissue type to obtain R2 values.   
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Table 4.1.  Rat Ugt/Transporter stable isotope labeled peptide standards and 
MRM transitions used for rat enzyme expression studies with QTRAP 5500 
system.  Optimal MRM transitions were obtained following direct infusion of 
heavy labeled standards (1 μg/mL). 
 
Peptide 
Number 
Protein of 
Interest 
Peptide Sequence MRM 
Transitions 
Peptide 1 rUgt1a1 SVFP(13C5,15N)QDPFLLR 663.0/651.5 
663.0/634.5 
Peptide 2 rUgt1a1 EGSF(13C9,15N)YTMR 500.9/407.1 
500.9/570.4 
Peptide 3 rUgt1a6 ENQF(13C9,15N)DALFR 575.4/621.4 
575.4/506.4 
Peptide 4 rUgt1a6 SVFP(13C5,15N)VPYNLEELR 735.5/773.3 
735.5/936.4 
Peptide 5 rUgt1a7 YFSLP(13C5,15N)SVVFSR 654.5/797.5 
654.5/997.5 
Peptide 6 rUgt1a7 TYSV(13C5,15N)SHTSQEDQEDLNR 778.2/875.4 
778.2/774.3 
Peptide 7 rMrp2 ALTL(13C6,15N)SNLAR 483.5/560.1 
483.5/656.0 
Peptide 8 rMrp2 AFTSITL(13C6,15N)FNLLR 
 
701.9/883.5 
701.9/662.3 
Peptide 9 rMrp2 LIHDLLVF(13C9,15N)LNPQLLK 596.1/479.2a 
596.1/592.3a 
Peptide 10 rMrp3 TAII(13C5,15N)GVLYR 506.4/613.0 
506.4/726.6 
Peptide 11 rMrp3 TTYP(13C5,15N)YIASNR 596.4/723.4 
596.4/826.3 
Peptide 12 rMrp3 YP(13C5,15N)GLELVLK 519.8/612.3 
519.8/723.2 
Peptide 13 rBcrp VGTQF(13C9,15N)TR 409.8/276.2 
409.8/240.1a 
Peptide 14 rBcrp AELDQLP(13C5,15N)VAQK 609.4/548.1 
609.4/661.6 
Peptide 15 rBcrp TIIF (13C9,15N)SIHQPR 663.5/551.4 
663.5/663.2 
 
a: Transitions were b ions.  All other transitions represent y ions. 
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Table 4.2.  MPA pharmacokinetic estimates in rats were obtained using Noncompartmental pharmacokinetic endpoints 
after 50 mg/kg single dose of MMF (33 mg/kg in MPA equivalents).  AUC and clearance values were measured for 
individual rats then averaged.  Numbers in bold indicate significant difference (p<0.05) using one way ANOVA.  Values 
not available are denoted with an * while MPA exposure levels were calculated as indicated in the footnotes below.   
 
Pharmacokinetic 
Parameter 
IV BDa Cannulated 
Wistar rats 
(n=5) 
PO BDa 
Cannulated 
Wistar rats 
(n=5) 
PO BDa 
Cannulated 
TR- rats  
(n=4) 
IV BDa Intact 
Wistar rats 
(n=4) 
PO BDa Intact 
Wistar rats  
(n=4) 
Tmax (min) * 36.0±13.4 75.0±30.0 * 220.0±34.6 
Cmax (µg/mL) 145.4±40.3 89.1±21.6 20.1±3.4 50.8±12.6 34.9±10.7 
t1/2 (hr) 2.5±0.7 3.0±0.7 2.9±0.5 2.0±0.6 2.2±0.8 
AUC(MPA0---inf) 
(mg/mL*min) 10.3±1.7 11.6±1.2 6.1±1.2 14.3±3.3 12.3±4.6 
AUC(MPAG0---inf) 
(mg/mL*min) 6.7±2.8 6.0±1.7 42.1±3.9 16.1±2.5 14.2±2.5 
AUCMPAG/AUCMPA 0.63±0.28 0.53±0.15 6.94±2.13 1.24±0.28 1.21±0.34 
CLbiliary (mL/min)e 1.1±0.3 0.81±0.23  0.09±0.03 * * 
Total Clearance 
(mL/min) 1.7±0.3 1.2±0.1
b 
 
2.5±0.4b 
 
1.9±0.3 1.8±0.5 
Febilec 0.64±0.14 0.68±0.09 0.031±0.009 * * 
MPA exposure 
derived from EHCd * 
* 
* 0.39 0.20 
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Data are presented as mean±SD. 
a: BD= bile duct 
b: CL/F for oral dosing 
c: Sum of MPAG and acMPAG in bile collected over 8 hours 
d: %EHC= 
)(inf)0(
)(inf)0()(inf)0(
)(
)()(
Cannulated
CannulatedIntact
MPAAUC
MPAAUCMPAAUC
→
→→ −  
e: Apparent CLbiliary=
 AUC
)(
inf)(MPA0 →
∑ + bilebile acMPAGMPAG  
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Sample rUgt1a1 rUgt1a6 rUgt1a7 rMrp2 rMrp3 rBcrp 
aWistar Liver 8.3 2.1 0.8 * * * 
(%C.V.) (6.3) (16.0) (6.6) * * * 
cWistar Liver 
Membrane * * * 1.9 0.7 1.9 
(%C.V.) * * * (5.7) (19.1) (15.6) 
 
 
 
**Samples were analyzed on the nanoACQUITY UPLC-QTRAP 5500 instrument with a BEH 
column (150 μm X 100 mm X 1.7 μ) at 2 μL/min using a linear gradient conducted as follows:  0 
min, 15% B; 5 min, 15% B; 25 min, 65% B; 25.1 min, 99%B; 30 min, 15% B; reequilibration until 
40 minutes. QTRAP5500 was operated in positive mode with the Nanospray III source using 
Scheduled MRMs optimized as indicated in METHODS.   
 
 
 
 
 
 
 
 
 
 
 
Table 4.3.  Assay method validation of intraday variability of rUgt enzymes and 
membrane transporter expression levels were averaged from five replicate 
measurements.  Units are expressed as pmol/mg microsomal protein (n=5) 
* Indicates samples were below limit of detection (<0.01 pmol/mg protein) 
a Denotes intraday rUgt measurements from Wistar liver microsomes 
bDenotes intraday transporter measurements from Wistar liver membrane 
fractions 
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Table 4.4. Interday Variability of rUgt enzymes and membrane transporter 
expression levels were averaged from five replicate measurements in pmol/mg 
protein 
Sample rUgt1a1 rUgt1a6 rUgt1a7 rMrp2 rMrp3 rBcrp 
aWistar 
Liver 8.1 1.9 1.0 * * * 
(%C.V.) (7.9) (11.0) (15.6) * * * 
bWistar 
Liver 
Membrane 
* * * 1.7 0.7 1.4 
(%C.V.) * * * (18.6) (12.6) (8.8) 
 
* Indicates samples were below limit of detection (<0.01 pmol/mg protein) 
a Denotes interday rUgt measurements from Wistar liver microsomes 
b Denotes interday transporter measurements from Wistar liver membrane 
**Samples were analyzed on the nanoACQUITY UPLC-QTRAP 5500 instrument with a BEH 
column (150 μm X 100 mm X 1.7 μ) at 2 μL/min using a linear gradient conducted as follows:  0 
min, 15% B; 5 min, 15% B; 25 min, 65% B; 25.1 min, 99%B; 30 min, 15% B; reequilibration until 
40 minutes. QTRAP5500 was operated in positive mode with the Nanospray III source using 
Scheduled MRMs optimized as indicated in METHODS.   
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Table 4.5. Individual peptide measurements of rUgt enzyme expression levels 
were averaged from five replicate measurements.  Two MRMs from each peptide 
were selected (Table 4.1) and averaged between each individual sample. 
 
Sample rUgt1a1 rUgt1a1 rUgt1a6 rUgt1a6 rUgt1a7 rUgt1a7 
Peptide 1 2 3 4 5 6 
rUgt 
(pmol/mg 
protein) 
5.53 7.25 1.47 1.08 1.31 1.10 
(%C.V.) (8.7) (16.1) (8.6) (12.3) (20.8) (6.3) 
 
*Samples were analyzed on the nanoACQUITY UPLC-QTRAP 5500 instrument with a BEH 
column (150 μm X 100 mm X 1.7 μ) at 2 μL/min using a linear gradient conducted as follows:  0 
min, 15% B; 5 min, 15% B; 25 min, 65% B; 25.1 min, 99%B; 30 min, 15% B; reequilibration until 
40 minutes. QTRAP5500 was operated in positive mode with the Nanospray III source using 
Scheduled MRMs optimized as indicated in METHODS. 
**Peptide Selection Rules for Quantification: 1) If recombinant protein available, must produce a 
linear standard curve with a %C.V. <25% at the base of the calibration curve, 2) must produce a 
%C.V. <25% on both interday/intraday validation, 3) if two peptides are used for protein 
quantification average protein concentrations must be within 50% of each other.  
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Table 4.6. Individual peptide measurements of rat transporter expression levels were averaged from five 
replicate measurements.  Two MRMs from each peptide were selected (Table 4.1) and averaged 
between each individual sample.  For each transporter three peptides were selected for quantification 
with the exception of rMrp3 due to the elimination of peptide 12 based on selection rules. 
 
Sample rMrp2 rMrp2 rMrp2 rMrp3 rMrp3 rBcrp rBcrp rBcrp 
Peptide 7 8 9 10 11 13 14 15 
Rat 
Transporter 
(pmol/mg 
protein) 
1.53 2.13 1.71 0.54 0.44 1.61 1.39 2.09 
(%C.V.) (14.5) (23.9) (11.9)_ (20.2) (19.2) (17.1) (17.6) (7.8) 
 
*Samples were analyzed on the nanoACQUITY UPLC-QTRAP 5500 instrument with a BEH column (150 μm X 100 mm X 1.7 
μ) at 2 μL/min using a linear gradient conducted as follows:  0 min, 15% B; 5 min, 15% B; 25 min, 65% B; 25.1 min, 99%B; 30 
min, 15% B; reequilibration until 40 minutes. QTRAP5500 was operated in positive mode with the Nanospray III source using 
Scheduled MRMs optimized as indicated in METHODS.   
**Peptide Selection Rules for Quantification:  1) If recombinant protein available, must produce a linear standard curve with a 
%C.V. <25% at the base of the calibration curve, 2) must produce a %C.V. <25% on both interday/intraday validation, 3) if two 
peptides are used for protein quantification average protein concentrations must be within 50% of each other.  
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The experiments presented here utilizing novel methods for the 
quantitative analysis of UGTs and transporters have increased our understanding 
of MPA metabolism and disposition while beginning to establish relationships 
between quantitative expression of drug metabolizing enzymes and metabolic 
profiles.  MPA is metabolized and detoxified through the actions of UGT enzymes 
almost exclusively, making it an excellent compound for studying effects of 
varying expression levels of UGTs and membrane transporters on MPA 
exposure.  Because MPA is metabolized into two forms of glucuronide 
conjugates, an inactive phenolic and the labile acyl, it is also imperative to 
examine any potential toxicity resulting from excessive acMPAG exposure.  
Potential toxicity resulting from acyl glucuronide exposure has been reported 
since the 1970s, and despite conflicting reports, acMPAG had been postulated 
as a potential factor in MPA based GI toxicity (Bailey and Dickinson, 2003; Faed, 
1984; Shipkova et al., 2003).  It was important to evaluate acMPAG stability and 
reactivity in order to validate that glucuronidation activity is beneficial within the 
GI tract, and subjects with moderate or elevated UGT activity within the intestine 
are likely less susceptible to MPA toxicity due to lower levels of MPA regional 
tissue exposure compared with subjects deficient in UGT enzymes within the 
intestinal tract.   
 Our experiments indicated that acMPAG is neither highly reactive nor 
highly unstable.  When these experiments are coupled with previous in vivo 
evidence that found no correlations between acMPAG exposure and GI toxicity, it 
supports the argument that acMPAG is not a primary factor to consider in MPA 
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toxicity.  With acMPAG discounted as a primary factor in MPA toxicity, 
glucuronidation within the GI tract can be viewed as a detoxification process that 
is beneficial to enterocytes and also a secondary parameter when evaluating 
MPA toxicity in patients.   
 Pharmacogenomics is a rapidly growing field with respect to 
understanding the effect of altered enzyme expression and drug toxicity.  The 
recent modification of adding Gilbert’s Syndrome (UGT1A1*28 polymorphism), 
which results in a reduction of UGT1A1 activity in humans by 70%, warnings to 
labels on irinotecan products is a prime example of how genetic variations in 
enzyme expression can affect drug safety in the clinical setting (Guillemette, 
2003; Nagar et al., 2006).  Yet one primary problem with developing drug 
warnings based on polymorphisms is that it is difficult to accurately quantify the 
precise changes in enzyme expression using traditional antibody assays 
commonly employed.  In humans, there are over thirty known polymorphisms 
affecting UGT1A1 expression alone and numerous others affecting expression of 
the remaining UGT1As (Guillemette, 2003; Tukey and Strassburg, 2000; 
<http://som.flinders.edu.au/FUSA/ClinPharm/UGT/>).  Without the development 
of more sensitive or reliable testing, scientists have had to rely on mRNA 
expression studies, which may correlate poorly with protein expression or 
Western Blots, which are difficult to correlate between labs, lack specific 
antibodies for numerous enzymes, and have limited sensitivity and dynamic 
ranges. 
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 Quantitative proteomics can be employed for both preclinical and clinical 
samples of interest based on the results using reliable methods for evaluating 
UGT expression in both humans and rats, along with membrane transporters in 
the rat kidney, liver and intestine.  A significant component of this dissertation 
project involved the development of these methods due to the need to overcome 
numerous hurdles during this process of methods development on several LC-
MS/MS platforms.  One of the primary obstacles during the method development 
process throughout this project was the selection of the proper internal 
standards.  The first 18 peptides selected for analysis of the hUGTs were beset 
by some difficulties in MRM product ion selection and inconsistent retention times 
on the LC-MS/MS.  Primarily, peptides in these experiments longer than 13 
amino acids containing a number of histidine residues were prone to excessive 
charge states resulting in inadequate sensitivity for reliable quantification.  A 
secondary problem with peptide selection, both during these experiments and for 
future studies, is that some proteins may only generate one or two acceptable 
tryptic fragments.  In this case, it may become necessary to examine alternative 
enzymes for proteolytic digests such as chymotrypsin or Lys-C or to combine 
proteases to expand the sequence coverage of each enzyme in hopes of 
generating more suitable peptides for quantification.   
Another issue to examine in future studies concerns flow rates and column 
selection for future applications.  While our lab performed the rat enzyme studies 
using a 150 μm ID column, we have also evaluated the utility of 100 μm and 300 
μm ID columns.   Compared to the 150 μm columns, the other two formats were 
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between two and five fold less sensitive on the 5500 QTRAP, indicating that the 
current column generates the best data for all current applications and is the best 
current compromise between sensitivity and robustness (data not shown).  
However, it should be noted that larger ID columns could be applied for future 
studies where absolute sensitivity can be sacrificed for increased throughput and 
column lifetime.      
Even though targeted quantitative proteomics produces a number of 
advantages for scientists, there are still drawbacks.  One of the primary criticisms 
of quantitative proteomics continues to be the upfront cost in both LC-MS/MS 
instrumentation along with annual maintenance.  An additional problem is that 
even though several new software packages have been recently produced by a 
number of companies attempting to make LC-MS/MS more user friendly, there is 
a still a steep learning curve.  While the development of multiple protease digests 
has generated an increasing amount of potential stable isotope standards, there 
will still be proteins that are not amenable to the current methods in quantitative 
proteomics due to insufficient peptide candidates that lend themselves to high 
sensitivity LC-MS/MS detection.   
  What the development of targeted quantitative proteomics allows for is to 
precisely evaluate altered expression of proteins of interest with their biological 
significance.  In particular, these experiments can highlight sources of potential 
differences in metabolite exposure using quantitative proteomics compared with 
either mRNA expression or in vitro metabolism studies.  One example that can 
be highlighted in this project involves evaluating differences in MPAG levels seen 
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in TR- rat plasma compared with Wistar rats.  Following MPA administration and 
bile cannulation, there was a significant difference in MPAG exposure seen in 
TR- rats, while there were no differences in in vitro glucuronidation rates between 
TR- rats and Wistar rats.  However, when transporter and rUgt levels are 
compared between the two strains, there was a significant increase in rUgt1a1 
and rMrp3 expression within the liver in TR- rats.  Because rUgt1a1 and rMrp3 
are two of the primary proteins responsible for MPAG formation and efflux, 
respectively, into the blood, it is likely that the upregulation of these two proteins 
coupled with the absence of Mrp2 for biliary excretion in TR- rats results in 
increased MPAG plasma levels.  This illustrates that quantitative proteomics can 
be a powerful tool in explaining differences in metabolism, elimination and toxicity 
that may be irresolvable using more traditional methods. 
  One of the more frustrating aspects within the field of quantitative 
proteomics is the lack of applications directly linking protein expression with 
clinical outcomes.  Recently, there have been a number of published reports for 
quantifying a number of biologically significant drug metabolizing enzymes and 
biomarkers including CYPs, membrane transporters, C-reactive protein and 
prostate specific antigen (Barnidge et al., 2004; Jenkins et al., 2006; Kuhn et al., 
2004; Li et al., 2008; Wang et al., 2008).  Yet despite the wealth of knowledge 
and resources, scientists have been unable to apply these methods to evaluate 
potential differences in enzyme expression with any events of biological 
significance.  One of the primary goals of this project was to begin to bridge the 
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gap between proteomic experiments performed primarily by analytical chemists 
and clinicians lacking the tools needed for applications in quantitative proteomics.   
 A secondary goal of this project was to begin to set up preliminary 
methods to be able to analyze large numbers of samples for targeted quantitative 
proteomic analysis.  One primary advantage that the AQUATM peptide selection 
rules provide is that the resulting peptides will retain similar chromatographic 
profiles due to size and residue restrictions.  Because of this, method alterations 
to accommodate the analysis of different proteins will likely be minor, enabling 
faster method development and minimal variations in LC gradients.  The 
advantages of rapid method development, faster LC runs and precise and 
sensitive quantification provided will make targeted quantitative proteomics more 
accessible to biologists and clinicians than ever before. 
 Within the areas of UGTs and transporters, there are several different 
avenues where this research may be applied.  One of the primary interests to 
scientists is the effect of genetic polymorphisms on protein expression.  As noted 
earlier, there are over thirty polymorphisms within the UGT1A1 isoform alone 
(Guillemette, 2003; Nagar et al., 2006; Tukey and Strassburg, 2000).  One 
potential benefit could be gained by evaluating different expression levels of UGT 
enzymes across a number of microsomal donors and correlating these levels 
with any SNPs discovered during genotyping.  Using both of these methods will 
help evaluate whether the polymorphisms of interest significantly affect isoform 
expression, resulting in decreased UGT activity.  An additional area of interest to 
clinicians could be in evaluating patients undergoing either irinotecan or MPA 
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therapy for UGT levels to help determine patient susceptibility to GI toxicity.  
Patients on either treatment regimen may undergo colonic biopsies that may be 
analyzed for UGT expression with our current protein requirements (~10 μg per 
assay).  Susceptible patients displaying diminished UGT levels might be carefully 
monitored over the course of treatment and may open other areas of adjuvant 
therapy, including coadministration with potential UGT inducers to help improve 
therapeutic outcomes. 
 In summary, the work presented within this project has advanced our 
understanding of acMPAG stability and reactivity relating to MPA toxicity, along 
with the development and application of targeted quantitative proteomics to 
evaluate enzyme expression in both rats and humans.  Most importantly, through 
the use of proteomics and in vitro/in vivo models, we have begun to establish 
relationships between tissue expression and xenobiotic metabolism and 
elimination.  Furthermore, these relationships open up a number of areas of 
research into possible coregulation of enzymes and transporters and relating 
metabolite profiles using both Phase II and Phase III metabolism.  In addition, 
because of the low protein requirements of our current methods, clinical 
applications evaluating drug metabolism and toxicity are also possible.  Finally, 
we hope that this research eventually helps clinicians and scientists tailor 
treatment regimens to susceptible populations resulting in improved therapeutic 
outcomes with less adverse reactions and toxicity. 
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A.  INTRODUCTION 
UGT enzymes catalyze the formation of glucuronic acid conjugates of Phase 
II metabolism. Glucuronidation is the most important Phase II metabolic pathway 
for drugs [Evans and Relling 1999] and is also a primary elimination route for 
other xenobiotics and endogenous compounds [Meech and Mackenzie 1997, 
Tukey and Strassburg 2000, Guillemette 2003, Wells et al. 2004]. Quantification 
of UGTs in biological matrices has traditionally been done by immunometric 
methods such as Western blots and ELISA. These methods can be time 
consuming and cumbersome, and require the raising of antibodies, which are 
often unsuccessful in achieving specificity. Indeed, there is a high degree of 
sequence identity among the UGT1A subfamily of enzymes, and antibodies have 
been found to be cross reactive between isoforms. Quantitative measurements 
by Western blot can be highly variable, with very limited dynamic range, and 
often provide imprecise quantification results, even if done relative to a control 
experiment. The ELISA method is more sensitive, and linearity can be greater, 
but considerable effort is needed to validate an ELISA assay, even when a 
specific antibody is available. 
Other techniques for quantitative analysis of proteins have been developed in 
recent years. These include the Difference Gel Electrophoresis (DIGE) method 
[Friedman et al. 2007, Tonge et al. 2001] which employs fluorescent tags and gel 
electrophoresis for separation and relative quantification, and antibody arrays 
[Wellmann et al. 2002]. Methods based on isotopic labeling have also been 
developed. These include stable isotope labeling 
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with amino acids in cell culture (SILAC) [Ong et al. 2002], Isotope Coated Affinity 
Tags (ICAT) [Gygi et al. 1999, Jenkins et al. 2006, Smolka et al. 2001, Turecek 
2002], and iTRAQ reagents [Ross et al. 2004, Skalnikova et al. 2007]. ICAT 
targets a specific amino acid, cysteine, on the protein sequence, while iTRAQ 
enables coverage of an entire peptide sequence by N-terminal labeling of all 
peptides. Many of these techniques can at best only be described as semi-
quantitative because they establish relative differences in protein expression 
between samples. iTRAQ and ICAT can be used for absolute quantification when 
employed with standards of known concentration as calibrants. 
The approach of using heavy isotope labeling for absolute quantification has 
previously been established [Barnidge et al. 2003, Barr et al. 1996, Gerber et al. 
2003, Kuhn et al. 2004] and has become increasingly popular with the ongoing 
development of higher sensitivity analytical instrumentation [Kamiie et al. 2008, 
Kirsch et al. 2007, Lin et al. 2006]. The determination of absolute concentration 
enables better interpretation of metabolic studies by, for example, allowing 
transfer of data between laboratories without needing to normalize to different 
controls. It also enables better comparison of data between biological tissue 
types. Barr et al. [Barr et al. 1996] used heavy labeled peptides, unique to the 
protein, to quantify apoliproprotein A-I. They found the concentration obtained to 
be in good agreement with the known concentration of the Apo A-I standard. 
Gerber et al. [Gerber et al. 2003] used the technique, with tandem MS (including 
selected reaction monitoring), to quantify proteins and phosphoproteins from cell 
lysates, and introduced the term AQUA (absolute quantification). Myoglobin was 
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measured in the presence of whole yeast and was found to equal the known 
amount of myoglobin added. Kuhn et al. [Kuhn et al. 2004] quantified C-reactive 
protein in serum using 13C-labeled peptide standards. They cautioned against 
claims of absolute quantification due to possible peptide losses during sample 
preparation or incomplete trypsin digestion. Their sample preparation procedure 
was complex (size exclusion chromatography and SDS-PAGE analysis) and 
heavy labeled peptides were added after trypsinization. Barnidge et al. [Barnidge 
et al. 2003] quantified prostate specific antigen in serum using a synthetic 
peptide containing two glycine atoms each labeled with two 13C atoms and one 
15N atom. Although they found values determined to be lower than those 
obtained by immunoassay, the method was deemed worth pursuing as a 
possible means of standardizing commercially available immunoassays 
performed in serum. The inclusion of the reactive amino acids cysteine and 
tryptophan in their heavy labeled peptide may have contributed to the lower 
values obtained. Lin et al. [Lin et al. 2006] used a single quadrupole ion trap for 
isotope labeling determinations and found it sufficient for their purposes of 
quantifying intermediate abundance proteins in human serum. Kirsch et al. 
[Kirsch et al. 2007] quantified two human growth hormone serum biomarkers in 
samples containing approximately 8 mg of serum protein (100 μL volume) by 
tandem LC-MS. They considered their isotope dilution method to be easily 
adaptable to other proteins and possibly to other species. More recently Kamiie 
et al. [Kamiie et al. 2008] used stable isotope labeled peptides as internal 
standards for quantification of 34 transporter proteins in liver, kidney and blood-
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brain barrier of mouse. They used one representative peptide per protein and the 
average of three MRM product ions per peptide for quantification. A long LC 
(liquid chromatography) run time of 50 min was used to enable the assay of 
many analytes. 
An alternative, but related, method has recently been reported by Beynon et 
al. (Beynon et al. 2005), where the formation of a concatenation of tryptic 
peptides (a QCAT protein) encoded from an artificial gene was employed. The 
peptides in the QCAT protein are present in strict 1:1 stoichiometry and each is 
derived from a naturally occurring tryptic peptide in the parent protein of interest. 
A single cysteine containing extension is added at the C terminus and used for 
calibration of the QCAT protein. Although effort is required to construct the 
artificial gene, repeated expression of the QCAT is facile, and there is no need 
for individual peptides to be quantified before use. The QCAT can also be heavy 
labeled by being expressed in medium containing 15NH4Cl to afford internal 
standard for calibration. 
The use of stable isotope labeled peptides as internal standards for the assay 
of digested proteins is a logical development based on the earlier reported 
methods. This has led to the commercial availability of custom labeled peptides. 
Here we present a tandem mass spectrometry method, using such labeled 
peptides, for the absolute quantification of human UGT enzyme isoforms 1A1 
and 1A6 in microsomal tissue preparations. The method reported here provides a 
basis for extension of the assay to the entire UGT family of proteins, many of 
which do not have adequate antibodies available due to high sequence identity. 
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B.  METHODS 
Materials 
Analytical grade acetonitrile and methyl alcohol (anhydrous) were purchased 
from Fisher Scientific Co. (Pittsburg, PA). Ammonium bicarbonate, dithiothreitol, 
iodoacetamide, ammonium hydroxide, formic acid, 2,2,2-trifluoroethanol (TFE) 
and TPCK (L-1-tosylamide
-2-phenylethyl chloromethyl ketone) treated trypsin from bovine pancreas 
(≥ 10,000 BAEE units/mg protein) were purchased from Sigma-Aldrich Co. 
(St. Louis, MO). Bond Elut solid phase extraction cartridges (C18 100 mg, 1 mL) 
were purchased from Varian, Inc. Recombinant UGTs 1A1, 1A6 and control 
supersomes were purchased from BD Biosciences (San Jose, CA). Human liver 
microsomes (HLMs)(20 mg/mL) were purchased from BD Biosciences (pool of 
33; 15 female, 18 male) and Xenotech LLC (Lenexa, KA) (pool of 50; 26 female, 
24 male). A human liver microsome library of individual donors (n=10, 3 female, 7 
male, 20 mg/mL) was purchased from Human Biologics International (Scottsdale, 
AZ). Rat liver microsomes (RLMs), for normalizing total protein content of 
samples, were prepared from male and female Sprague-Dawley rats using 
standard methods. Protein concentrations were determined using the Pierce BCA 
Protein assay Kit, in which bovine serum albumin is used as the standard. 
Human intestinal microsomes (HIMs) (duodenum and jejunum derived) were 
obtained from Xenotech LLC (Lenexa, KA) (pool of 8 donors, 5 female, 3 male). 
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Instrumentation 
Analysis was by reverse phase LC-MS/MS, using a Hewlett Packard 1100 LC 
equipped with a Phenomenex Luna C18 (length, 5 cm; internal diameter, 2 mm; 
particle size, 3 µm; pore size, 100 Å) column, coupled to an API3000 triple 
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) with a 
turbo ionspray source. The mass spectrometer was operated in positive ion 
mode, with acquisition by multiple reaction monitoring (MRM). Peak areas were 
determined using Analyst 1.4.2 (build 1236) software (Applied Biosystems). 
 
Stable Isotope Labeled Synthetic Peptides 
Synthetic peptide standards (8-12 mer), each containing one amino acid 
heavy labeled with 13C [98 %] and 15N [95 %], were purchased from Thermo 
Electron (Thermo Scientific, Waltham, MA). Two of the peptides were uniquely 
representative of human UGT1A1 and three were uniquely representative of 
human UGT1A6. The peptides were selected according to manufacturer 
recommendations and previously published guidelines [Beynon et al. 2005, 
Gerber et al. 2003]. The amino acid sequences (for UGT1A1 and UGT1A6) were 
obtained using the Universal Protein Resource Knowledge Base 
(UniProtKB)(funded mainly by the National Institutes of Health). Peptide 
uniqueness of tryptic fragments was verified by NCBI Blast (National Center for 
Biotechnology Information Basic Local Alignment Search Tool). Amino acid 
analysis was conducted on each peptide to determine exact amount present. The 
analysis involved acid hydrolysis, derivatization with phenylisothiocyanate and 
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separation of the phenylthiocarbamyl-amino acid derivatives by reverse phase 
HPLC. The analysis was conducted at the Center for Structural Biology, Wake 
Forest University School of Medicine, Winston-Salem, NC, USA. Some amino 
acids were excluded from the analysis because of known acid hydrolysis effects 
(e.g. bonds between isoleucine and valine [peptide 3] are not easily broken) and 
the possible cyclization and isomerization of aspartic acid adjacent to glycine or 
isoleucine (peptides 2 and 3) [Vinther et al. 1996, Fledelius et al. 1997].  The 
peptides purchased are listed in Table 1. Selection criteria included peptides 
which were not too hydrophilic or hydrophobic, did not contain reactive amino 
acids (e.g. M, C), and did not contain chemically unstable sequences (e.g. N-
terminal Q, N-terminal N). 
Known variable Single Nucleotide Polymorphisms (SNPs) were also 
considered during selection (see discussion). It was intended to obtain two 
peptides for each UGT isoform, but a third was obtained for UGT1A6 because 
initial investigations suggested that there may be difficulties with peptide 3. This 
proved not to be the case. One peptide, initially selected for UGT1A6 (peptide 5, 
Table 1) was ignored for most of the investigations when a large co-eluting peak 
was consistently observed for one of its two MRMs. All five peptide sequences 
were found to lack the predicted posttranslational modifications using the 
software indicated in parentheses: N-linked glycosylation (NetNGlyc), O-linked 
glycosylation (NetOGlyc), sulfation (Sulfinator), methylation (MeMO), acetylation 
(NetAcet), palmitoylation (NBA-Palm), myristoylation (NMT), and sumoylation 
(SUMOsp). Results of analysis for predicted phosphorylation sites lacked 
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agreement and depend on the software used (Kinase Phos or NetPhos). No sites 
were identified in the two UGT1A1 peptides. Kinase Phos identified tyrosine-77 in 
peptide 5 as a potential site, whereas NetPhos suggested that serine-50 in 
peptide 3, threonine-110 in peptide 4, and tyrosine-112 in peptide 4 are likely 
phosphorylation sites. These predictions do not take into account the 
endoplasmic reticulum localization of the UGTs where they likely have restricted 
access to most cellular kinases. Stock solutions of each peptide were prepared in 
50 % acetonitrile/50 % acetic acid 1.6 % and stored, in 300 and 400 µL aliquots, 
at -20 ºC in polypropylene vials. 
 
Sample Preparation and digestion 
Calibrators, containing 1.5, 3, 6, 12 and 25 µg of commercially available 
recombinant UGTs 1A1 and 1A6, with protein normalized to 200 µg by the 
addition of RLMs, a blank containing 50 µg of UGT control supersomes, with 
protein normalized in the same way, and HLM samples (pooled and individual 
donor samples) containing 200 µg of protein, were prepared. Samples were 
denatured and reduced by heating at 95 ºC for 11 min in 5 mM dithiothreitol 
(sample volume 90 µL; buffer 50 mM ammonium bicarbonate). This was followed 
by alkylation with iodoacetamide (10 µL of 100 mM solution added) for 20 min in 
the dark. Heavy labeled peptides were then added as internal standards (10 μL 
of solution containing 10 pmol of peptides 1, 3, 4, 5 and 20 pmol of peptide 2) 
and the residual acetonitrile (< 5 µL) was removed by evaporation under nitrogen 
for ~5 min. Samples were then digested with trypsin in 50 mM ammonium 
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bicarbonate; enzyme/protein ratio = 1:50; for 4 h at 37 ºC, which was found to 
provide maximal response to peptides monitored from recombinant UGTs. The 
reaction was then quenched by addition of three volumes of acetonitrile. 
Following centrifuging at 800 x g for 10 min the organic content was removed by 
evaporation under nitrogen for ~10 min. Ammonium bicarbonate (50 mM, 0.9 mL) 
was then added in preparation for solid phase extraction. SPE cartridges were 
conditioned with 1 mL methanol and 1 mL distilled water. Samples were then 
added and the cartridges were washed with 1 mL 50 mM ammonium 
bicarbonate. Cartridges were eluted with 1 mL acetonitrile/25 mM formic acid 
(40:60). The eluate was evaporated to dryness under nitrogen at 42 ºC in a water 
bath and samples were reconstituted with 100 μL acetonitrile/25 mM formic acid 
at pH 3 (pH was adjusted to 3 by drop wise addition of ammonium hydroxide). 
Samples were stored at -20 ºC until analyzed by LC-MS/MS. 
 
LC conditions 
Mobile phase was acetonitrile (solvent B) and 25 mM formic acid with pH 
adjusted to 3 (solvent A) by addition of ammonium hydroxide. Injection volume 
was 50 μL (50 % of sample), and flow rate was 0.4 mL/min. Gradient; 10 % 
solvent B to 100 % at 4 min, to 10 % at 5 min, held at 10 % for equilibration until 
10 min. Sample was split before introduction into the turbo ionspray source of the 
mass spectrometer (half of effluent was allowed into the source). 
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MS/MS conditions 
All heavy labeled peptides were found to be doubly charged when infused 
into the mass spectrometer in ~2 μM concentrations in mobile phase (50:50). 
Two MRM transitions, with product ion for each > 500 Da (and precursor ion as 
doubly charged ion), were chosen for each heavy labeled peptide following 
optimization. Using these, two further MRM transitions were elucidated for the 
corresponding unlabeled peptides from digested recombinant enzyme and 
microsomal samples. Thus there were four MRM transitions monitored per 
peptide, giving a total of 20 MRMs which were acquired. As the peptides eluted 
within a narrow time frame the MRMs were not grouped and were therefore all 
acquired within each cycle. Following optimization, dwell time was set at 60 ms, 
with a pause time of 5 ms. Cycle time was therefore 1.3 s. MRM product ions 
were named according to peptide fragmentation nomenclature [Roepstorff and 
Fohlman 1984] (Table 2). 
 
Calibration Curves 
The concentration of enzyme in recombinant material (pmol/mg recombinant 
protein) was calculated, following preparation and analysis of five replicate 
calibrant sets (total 25 samples; a calibrant set consisted of five samples, each a 
different concentration within the calibration range), from the known amount of 
heavy labeled peptide added to each sample as internal standard. The amount of 
heavy labeled peptide added was designed to fall within the (unweighted) linear 
range, and equality of response between labeled and unlabeled peptide was 
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assumed. Complete trypsin digestion was also assumed as increasing time of 
digestion did not improve responses. The same batches of recombinant UGTs 
1A1 and 1A6 were used throughout the study. Calibration curves were 
constructed by plotting recombinant enzyme concentration against the peak area 
of each MRM representing unlabeled (recombinant) tryptic peptide relative to the 
peak area of each corresponding MRM representing labeled synthetic peptide 
internal standard, using a weighted (1/x2) linear regression fit. The calibration and 
assignment of enzyme concentration was based upon the known amount of 
labeled synthetic peptide internal standard added to each sample, and assuming 
equality of response, as commonly done for isotope dilution methods.  Thus for 
each peptide there were two calibration curves, and for each enzyme there were 
at least four calibration curves, from which the optimal peptides and MRM 
transitions could be determined. 
 
Validation 
Solid phase extraction efficiency 
Solid phase extraction efficiency was determined for the labeled internal 
standard peptides in calibrant samples which were put through the entire sample 
preparation procedure. Two concentrations of calibrant were used. For each 
concentration the labeled standards were added to three samples just before 
solid phase extraction, and to three further samples just after solid phase 
extraction. 
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Sample preparation – denaturation and trypsinization 
The use of heating (95 ºC for 11 min), in our method, to denature the protein 
samples was compared with use of an organic co-solvent, TFE [Roepstorff and 
Fohlman 1984], to denature. For the co-solvent method TFE (35 μL of the final 
90 μL volume) was added at the very beginning, and samples were incubated 
with shaking at 37 ºC for 2 h. Two samples from the HLM library were analyzed 
in triplicate by each method and average concentrations calculated. To examine 
use of a lower temperature to denature, two samples of a high concentration 
within the calibration range were denatured at 60 ºC for 30 min and compared to 
five replicate calibrant samples of the same concentration denatured at 95 ºC for 
11 min. 
 
Intra- and inter-day assay variability 
For intra-day variability, five replicate calibration curves were prepared on the 
same day, and analyzed. Peak area ratios were examined as a measure of 
variability. This was repeated with a further five replicate calibrant sets, without 
adding rat liver microsomes to normalize protein content, to examine for matrix 
effects. For inter-day variability two batches of pooled human liver microsome 
samples, from different sources, were analyzed with each calibrant set. 
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Human liver microsome (HLM) library 
To test the application of the developed method, samples from a library of ten 
individual HLM donors were analyzed in triplicate, with a calibrant set and pooled 
HLM inter-day control samples. 
 
Human intestinal microsomes (HIMs) 
Samples from one batch of HIMs were analyzed in triplicate, with a calibrant 
set and pooled HLM inter-day control samples. 
 
Western blot analysis of HLM library and digested and non-digested 
samples 
As demonstration of the reliability of the developed LC-MS/MS method, the 
HLM library was analyzed for UGTs 1A1 and 1A6 by (relative quantification) 
Western blot. Correlations between the results for each method were evaluated. 
Two immunoblots were prepared, one for UGT1A1 and one for UGT1A6. The 
primary antibodies, one for each isoform, were both developed in the Ritter lab 
[Chen et al. 2005, Ritter et al. 1999]. For each blot a 7.5 % polyacrylamide 
resolving gel and a 4 % polyacrylamide stacking gel were poured and 25 µg of 
protein loaded for each HLM sample. Samples were electrophoresed at 150 V 
through the stacking gel and 175 V through the resolving gel. After transfer of the 
proteins to a nitrocellulose membrane, the blots were probed for expression of 
the relevant UGT isoform, at a 1:1000 dilution of the primary antibody, by 
incubation for an hour at room temperature. The blots were then probed for the 
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secondary antibody (sheep anti-mouse HRP linked) which was added at a 
dilution of 1:15,000, also for an hour at room temperature. Amersham ECL 
products were used to detect and visualize expression of peptides. Also analyzed 
with each immunoblot were four samples (each of highest calibrant 
concentration) which had been put through the initial stages of the LC-MS/MS 
sample preparation procedure, but taken no further than the digestion step. Two 
of the samples were digested (procedure stopped following 4 h digestion step at 
37 ºC) and two were not digested (procedure stopped following addition of 
internal standard). All four samples were evaporated to dryness under nitrogen 
and reconstituted in 10 μL 50 mM ammonium bicarbonate for analysis by 
Western blot. 
C.  RESULTS 
Selection of MRMs 
For MRM transitions the product ions of highest intensity, > 500 Da, obtained 
from infusion of the heavy labeled peptides were chosen (Fig. (1)). If any MRMs 
were subsequently shown to give unsatisfactory calibration curves, as in the case 
of peptide 5, the product ion of next highest intensity was also examined. In the 
case of peptide 5 this was also unsatisfactory, due to a co-eluting peak. Product 
ions in all cases were y ions (Table 2). All product ions chosen for the heavy 
labeled synthetic standards, except that for the lower mass product ion of peptide 
2, contained the heavy label. All MRM transitions used in the analyses are shown 
in Table 2 (the MRM2 shown for peptide number 5 was the last MRM tested for 
that peptide). 
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Chromatography 
Following application of the sample preparation procedure MRM 
chromatograms were obtained for calibrant samples, blank samples and pooled 
and individual donor human liver microsome samples.   Representative 
chromatograms are shown in Fig. (2). All peaks, except those of MRM2 for 
unlabeled enzyme derived peptides 4 and 5, were free of co-eluting peaks. For 
peptide 4 MRM2 the interfering peak, only seen in the blank control, was 
sufficiently small for the blank peak area ratio to be subtracted for each calibrant, 
for all calibrant sets prepared. The interfering peak was shown to originate from 
the rat liver microsomes used to normalize total protein amount in calibrants and 
blanks, thus it was not observed in human liver microsome samples. For enzyme 
derived peptide 5 MRM2 (747.5/1217.8) a large co-eluting peak was seen in 
calibrant, blank control and HLM samples such that peak areas could not be 
accurately determined. Data for this MRM and peptide was therefore not 
subsequently studied as two other peptides could be reliably employed for the 
UGT1A6 quantification. 
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Calibration Curves and Extraction Efficiency 
The concentrations (pmol/mg protein) of each enzyme isoform in recombinant 
material, used to construct calibration curves, and calculated as described in the 
Methods section, are shown in Table 3. Representative curves, which were linear 
and reproducible, are shown in Fig. (3). The lowest concentrations shown in 
Table 3 represent limits of quantification (~5 pmol/mg protein for UGT1A1, and 
~2 pmol/mg protein for UGT1A6). Limits of detection were approximately one 
third of these values. Correlation (r) values for calibration curves were generally 
> 0.98. Solid phase extraction efficiencies of synthetic heavy labeled peptide 
internal standards were found to be > 87 % for peptides 1, 3 and 4, and > 73 % 
for peptide 2. 
 
Sample preparation – denaturation and trypsinization 
Concentrations determined by co-solvent denaturation were slightly higher 
than those obtained by heating (95 ºC for 11 min) in HLM samples analyzed. For 
example, for HLM 216 the average UGT1A1 concentration increased from 25.3 
to 27.5 pmol/mg protein. The average UGT1A6 concentration increased from 4.0 
to 6.0 pmol/mg protein. When a lower temperature was used to denature 
samples, peak area ratios (PARs) were less reproducible. 
 
Intra- and Inter-day Assay Variation 
Intra-day variation, represented by the range of %C.V.s (n=5) of peak area 
ratios over the standard curves for each MRM, varied depending on the peptide 
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and MRM. Peptide 1 and peptide 4 MRMs gave the best reproducibility for 
UGT1A1 and UGT1A6, respectively. Intra-day C.V.s were below 20 % for peptide 
1 and below 25 % for peptide 4. Human liver microsome matrix was found to be 
“cleaner” than rat liver microsome matrix (which was used to normalize for total 
protein in calibrant samples) and hence lower concentration variability was 
observed for this matrix (Table 5; n=3). Inter-day assay variation data is shown in 
Table 4. Peptides 1 and 4 were again superior with respect to %C.V.s, and the 
choice of MRM influenced reproducibility. 
 
Human Liver Microsome Library (LC-MS/MS and Western Blot Analysis) 
Absolute quantification results from LC-MS/MS analysis of the human liver 
microsome library of ten individual donors are shown in Table 5. Using peptides 
1 and 4, representing UGTs 1A1 and 1A6 respectively, and mean values of the 
two MRMs, there was a seven fold difference between the highest and lowest 
UGT1A1 concentration (HLM 222, 52 pmol/mg protein; HLM 228, 7.8 pmol/mg 
protein) and a 3.1 fold difference between the corresponding UGT1A6 
concentrations (HLM 233, 7.9 pmol/mg protein; HLM 218, 2.6 pmol/mg protein). 
Ratios of UGT1A1 to UGT1A6 for each sample ranged from 1.6 for HLM 228 to 
9.3 for HLM 225. There was no correlation between UGT1A1 and UGT1A6 
concentrations within individuals (r = 0.335, using peptides 1 and 4). Results of 
Western blot analysis of the HLM library are shown in Fig. (4). Correlations (r)
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between the absolute concentrations obtained by LC-MS/MS and the relative 
values obtained by Western blot (normalized to 100 % for the lowest density) for 
each MRM of peptides 1 and 4, are shown in Fig. (5). 
 
Human Intestinal Microsomes 
The UGT1A1 concentration determined in one batch of pooled human 
intestinal microsomes, analyzed in triplicate, was on average (n=3), peptide 1, 
MRM1, 5.8 pmol/mg protein, MRM2, 7.4 pmol/mg protein. These data were in 
good agreement for the MRMs monitored. Peptide 2 concentrations (data not 
shown) were in a similar range, but showed higher variability. UGT1A6 
concentrations in intestinal microsomes were below the limit of quantification. 
 
D.  DISCUSSION 
This study demonstrates the use of stable isotope labeled synthetic peptides 
for the absolute quantification of endogenous enzyme proteins by tandem mass 
spectrometry operated in the MRM mode. The approach is applied here to Phase 
II metabolic enzymes for the first time. Specifically it is applied to UGT1A1 and 
UGT1A6, two enzymes with specific antibodies, to enable a comparison and 
evaluation of the new approach. 
Selection of stable isotope labeled synthetic peptide is clearly an important 
step, both for enzyme identification purposes (the peptide must be unique to the 
enzyme being quantified) and for analytical reasons (the peptide needs to have 
good chromatographic properties, ionize well, and give sensitive and selective 
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MRM signals). Each of the nine functional known UGTs in the 1A subfamily of 
enzymes is comprised of approximately 530 amino acids (Uniprot). There is 
sequence identity at the C terminus region, which is encoded for each isoform by 
the common exons 2 to 5 of the UGT1A gene. Therefore, the N terminus region, 
which is less homologous, and encoded for by a unique exon 1 for each isoform 
was the site for unique peptides. We found, when searching for suitable peptides 
for labeling, that there were no apparent unique sequences beyond approximate 
amino acid number 210. For the isoforms quantified here, UGTs 1A1 and 1A6, 
there were few tryptic peptides that fit the criteria for use in the method. For 
UGT1A1 the enzyme sequence D70GAF(13C5,15N)YTLK77 was selected as the 
second peptide (peptide 2) because it was the only remaining peptide of 
sufficient length (< 16 amino acids), even though it was known that the DG 
linkage could possibly undergo cyclization or isomerization [Vinther et al. 1996, 
Fledelius et al. 1997], particularly at neutral or basic pH. This peptide could also 
be affected by a reported G71R polymorphism (UGT1A1*6) that is more common 
in Asians and found to produce Gilbert Syndrome [Akaba et al. 1998, Maruo et 
al. 2005]. For UGT1A6 one other peptide could possibly have been used. This 
was S185PDPVSYIPR194. It was not chosen because of a reported R184S 
polymorphism [Basu et al. 2005], which if present would alter the length of the 
tryptic peptide. Some additional SNPs for UGT1A1 have been reported for the 
peptides employed, though these were relatively rare with allele frequencies that 
are very low. Certainly, one must consider nonsynonymous SNPs when 
interpreting quantitative proteomic data, but it may also be possible to use this 
 214 
method to measure expression of the variant isoforms in subjects that are 
heterozygous. The other concern with the method is that it does not consider 
possible posttranslational modifications. The peptides selected here (Table 1) did 
not include asparagine (N), a possible site for glycosylation, but were replete with 
serine (S) and tyrosine (Y), which are possible sites for phosphorylation. To date 
there is limited information on phosphorylation of UGTs [Basu et al. 2004, Ciotti 
et al. 1997]. Alternative methods based on antibody detection may also, in any 
case, be affected by phosphorylation. 
The use of dithiothreitol and iodoacetamide for reduction and alkylation of 
protein samples is well established. The use of heating to denature is less 
common. Our method was validated by showing little difference between heating 
at 95 ºC and using TFE to denature samples. A lower temperature produced 
peak area ratios that were less reproducible. The use of detergents sodium 
dodecyl sulfate and CHAPS [3-((3-cholamidopropyl)dimethylammonio)-1-
propane-sulfonic acid] to denature the proteins was also examined. However, 
these were found to produce interfering peaks by full scan mass spectrometry, 
thereby possibly affecting ionization and mass spectrometry performance. 
Detergents could also possibly affect chromatography performance. Our sample 
work up, using SPE, was simple and provided samples that easily interfaced with 
LC-MS/MS. A point worth noting is that trypsinization is assumed to be 100%. 
Other than optimizing the conditions for trypsinization, for example with respect 
to time and trypsin concentration, as was done in our method development, it is 
difficult to examine the efficiency of the reaction. It is also assumed that there are 
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no protein losses during denaturation and reduction. Labeled peptides are added 
prior to digestion and SPE to compensate for possible peptide losses during 
these steps. Loss of peptide would mean under calculation of UGT 
concentration. 
For initial method development a 15 cm column was tested due to the 
complexity of the digested peptides. Peak shape was not optimal with a longer 
column, therefore the 5 cm column was evaluated and found to provide adequate 
chromatography with much shorter run times and higher sensitivity. Product ions 
of > 500 Da were chosen for MRMs because of increased selectivity at higher 
mass values (Fig. (1)) [Anderson and Hunter 2006]. The peak intensities 
between MRMs were in good agreement for each peptide (MRM1/MRM2 ratio 
range for peptides 1 to 4 was ≥ 0.45 ≤ 1.51). The dwell time (60 ms) was chosen 
as a compromise between sensitivity needed and cycle time. The cycle time 
(1.3 s) was sufficient for approximately 15 data points per peak, most peaks 
being approximately 20 s wide. Peak intensities for peptide 2 MRMs were lower 
than for the other peptides, possibly a consequence of the potential DG 
cyclization and isomerization described earlier [Chen et al. 2005, Ritter et al. 
1999]. The peak intensity of MRM2 in particular was low. This was interesting 
because the product ion of this MRM was the only product ion of all MRMs 
selected that did not contain the synthetic peptide label (Table 2). 
Calculated concentrations of enzyme in recombinant material were consistent 
between MRMs and between peptides for each UGT isoform. However, 
reproducibility and the sensitivity are improved if optimization for the best peptide 
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and MRM is performed. Intra- and inter-day assay variation results indicated that 
peptides 1 and 4 were the best peptides to use for the UGTs 1A1 and 1A6 
quantification respectively. Peptides 2 and 3 could be used as support 
verification. Intra-day variation would have been expected to be less than inter-
day variation, but examination of the data suggested that this was not so. This 
could possibly be explained by the use of rat liver microsomes in calibrants 
(intra-day samples) to normalize total protein content. The rat liver microsomal 
matrix appeared to be more complex, with greater background interference than 
the human liver microsomal matrix. Analysis of the human liver microsome library 
provided a form of intra-day measure (samples were prepared and analyzed in 
triplicate) free from rat liver microsomal matrix, with %C.V.s being better than 
those obtained when rat liver microsomal matrix was present (Table 5). Results 
again showed that peptides 1 and 4 were best because of the lower %C.V.s 
obtained for those peptides. 
Concentrations of UGT1A1 were greater than UGT1A6 in all 10 HLM library 
samples when measured by LC-MS/MS (Table 5). Comparisons of 
concentrations are not possible with Western blots since different antibodies 
would be employed for distinct enzymes. For UGT1A enzymes, because they 
share a common C-terminus via exon sharing, one could use the 1A common 
antibody to estimate relative concentrations between isoforms assuming the 
response is similar. However, the LC-MS/MS method employed here is generally 
applicable to diverse proteins and provides greater precision than is commonly 
obtained with Western blot combined with densitometry. There was no 
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correlation between the concentrations of the two isoforms (r = 0.335, for 
peptides 1 and 4). High correlations were observed between the absolute 
concentrations of UGT1A1 determined by LC-MS/MS and the relative 
concentrations determined by Western blot (Fig. (5)). The dynamic range for LC-
MS/MS was greater and was thus more discriminatory (Fig. (5)), while Western 
blot is easily saturated, and thus provides a possible explanation for the UGT1A1 
correlation lines of Fig. 5 not crossing the y-axis at the origin. The corresponding 
correlations (Western blot v. LC-MS/MS) for UGT1A6 were not as high. Reasons 
for this may have included that the UGT1A6 concentrations occurred at the lower 
end of the LC-MS/MS calibration curve (the dynamic range of the UGT1A6 
concentrations was also lower than that of the UGT1A1 concentrations). Also, we 
believe that the specificity of the UGT1A1 antibody is greater than that for 
UGT1A6 since there appear to be two bands in the UGT1A6 Western blot (Fig. 
(4)). The correlations, and improvements in dynamic range observed when using 
LC-MS/MS (Fig. (5)), demonstrated nonetheless the applicability of the 
LC-MS/MS method for the absolute quantification of the UGTs in human liver 
microsomes. 
Application of the LC-MS/MS method to HIMs was also successful, with 
concentrations of UGT1A1 being approximately 30 % those of HLMs. This is in 
broad agreement with the findings of Wen et al. [Wen et al. 2007] who, using 
etoposide as a UGT1A1 probe substrate in vitro, showed the V(max) of HIMs to be 
approximately half that of the V(max) of HLMs. UGT1A6 concentrations were also 
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lower than in HLMs but could not be measured as they were below the limit of 
quantification using the method and equipment employed here. 
A method for the absolute quantification of the human UGT isoforms 1A1 and 
1A6, using heavy labeled peptide standards, by tandem LC-MS, has been 
developed. The method assumes 100% digestion with trypsin, and no protein 
losses during denaturation and reduction. It can be employed in a variety of 
matrices, in this case HLMs, HIMs, RLMs and supersomes. As mentioned in the 
introduction, these methods evolved from previous efforts in proteomic analysis 
using LC-MS, often employed for relative quantification, and are being extended 
to provide absolute quantification with accurate and precise quantification 
through the use of heavy labeled peptides. Targeted absolute quantification to 
study Phase I enzymes [Wang et al. 2006] and transporters [Kamiie et al. 2008] 
are being reported, thus the methods may become common procedures in drug 
metabolism and drug development studies. Results indicate that the method is 
robust and reproducible and can be employed over a wide dynamic range, 
sample-dependent matrix effects notwithstanding. The sensitivity of LC-MS/MS is 
in the fmole - amole range on-column, which translates to low pmole/mg 
detection as presented here, and should improve to sub pmole/mg protein with 
the use of capillary LC and newer equipment than the API-3000 employed. This 
sensitivity is competitive with other methods such as DIGE [Friedman 2007, 
Tonge et al. 2001] for protein analysis, and LC-MS/MS with stable isotope 
standards benefits from improved reproducibility and the ability for absolute 
quantification rather than relative quantification in most other methods. 
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Pre-selection of peptide is important, for example to minimize polymorphic effects 
on concentrations determined, and time and attention needs to be given to the 
validation of each peptide. Use of multiple peptides per protein supports the 
validity of results obtained, and provides verification of results that may be 
confounded by known or unknown nonsynonymous SNPs. It is important for the 
use of this method to carefully consider protein variants. However, the method 
also has the potential benefit of being able to measure relative levels of 
expression of such variants, if known, and if present in a peptide amenable to the 
method. 
We found that peptide 1, representative of UGT1A1, and peptide 4, 
representative of UGT1A6, gave greater reproducibility than the corresponding 
isoform representative peptides 2 and 3, though peptides 2 and 3 (UGT1A1, 1A6, 
respectively) gave similar average concentrations of proteins. HLMs contain 
more UGT1A1 (~0.140 % w/w; ~23.4 pmol/mg protein; peptide 1: Table 5) than 
UGT1A6 (~0.029 % w/w; ~4.8 pmol/mg protein; peptide 4: Table 5). Human 
intestinal microsomes contain less of each enzyme (UGT1A1 concentrations 
were approximately 30 % those of HLMs, and UGT1A6 concentrations were 
below the limit of quantification). Concentrations obtained by LC-MS/MS were 
found to correlate with relative values obtained by Western blot analysis. 
Excellent correlations seen for UGT1A1 were better than for UGT1A6, possibly 
due to UGT1A6 concentrations being at the lower end of the calibration curve 
and/or possibly due to greater specificity of the UGT1A1 antibody. The method 
can potentially be applied to the entire UGT family of proteins and other 
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endogenous proteins and enzymes. Targeted quantitative proteomics using 
heavy labeled peptides allows absolute rather than relative quantification and 
should revolutionize the measurement of specific proteins in complex biological 
matrices. Application of these methods will enhance the study of drug 
metabolism, and hence drug discovery and development, by providing accurate 
and precise measurement of specific proteins, including many not previously 
amenable to measurement due to the lack of specific antibodies. Moreover, this 
LC-MS approach for protein quantification will be easily translated from species 
to species via the wealth of genomic data available today. 
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Figure 6.1. MRM optimization scans for peptides 1 and 4, highlighting prominent 
product ions of mass > 500 Da. Two MRMs, using the two product ions of highest 
intensity, were chosen for each peptide. The ions y4 and y6 for peptide 1, and y6 
for peptide 4, are more intense due to the ‘proline effect’ whereby formation of y-
ions by amide bond cleavage N-terminal to proline is preferred. 
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Figure 6.2. MRM chromatograms following isolation of tryptic peptides from a 
human liver microsomal donor sample, showing total ion chromatogram (5 
peptides, 20 MRMs)(top), and extracted chromatogram of enzyme derived 
MRM1 peptide 1 (T78YPVPFQR85, UGT1A1 representative). The sample was 
prepared from 200 μg of microsomal protein. 
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Figure 6.3. Representative calibration curves (n = 5 replicate samples for each 
concentration), constructed using a weighted (1/x2) linear regression fit, for 
MRMs 1 and 2 of peptides 1 and 4. Peptide 1 is uniquely representative of 
human UGT1A1. Peptide 4 is uniquely representative of human UGT1A6. 
Concentration of enzyme in recombinant material was calculated for each MRM 
of each peptide from the known amount of heavy labeled peptide added as 
internal standard. The amount added was designed to fall within the 
(unweighted) linear range. Equality of response between labeled and unlabeled 
peptide MRMs was assumed. 
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Figure 6.4. Western immunoblot analysis of human liver microsome library of ten 
individual donors. Also shown are images of four highest concentration calibrant 
samples, two of which had not been digested by trypsin and two of which had 
been digested. 
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Figure 6.5. Human liver microsome library analysis of ten individual donors; 
correlation of absolute quantification values obtained by LC-MS/MS with relative 
quantification values obtained by Western immunoblot, for both MRMs of 
peptides 1 (UGT1A1 representative) and 4 (UGT1A6 representative). The 
Western blot with the lowest densitometry reading was assigned a value of 
100%, with others relative to this. 
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Table 6.1. Unique human UGTs 1A1 and 1A6 representative heavy 
labeled peptides selected for use as internal standards for absolute 
quantification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Number UGT Isoform Amino Acid Sequence 
Peptide 1 UGT1A1 T78YPVPF(13C9,15N)QR85 
Peptide 2 UGT1A1 D70GAF(13C9,15N)YTLK77 
Peptide 3 UGT1A6 D44IVEV(13C5,15N)LSDR52 
Peptide 4 UGT1A6 S103FLTAP(13C5,15N)QTEYR113 
Peptide 5 UGT1A6 I77YPVP(13C5,15N)YDQEELK88 
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Table 6.2  MRM Transitions for UGT stable isotope standards 
 Peptide 1 Peptide 2 Peptide 3 Peptide 4 Peptide 5 
 MRM1 MRM2 MRM1 MRM2 MRM1 MRM2 MRM1 MRM2 MRM1 MRM2 
           
Product 
Ion 
y4 y6 y4 y5 y6 y7 y6 y8 y8 y10 
           
 Labeled (internal standards)     
MRM 509.4/557.5 509.4/753.7462.8/524.4462.8/681.5 526.5/724.6526.5/823.6 660.1/799.6660.1/971.6750.5/1027.5750.5/1223.8
Label a Yes Yes No Yes Yes Yes Yes Yes Yes Yes 
           
Unlabeled 
(calibrants) 
         
MRM 504.4/547.5 504.4/743.7457.8/524.4457.8/671.5 523.5/718.6523.5/817.6 657.1/793.6657.1/965.6747.5/1021.5747.5/1217.8
a: Retention of heavy isotope label in product ion.  
Table 6.2. Chosen MRM transitions (transitions of highest sensitivity product ions) for synthetic heavy 
labeled and recombinant enzyme derived tryptic peptides showing product ion position in peptide, and 
whether product ions for the internal standards contain the labeled amino acid. Peptides 1 and 2 are 
uniquely representative of human UGT1A1, and peptides 3, 4 and 5 are uniquely representative of 
human UGT1A6. 
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Table 6.3  Recombinant enzyme amount unit conversions to pmol/mg protein 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3. Calculation of enzyme amounts (pmol/mg protein) in recombinant UGT 
microsomes. Amounts were calculated following preparation and analysis of five 
replicate calibrant sets (total 25 samples) from the known amount of heavy labeled 
peptide added to each sample as internal standard. The amount added was 
designed to fall within the (unweighted) linear range. Equality of response between 
labeled and unlabeled peptide MRMs was assumed. The lowest values shown were 
limits of quantification when added to RLM to provide 200 g total protein per 
sample. 
 
 
Recombinant 
microsome 
UGT1A1 (pmol/mg protein) 
Peptide 1                 Peptide 2 
UGT1A6 (pmol/mg protein) 
Peptide 3                  Peptide 4 
(µg) MRM1 MRM2 MRM1 MRM2 MRM1 MRM2 MRM1 MRM2
1.5 5.2 6.0 7.9 7.6 2.5 3.1 2.4 1.9 
3 10.4 11.9 15.7 15.2 4.9 6.2 4.9 3.9 
6 20.8 23.9 31.4 30.4 9.8 12.5 9.8 7.8 
12 41.6 47.7 62.9 60.8 19.7 24.9 19.5 15.5 
25 86.7 99.5 131 127 40.9 51.9 40.7 32.3 
  
 228 
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   Table 6.4  Interday precision data for UGT isoforms 1A1 and 1A6 
          UGT1A1 (pmol/mg 
protein) 
Peptide 1                  Peptide 2 
UGT1A6 (pmol/mg protein) 
Peptide 3                   Peptide 4 
HLM MRM1   MRM2     MRM1    
MRM2 
MRM1   MRM2     MRM1   
MRM2 
18.4 21.1 26.2 29.6 3.3 2.8 3.6 3.0 Batch 1     
Average 
(% C.V.) 
7.9 11 18 13 17 15 18 28 
21.4 24.0 35.5 32.4 3.7 3.2 4.6 3.9 Batch 2     
Average 
(% C.V.) 
6.7 10 24 17 43 37 19 28 
Table 6.4. Inter-day precision data for absolute quantification of the human UGT 
enzyme isoforms 1A1 and 1A6. Two batches of pooled human liver microsome 
samples (200 μg), obtained from different sources, were used in the 
determinations (n=5). 
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Table 6.5.  Absolute quantification of UGTs 1A1 and 1A6 in human liver microsome library 
of ten individual donors by LC-MS/MS. 
UGT1A1 (pmol/mg protein)a 
Peptide 1                  Peptide 2 
UGT1A6 (pmol/mg protein)a 
Peptide 3                  Peptide 4 
 
 
  Sample MRM1     
MRM2 
MRM1     
MRM2 
MRM1     
MRM2 
MRM1     
MRM2 
21.8 28.8 37.1 27.5 5.4 2.4 3.9 4.2 
13 5.4 14 6.1 6.4 81 15 10 
HLM 216     
Average 
                      % 
C.V. 
  
14.7 18.5 19.8 25.4 2.8 1.8 2.6 2.6 
6.1 7.0 28 12 14 51 12 4.7 
HLM 21     Average 
                      % 
C.V.   
16.2 20.4 27.4 23.7 5.3 1.9 3.9 4.5 
7.6 6.0 13 6.1 14 58 11 21 
HLM 219    
Average 
                      % 
C.V. 
  
45.7 58.9 91.5 68.2 6.3 3.9 7.0 6.3 
9.7 2.6 20 8.5 13 23 2.0 5.8 
HLM 222    
Average 
                      % 
C.V. 
  
19.1 23.7 27.8 29.1 4.0 1.5 3.8 3.3 
5.0 8.4 37 4.9 9.2 55 7.8 5.0 
HLM 224     
Average 
                       % 
C.V. 
  
37.0 46.9 60.9 48.4 5.8 3.3 4.8 4.2 
1.4 14 9.5 6.5 19 25 7.0 10 
HLM 225    
Average 
                       % 
C.V. 
  
7.0 8.5 13.6 11.0 3.4 2.0 4.4 5.0 HLM 228    
Average 16 5.4 16 7.9 38 84 12 6.5 
  
  
 230 
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                      % 
C.V. 
  
15.6 19.1 25.7 22.2 4.6 3.5 6.3 5.7 
3.8 13 26 1.6 9.6 59 8.3 9.4 
HLM 230     
Average 
                       % 
C.V. 
  
18.5 22.9 27.6 26.6 11.2 9.4 9.1 6.7 
12 5.3 17 10 12 27 7.3 4.7 
HLM 233     
Average 
                       % 
C.V. 
  
11.2 12.9 20.6 20.0 4.3 3.1 3.2 4.0 
18 17 26 15 15 42 4.9 6.3 
HLM 234     
Average 
                      % 
C.V. 
  
20.7 26.1 35.2 30.2 5.3 3.3 4.9 4.6 Average (MRM) 
(all ten HLM)   % 
C.V. 
57 59 67 54 44 70 41 28 
 
  a n=3 for all individual microsome data 
Table 6.5. Microsomes (200 μg) from each donor were analyzed in triplicate and 
concentrations were extrapolated from calibration curves constructed from the analysis of 
calibrant samples containing recombinant UGTs 1A1 and 1A6. Calibrant samples also 
contained rat liver microsomes to normalize total protein content to 200 μg. 
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